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Abstract 
 
Glutathionylation is the reversible redox modification of protein thiols by disulphide 
formation with glutathione. Glutathionylation can alter protein structure and activity in 
response to changes in the oxidation state of the protein, thus modulating protein 
stability. The forward reaction is largely spontaneous while the reverse reaction 
(deglutathionylation) is predominantly catalysed by the Glutaredoxin (Grx) family of 
thioltransferases. Glutathione transferase Omega 1 (GSTO1-1) is an atypical glutathione 
transferase that has minimal functional resemblance with other members of the 
superfamily. GSTO1-1 has previously been shown to have high thioltransferase activity 
like glutaredoxins. Interestingly, GSTO1-1 has been reported to be differentially 
expressed in neurodegenerative diseases. Although the studies reporting these 
differences speculate on the GST-like activity of GSTO1-1, it is evident from data 
published by our laboratory that the primary role of GSTO1-1 is yet to be identified. 
This study investigated the role of GSTO1-1 in the glutathionylation cycle.  
Here, we show that human GSTO1-1, with a unique conserved cysteine at its active site, 
can catalyse the deglutathionylation of protein thiols in vitro and in cell lines. The 
kinetics of the catalytic activity of GSTO1-1 was determined in vitro by assaying the 
deglutathionylation of a synthetic peptide by tryptophan fluorescence quenching and in 
cell lines by means of immunoblotting and immunoprecipitation. We generated stable 
GSTO1-1 transfectants in T47-D breast cancer cells which are devoid of endogenous 
GSTO1-1. The over-expression of GSTO1-1 in these cells resulted in a global 
abatement of protein glutathionylation. Furthermore, we demonstrated that a mutation 
in the active cysteine residue (Cys-32) ablates the deglutathionylating activity, 
confirming the role of GSTO1-1 as a redox switch in regulating protein post 
translational modification. Mass spectrometry revealed four deglutathionylated targets 
of GSTO1-1, of which β-actin was validated by extensive immunoprecipitation studies 
and the physiological impact of deglutathionylated β-actin was confirmed by 
immunostaining. This study introduces GSTO1-1 as a novel member of the family of 
deglutathionylating enzymes which is currently restricted to glutaredoxins and 
sulfiredoxins and identifies specific proteins targeted by GSTO1-1 in cells. 
Additionally, we have developed and employed a novel and rapid method to quantify 
global glutathionylation in vitro to confirm the catalytic role of GSTO1-1 in the 
glutathionylation cycle.  
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GSTO1-1 has been investigated in relation to a number of biologically and clinically 
significant pathways and disorders including drug resistance, Alzheimer’s disease, 
Parkinson’s disease, the action of anti-inflammatory drugs and susceptibility to chronic 
obstructive pulmonary disease (COPD). Since glutathionylation has also been 
implicated in the pathology of Alzheimer’s disease, Parkinson’s disease, COPD and 
inflammation, it is proposed that GSTO1-1 dependent glutathionylation and/or 
deglutathionylation could be a common factor. The data gathered from the initial phase 
of the project directed us to determine whether GSTO1-1 is required for inflammatory 
signalling in phagocytic immune cells such as macrophages. Inflammatory stimulants 
such as bacterial lipopolysaccharide (LPS) have been shown to induce the generation of 
reactive oxygen species (ROS) through the activation of Toll like receptor 4 (TLR4) and 
the recruitment of downstream signalling proteins resulting in the subsequent induction 
of pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α and ROS generating 
NADPH oxidase 1 (NOX1). Following from the previously reported involvement of 
glutathione GSTO1-1 in the secretion of IL-1β and our recent discovery of its 
deglutathionylation activity, we have identified a novel role for GSTO1-1 in regulating 
the generation of ROS following LPS activation of the TLR4 pro-inflammatory 
cascade. We discovered that J774.1A macrophages deficient in GSTO1-1 do not 
respond to LPS and fail to elicit pro-inflammatory responses including the generation of 
ROS via NADPH oxidase 1 and the expression of pro-IL-1β. The present data also 
show that the suppression of several antioxidant enzymes (catalase, glutathione 
peroxidase, glutamate-cysteine ligase) that normally protect against the effects of 
oxidative stress in LPS treated J774.1A cells is dependent on the presence of GSTO1-1. 
In order to confirm that the redox events unfolding in the presence of GSTO1-1 were 
due to its catalytic activity, we tested the GSTO1-1 inhibitor ML175 on wildtype 
J774.1A macrophages. The production of ROS and the suppression of antioxidant 
enzymes after LPS stimulus were blocked significantly by pre-treating cells with 
ML175, clearly mimicking the response of GSTO1-1 knockdown cells.  
Taken together, our data demonstrate the significant attenuation of ROS in GSTO1-1 
deficient cells, thus identifying a novel component of the ROS production pathway in 
LPS activated macrophages and placing GSTO1-1 in the TLR4 signalling pathway, 
upstream of NF-κB. TLR4 ligands such as LPS modulate the metabolic activity of 
macrophages, skewing cells towards a more glycolytic phenotype which is 
characterized by an increase in metabolic flux through the pentose phosphate pathway 
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(PPP) and lower oxygen consumption (OCR). We show that the glycolytic switch is 
significantly attenuated in GSTO1-1 deficient macrophages, which we propose results 
from an upstream block in the TLR4 signalling pathway. Our studies on GSTO1-1 
deficient cells demonstrate that AMPKα, a key metabolic stress regulator is maintained 
in a phosphorylated (active) state in macrophages after LPS stimulation, supporting its 
anti-inflammatory role. In addition, Gsto1 knockdown cells were unable to induce 
HIF1α in response to LPS, thus indicating their failure to acquire a glycolytic 
phenotype. This was confirmed by their low extracellular acidification rate (ECAR).  
The findings in the cell line studies translated well in vivo as the Gsto1
-/-
 mice failed to 
elicit an adequate inflammatory response when injected with sub-lethal and lethal doses 
of LPS intra-peritoneally. Subsequent studies focused on identifying the target(s) of 
GSTO1-1 in the TLR4 pathway. We have successfully placed GSTO1-1 upstream of 
NF-κB and IRAK4 and narrowed down the target(s) to the myddosome complex 
comprised of TLR4, MyD88 and MyD88 adaptor like protein (MAL). Preliminary data 
strongly indicate the glutathionylation of MAL on LPS stimulation which is abolished 
in GSTO1-1 deficient macrophages. The functional implications of the 
glutathionylation state of MAL are yet to be fully understood. Further studies are in 
progress to identify the underlying mechanism by which GSTO1-1 regulates TLR4 
mediated inflammation in vivo. 
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CHAPTER 1 
Introduction 
1.1 Cellular redox biology 
Redox regulation involves mechanisms that make reversible post translational 
alterations to proteins that confer temporary tolerance to changes in the immediate 
redox environment [4, 5]. Under normal physiological conditions, reactive molecules 
such as reactive oxygen species (ROS) and reactive nitrogen species (RNS) are 
continuously produced by cells. The generation and elimination of these species need to 
be constantly monitored by cellular defence mechanisms involving glutathione and 
redox sensitive enzymes including glutathione transferases (GSTs), peroxidases, 
catalases and superoxide dismutases [6]. Oxidative stress manifests when the delicate 
balance between the generation and elimination of endogenous and exogenous reactive 
electrophilic species is disturbed.  Basal levels of reactive species are necessary for the 
normal cellular function and survival. For example, they can act as cell signalling 
messengers regulating mitochondrial activity and cell death [7, 8]. However, increased 
generation of ROS can be detrimental to a cell as they destabilize the redox homeostasis 
leading to post translational modification or/and disruption of proteins, DNA and lipid 
molecules [9, 10] (Figure 1.1).  
 
Figure 1.1: Consequences of oxidative stress on cellular components 
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1.2 Glutathione homeostasis 
Glutathione is the most abundant thiol (glutamyl-L-cysteinyl glycine) present in all cells 
[11, 12]. Glutathione exists in two states: the reduced form referred to as GSH and the 
oxidized disulphide GSSG. GSH is the predominant form of glutathione occurring in 
cells, contributing to >98% of the total glutathione pool. The physiological level of 
GSH is generally maintained at 1-10 mM across different tissues [13, 14]. However, the 
GSH/GSSG ratio is significantly altered depending on the redox conditions in the cell, 
with the ratio dropping from 100:1 to 1:100 under increased oxidative stress. The 
glutathione pool exists mainly in the cytosol though a fraction does occur in the nucleus, 
contributing to the nuclear glutathione cycle [15]. The redox environment in the ER is 
more oxidizing than the cytosol to maintain and promote protein folding and post 
translational modifications (GSH/GSSG = 1:3) [16, 17].  
Because of its unique γ-glutamyl linkage glutathione cannot be translated from a 
glutathione gene and is generated enzymatically.  Synthesis of glutathione occurs via 
two steps (Figure 1.2): In the first step the carboxyl side chain of glutamate is ligated to 
the amine of cysteine, forming γ-glutamylcysteine. The reaction is catalysed by γ-
glutamate cysteine ligase which is composed of catalytic (GCLc) and modulating 
(GCLm) subunits [12, 14, 18]. In the second step, glutathione synthase (GS) catalyses 
the addition of glycine to γ-glutamylcysteine generating γ-glutamylcysteinylglycine or 
GSH. GSH can be transported across the cell membrane via γ-glutamyltranspeptidase 
(GGT) and recycled back to the source amino acids via the action of GGT and 
dipeptidases [19].  
The antioxidant activity of GSH is mediated by glutathione peroxidases which reduce 
endogenously produced hydrogen peroxide and lipid peroxides by simultaneously 
oxidizing GSH to GSSG. The GSSG thus generated is continuously recycled back to 
GSH by glutathione reductase at the expense of NADPH. However, increased GSSG 
levels during oxidative stress can glutathionylate protein thiols, (forming P-SSG) 
transiently protecting them from oxidation. This reaction is predominantly spontaneous 
though enzymes such as glutaredoxins and glutathione transferase Pi (GSTP) have been 
demonstrated to catalyse the addition of glutathione to proteins in a target specific 
manner [20-22].  
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1.3 Redox modification of proteins 
Protein thiols are highly sensitive targets of ROS and redox regulators including 
glutaredoxins, sulfiredoxin, glutathione peroxidases, glutathione transferases and 
glutathione are integral to maintaining the integrity and stability of cysteine thiols 
against oxidative stress induced irreversible damage and subsequent protein 
degradation. The various redox modifications occurring under normal physiological 
conditions and under oxidative stress are described in this section (Figure 1.3).  
Figure 1.2: Glutathione synthesis pathway 
The carboxyl side chain of glutamate (Glu) reacts with the amine group in cysteine 
(Cys) to form γ-glutamylcysteine (γ-Glu-Cys). This rate-limiting reaction is catalysed 
by γ-glutamate cysteine ligase (γ-GCL). Glycine (Gly) is added on to γ-Glu-Cys by 
glutathione synthase (GS) to form glutathione which is transported extracellularly via 
transporters called γ-glutamyltranspeptidase (GGT) and can be recycled back to the 
precursor amino acids by dipeptidases. 
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Figure 1.3: Redox modifications of protein thiols 
Protein thiol modifications are classified into two categories: irreversible oxidation and 
reversible modifications.  
Irreversible: Reactive oxygen species can induce the oxidation of protein thiols to a 
sulfenic form which can be reversed by glutaredoxins. Over exposure of sulfenic acid 
thiol intermediates may result in the further irreversible oxidation into a sulfinic and 
sulfonic forms. A few studies have demonstrated the reversal of sulfenic acid oxidized 
thiols via the formation of a thiosulfinate intermediate. 
Reversible: These modifications include S-nitrosylation (–SNO) under nitrosative stress, 
S-glutathionylation (–SSG) can be either spontaneous or catalysed by glutaredoxins (Grx) 
and GSTP under oxidative stress, either intra- or inter disulphides (Pr-S-S-Pr), 
sulfhydration (-SSH) by reaction of protein thiols with glutathione persulphide (GSSH) 
on exposure to hydrogen sulphide, palmitoylation (Pr-S-FA) resulting from the reaction 
of protein thiols and fatty acids such as palmitate. 
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1.3.1 Irreversible posttranslational modification 
Sulfenylation and Oxidation 
Following oxidative insult, protein thiol groups can undergo a series of changes in their 
oxidation state which can determine the fate of the protein.  Cysteines exist as thiols 
(Cys-SH) with a net charge of –II, referred to as its oxidation state. The Cys-SH group 
is typically in equilibrium with its deprotonated thiolate form (Cys-S
-
) depending on the 
pKa of the thiol group [23, 24]. Thiols can form disulphide bonds with other thiol 
containing molecules such as GSH or proteins. Unfortunately, the thiolate form is 
highly susceptible to oxidation and is readily oxidized to sulfenic acid (R-SOH) 
(oxidation state: 0) on exposure to oxidative stress (Figure 1.3) [23, 25-28]. Sulfenic 
acid subsequently can be transformed into two forms- it can either interact with other 
thiols forming disulphides (oxidation state: -I) or be further oxidized by reactive oxygen 
species to form sulfinic acid (R-SO2H) (oxidation state: +II) and eventually sulfonic 
acid (R-SO3H) (oxidation state: +IV) [23, 26-28]. Oxidation of thiols to sulfenic acid 
and sulfinic acid can be enzymatically reversed by glutaredoxins, thioredoxins and 
sulfiredoxins though the formation of sulfonic acid is irreversible, targeting the protein 
for proteosomal degradation [21, 24, 29-31]. Thus, protein thiol groups can be 
transiently capped with glutathione (P-SS-G) to prevent further oxidation until the redox 
balance is restored upon which proteins can be enzymatically deglutathionylated by the 
‘redoxins’. This makes glutathione an indispensable player in the regulation of cellular 
redox homeostasis.   
1.3.2 Reversible modifications 
a. Sulfenic acid intermediates 
 Sulfenic acid intermediates are predominantly formed by the direct interaction of 
cysteine thiols with hydrogen peroxide and to a lesser extent, alkyl hydroperoxides, 
peroxynitrites and hypochlorous acid [23, 24]. The susceptibility of thiols is dictated by 
their ionization state, for instance thiolates are more nucleophilic than their protonated 
counterparts making them more likely targets of oxidation [24]. Sulfenic acid 
intermediates can also be formed via the hydrolysis of nitrosylated thiols, disulphides 
and oxidation of thiyl radicals. The over oxidation of sulfenic acids to sulfinic and 
further to sulfonic acid is dictated by the immediate oxidative environment. Sulfonic 
acids cannot be reversed even upon recovery of the normal redox state in a cell. 
However the same holds generally true for most sulfinic acid intermediates though an 
extremely low pH (< 4) can reverse the oxidative state to the sulfenic form [32]. It is 
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relevant to note that though typical redox catalysts such as thioredoxins and glutathione 
cannot catalyse the conversion of sulfinic to sulfenic acid, recent studies reported the 
sulfiredoxin mediated rescue of the sulfinic form of peroxiredoxins [33].    
b. Thiosulfinates 
Oxidation of 2-cysteine peroxiredoxins (2Cys-Prdxs) to the sulfenic oxidized form is 
catalysed specifically by sulfiredoxin and proceeds by the formation of two distinct 
intermediates: formation of a sulfinic phosphoryl ester intermediately followed by the 
reaction of a thiol group with the sulfinic phosphoryl ester to form a protein- 
thiosulfinate intermediate [33-35]. This intermediate subsequently reacts with reduced 
glutathione resulting in the generation of sulfenic acid oxidized 2-Cys Prdx. The 
sulfenic form of 2-Cys Prdx can then be enzymatically reversed by sulfiredoxin [35].  
The relevance of the formation of thiosulfinates to other proteins is not fully 
understood. 
c. Sulfenylamide 
Sulfenylamide intermediates are relatively lesser known transient modifications of 
cysteine thiols. A classic example of sulfenylamide formation occurs in Protein 
Tyrosine Phosphatase1B (PTP1B) which is one of the first identified targets of 
sulfenylamidation. PTPs are highly susceptible to oxidation and thus cysteine oxidative 
modifications [36]. Interestingly, the oxidation of PTP1B was found to follow an 
atypical path involving a previously unidentified oxidative intermediate. The initially 
formed sulfenic acid form of PTP1B underwent a further reaction with closely available 
amide nitrogen to form a cyclic ‘sulfenylamide’ intermediate. The sulfenylamide form 
of PTP1B can interact with other thiols such as GSH, converting it back to the initial 
thiol active state of the protein. Similar to that seen with other cysteine modifications, 
the sulfenylamide form can undergo further oxidation to the irreversible sulfinic and 
sulfonic oxidation forms on prolonged exposure to reactive species [36, 37].  
d. Sulfhydration 
Increasing evidence strongly indicates that physiological levels of hydrogen sulphide 
can act as a vasorelaxant [38]. Mice deficient in cystathionine γ-lyase (CSE), an enzyme 
catalysing the formation of H2S in cells, are hypertensive albeit the post translational 
modification of proteins by H2S was not evaluated [39, 40]. Parallel studies in the 
impact of H2S signalling in ER stress have shown the sulfhydration and subsequent 
inhibition of PTP1B by H2S can abolish protein activity [41]. This in turn resulted in the 
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inhibition of the dephosphorylation of protein kinase-like ER kinase (PERK) thereby 
maintaining phosphorylated/active PERK required for ER stress responses. CSE mutant 
mice experience constitutive oxidative stress due to the depletion in the glutathione pool 
[42, 43]. H2S synthesized by CSE modulated the DNA binding capacity of NF-κB due 
to the sulfhydration of cysteine 38 of the p65 subunit of NF-κB [44]. Furthermore, the 
sulfhydration of p65 was demonstrated to enhance the anti-apoptotic activity of NF-κB 
in wildtype mice on TNFα treatment. Interestingly CSE knockout mice failed to induce 
the sulfhydration of NF-κB and consequently showed diminished NF-κB dependent 
anti-apoptotic activity [44]. Though predominantly considered a stress response, 
sulfhydration of several proteins including actin, tubulin and GAPDH, was detected 
under physiological conditions as well [38]. The physiological role of H2S induced 
sulfhydration of GAPDH was further investigated in neural cells in response to IL-1β 
treatment [45]. IL-1β induces cognitive deficits and memory impairment in brain cells, 
an effect that was shown to be mediated by H2S. Increased H2S production by 
cystathionine beta lyase led to the sulfhydration of GAPDH consequently promoting its 
association with Siah (an E3 ligase protein). The association resulted in the physical 
interaction of the complex with the synaptic scaffolding protein PSD65, labelling the 
protein for ubiquitination and proteosomal degradation [45].  The loss of PSD65 led to 
the defective neuro-behaviour induced by IL-1β [45]. 
e. Palmitoylation 
Palmitoylation is the reversible addition of palmitate or other fatty acids to cysteine 
thiols. The family of palmitoyl acyltransferases (PATs) are generally golgi bound and 
have been shown to catalyse the reaction of palmitate and to a lesser extent other fatty 
acids with thiols [46, 47]. Unlike modifications such as glutathionylation and 
nitrosylation [48-50], palmitoylation does not recognize a specific consensus protein 
sequence within the target protein. Though palmitate is most common fatty-acid found 
to react with cysteine thiols, other fatty acids such as oleate, stearate and arachidonate 
moieties have also been seen to modify thiols in as similar manner. The reaction 
proceeds by the initial nucleophilic attack by a cysteine thiolate ion on the ester bond of 
palmitoyl coenzyme A (CoA), resulting in the formation of a thioester bond between the 
two moieties. The reaction can be reversed by the family of palmitoyl thioesterases (PT) 
which break the thioester bond and release palmitate, freeing the cysteine residue [46, 
47]. There is some evidence for protein target specificity and the balance between 
palmitoylated and depalmitoylated proteins may be considered as a redox switch 
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regulating protein function and localization [46]. For example, palmitoylation of 
membrane bound N-Ras has been shown to influence the cycling efficiency of the 
protein between the golgi and the plasma membrane [51]. Though not mandatory for the 
incorporation of membrane bound proteins into the cell membrane, palmitoylation may 
be considered as a secondary modification that enhances the integration and membrane 
specific localization of membrane proteins [51, 52]. 
f. Nitrosylation 
Exchange of electrons between reactive species ROS/RNS and protein cysteines can 
lead to the reversible modification of thiol groups to nitrosothiol (-SNO). Nitrosylation 
has been reported to modulate the activity of several metabolic enzymes, ion channels, 
protein kinases, phosphatases, oxidoreductases and signalling intermediates in 
inflammation and cancer (reviewed in [53, 54]). Nitrosylation of proteins such as ATP 
synthase has been demonstrated to mediate the cardio protective effects of nitric oxide 
in cardiomyocytes [37, 55]. During ischemic reperfusion, proteins have been shown to 
adopt nitrosylation as a mechanism by which they transiently protect their exposed 
thiols from irreversible oxidative damage. For example, Cys 294 in ATP synthase was 
found to be nitrosylated during cardiac resynchronization therapy in a canine model 
[56]. A detailed list of cardiac proteins undergoing various oxidative post translational 
modifications under different redox conditions is described in [37]. The reversal of 
nitrosylated thiols to the active thiol form has been shown to be predominantly 
catalysed by the thioredoxin/thioredoxin reductase system.  Though endogenous 
reactive species can spontaneously nitrosylate thiols, exogenously applied agents such 
as S-nitrosoglutathione (GSNO) has been shown to selectively induce protein 
nitrosylation and/or glutathionylation in a target specific manner [57]. The factors that 
dictate the propensity of a thiol to undergo either nitrosylation or glutathionylation by 
GSNO are not fully understood. However parameters such as consensus flanking 
sequence, pKa and steric hindrance have been shown to play a vital role in influencing 
the preferential glutathionylation or nitrosylation of the same residue under different 
redox conditions [57, 58]. A typical example of preferential glutathionylation occurs in 
papain. Cysteine 25 in papain resides adjacent to a histidine residue, which increases the 
nucleophilicity of the cysteine residue and promotes an attack on the S-NO bond of 
GSNO, resulting in the glutathionylation of Cys 25 [59]. On the contrary, the cysteine in 
aldehyde dehydrogenase (ADH) was not activated by histidine and thus the lower 
nucleophilicity promoted thiol nitrosylation by reacting with the sulphur atom in the 
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SNO bond [60].  The physiological relevance of nitrosylation is still unclear and open to 
further investigation.  
g. Glutathionylation 
Glutathionylation can be defined as the post translational modification of protein thiol 
groups by the formation of mixed disulphides with glutathione. Glutathionylation can 
alter protein structure and activity in response to changes in the oxidation state of the 
protein. The reaction may be spontaneous or can be catalysed by members of the 
Glutaredoxin (Grx) family of thioltransferases and glutathione transferase Pi (GSTP) 
[20, 26, 61-65]. Under physiological conditions, glutathione is the most prevalent thiol 
occurring in the cytosol. On oxidative insult, redox sensitive protein thiol groups are 
glutathionylated via the formation of generally reversible disulphide bonds with cellular 
glutathione (capping cysteine residues), thus shielding them from irreversible oxidation 
[66-68]. Glutathionylation reactions may be reversed depending on the oxidation state 
of the modified thiol group. Thus, glutathionylation may be seen as a defence 
mechanism to protect proteins from oxidative stress induced irreversible damage. 
Though glutathionylation is mainly considered as an oxidative stress triggered protein 
modification, reversible glutathionylation in the absence of oxidative stress has been 
shown to have an impact on the functions of proteins as illustrated by its impact on the 
contractile activity of actin and the phosphatase activity of PTP1B [29, 69]. The redox 
environment in cytosol is slightly reducing nature, as the GSH:GSSG ratio is normally 
maintained at 100:1[11]. It would take a steep increase in GSSG to bring the ratio to 1:1 
in order to achieve at least 50% glutathionylation under physiological conditions [11]. 
Thus, most cysteines that are glutathionylated during oxidative stress usually exist in an 
activated sulfenic acid or thiolate state within pockets of high ROS micro-environment. 
The typical pKa of cysteine residues is around 8.5, and a decrease makes them more 
favourable targets for glutathionylation as they are more likely to exist as thiolates that 
can undergo nucleophilic substitution with GSSG [70]. 
Deglutathionylation is the reversal of glutathionylation i.e. removal of protein bound 
glutathione. Though deglutathionylation was originally identified as a mechanism to 
reverse oxidative stress induced glutathionylation, there is increasing evidence 
indicating that some proteins can be actively deglutathionylated in response to oxidative 
stress [69, 71, 72]. Thus, protein thiols can be transiently modified by glutathione until 
the redox balance is restored upon which they can be enzymatically deglutathionylated. 
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The synergistic activity of glutathione, glutaredoxins and thioredoxin may be 
considered as the major gatekeepers of the cellular cysteine thiol pool [13, 73]. Non-
enzymatic glutathionylation occurs under oxidative stress without substrate specificity. 
On the contrary, deglutathionylation is tightly regulated by enzymes with target 
specificity even under normal physiological redox conditions [21, 57, 61, 62, 64, 72, 74-
76].  
1.4 Enzymes that catalyse the glutathionylation cycle 
1.4.1 Glutaredoxin 
Glutaredoxins are small heat stable ‘thioltransferases’ discovered as GSH dependent 
electron donors for ribonucleotide reductase (RNR) in 1976 by Holmgren et al. [77]. 
They were initially considered as a back-up mechanism for the characteristic functions 
of thioredoxins, the only oxidoreductases known in the early 1960-70s [78-85]. Since 
glutaredoxins exhibit a classic thioredoxin fold, they may be considered as a class 
within the superfamily of thioredoxins along with other proteins that share this fold such 
as protein disulphide isomerase (PDI), glutathione peroxidase (GPx) and the cytosolic 
GSTs though not all of these enzymes catalyse thioltransferase reactions [86, 87]. 
Although Glutaredoxins are considered to be the predominant thioltransferases, the 
most well described being Grx1, other proteins have been shown to catalyse similar 
reactions, courtesy of their glutaredoxin-domain [31, 73].  Glutaredoxins may be 
grouped into two classes based on the active site domain that contains either a dithiol 
motif (CXXC) or a monothiol motif (CXXS) [21, 31, 73, 87] (Figure 1.4). The N-
terminal cysteine (cys22) in Grx has a low pKa and catalyses the reduction of 
disulphides via the nucleophilic attack on the disulphide bond [87]. Grxs have been 
demonstrated to catalyse dithiol-dependent reduction reactions though not as efficiently 
as monothiolic reactions. The formation of an intramolecular disulphide between the 
two cysteines hinders the dithiol cyclic reaction, contributing to the poor efficacy of the 
enzyme [87]. 
Monothiol: Grxs most commonly catalyse deglutathionylation reactions via the 
monothiol mechanism wherein the glutathionylated protein undergoes a nucleophilic 
attack by the N-terminal thiolate of Grx [63, 87] (Figure 1.4). The resulting 
glutathionylated intermediate of Grx (Grs-SSG) is recycled by one molecule of GSH, 
giving GSSG as a product that is subsequently reduced to two molecules of GSH by 
glutathione reductase and NADPH.  
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Dithiol: Reduction of protein mixed disulphides via the dithiol mechanism occurs 
sequentially: first the protein mixed disulphide is attacked by the N-terminal thiolate of 
Grx, the C-terminal cysteine then reacts with the Grx-protein complex to form an 
intramolecular disulphide which is subsequently reduced by 2 molecules of GSH, 
glutathione reductase and NADPH [63]. Albeit thermodynamically all thioredoxin fold 
containing proteins with low pKa cysteines should catalyse oxidoreductase reactions, an 
elegant study carried out with mitochondrial proteins demonstrated Grx to be the most 
effective oxidoreductase in cells [88]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Mechanisms of disulphide reduction by glutaredoxin (modified from [2]).  
Monothiol reactions: The thiolate form of the cysteine in glutaredoxin reacts with 
target glutathionylated protein (P) resulting in the formation of glutathionylated 
glutaredoxin. Glutaredoxin is subsequently recycled to the active thiol state by free 
glutathione (GSH). Dithiol reactions: The thiolate form of cysteine in glutaredoxin 
attacks the disulphide bond within the target protein (P) resulting in the formation of 
a mixed disulphide bond between glutaredoxin and the target protein. A nucleophilic 
attack by the thiolate form of the second cysteine in the CXXC domain of 
glutaredoxin breaks the mixed disulphide bond between glutaredoxin and the protein, 
forming an intra-disulphide bond between the two cysteines in the CXXC domain. 
The cysteines in glutaredoxin are then recycled to the active state by two molecules 
of glutathione. 
Chapter 1 
12 
 
Deglutathionylation is predominantly catalysed by the glutaredoxin family of 
thioltransferases though other enzymes sharing the typical ‘thioredoxin’ fold such as 
GSTO and CLIC are gradually being characterized with similar glutaredoxin like 
activity [29, 89, 90]. In mammalian glutaredoxins, the deglutathionylation activities of 
glutaredoxin 1 & 2 (Grx1 & Grx2) are the most characterized. Unlike Grx1 and Grx2; 
Grx3, Grx4 and Grx5 are monothiolic and contain only one cysteine residue in the N-
terminal [91]. Grx5 contains another cysteine residue that is not conserved across the 
glutaredoxin family which has been shown to catalyse deglutathionylation reactions 
[92]. Grx1 and Grx2 share approximately 30% sequence similarity but differ in their 
cellular localization and target specificity [21, 26]. The active site domain CXXC 
common to both glutaredoxins bears a proline adjacent to the N-terminal cysteine (-
CPXC) in Grx1 while the proline is replaced by a serine in Grx2 [21, 26, 31, 73]. Grx1 
occurs predominantly in the cytosol and has been found to be expressed in the nucleus 
and intermembrane space in the mitochondria [93]. Grx2 is localized to the 
mitochondria and although less efficient than Grx1, Grx2 is responsible for the 
deglutathionylation of almost all reported mitochondrial proteins reported to be 
functionally regulated by the glutathionylation/deglutathionylation cycle [26, 73]. 
Mitochondrial proteins are more susceptible to redox modifications due to the redox 
micro environment [94]. The mitochondrial matrix is relatively alkaline, promoting the 
ionization of protein thiols and reaction with free glutathione [95]. Additionally, 
constant ROS generation in the mitochondria as a by-product of the electron transport 
chain (ETC), availability of GSH (~ 5 mM) and the relatively high mitochondrial 
protein thiol content in the matrix makes the mitochondria suitable for spontaneous 
protein glutathionylation [94, 95]. This further emphasizes the need for controlled 
deglutathionylation of proteins in order to reverse glutathionylation and restore protein 
activity.  For example, deletion of Grx2 led to increased glutathionylation of complex I 
and the subsequent inhibition of ATP production via the ETC [72], enforcing the 
indispensable role for deglutathionylating enzymes in reversing glutathionylation 
induced disruption of protein activity even under normal physiological conditions.   
Mechanism: The N-terminal cysteine in Grx1 occurs as a thiolate (low pKa) under 
normal physiological conditions [63, 93]. The thiolate ion attacks the disulphide bond in 
the target glutathionylated protein (PSSG), transferring the glutathione moiety to Grx1, 
forming a Grx-SSG intermediate [26, 63, 87] (Figure 1.5). The intermediate can be 
recycled back to the active thiol by free glutathione, restoring Grx-SH which can 
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continue catalysing nucleophilic attacks on glutathionylated proteins. A dithiol 
mechanism mediated via the formation of a transient disulphide bond between the two 
cysteine residues in Grx1 has also been proposed although it is considered far less 
efficient due to steric hindrance due to the intramolecular disulphide bond that may 
disrupt the cycling of glutathione between the interacting protein and Grx1 [63].  
 
 
 
 
 
Although glutaredoxins exhibit substrate specificity in deglutathionylation reactions 
(refer section 1.6), a review of published literature highlights functional redundancy in 
targets to a certain extent. This may provide a compensatory mechanism to over-ride the 
deficiency of one or more proteins and maintain normal redox homeostasis.  
1.4.2 Thioredoxin  
The founding member of the thioredoxin family was discovered in 1964 as an electron 
donor for ribonucleotide reductase (RNR) and is structurally made up of 3 α-helices and 
4 anti-parallel β-sheets [96-98]. It is important to note that the cis-proline is highly 
conserved among the family members, a trait shared with the later-discovered 
glutaredoxins. Albeit the functional and structural similarities of Grxs and thioredoxins 
(Trx), the two enzyme classes encompass different substrate specificity with minimal 
overlap [73]. Trxs are mostly associated with reduction of oxidized thiols more than 
protein mixed disulphides, owing to their lower redox potential [31, 99]. However, a 
few studies have provided evidence for Trx-dependent deglutathionylation reactions, for 
Figure 1.5: Mechanism of deglutathionylation by glutaredoxins 
A disulphide exchange between the glutathionylated target ‘P’ and glutaredoxin 
(Grx) occurs resulting in the formation of a transient glutathionylated Grx-SSG 
intermediate. The glutathionylated intermediate is recycled to the active state by 
reacting with 2 molecules of GSH and producing GSSG. The redox balance is 
maintained by the NADPH-glutathione reductase system which recycles GSSG 
back to GSH by oxidizing NADPH.  
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instance in yeast, the deglutathionylation activity of Trx was required to maintain 
protein glutathionylation levels for the progression of cells from a stationary to a 
vegetative growth phase [99]. Furthermore, the regeneration system potentiating Trx’s 
catalytic activity is a GSH-independent system comprising Trx reductase and NADPH 
whereas Grx requires GSH, NADPH and glutathione reductase to recycle its thiolate.  
1.4.3 Protein disulphide isomerase (PDI) in glutathionylation as ‘misfolded protein 
response’ 
Protein folding in the ER is dependent on the redox conditions, which in turn dictates 
the integrity of protein thiols [100]. The extreme oxidizing environment within the ER 
provides a suitable balance of GSH/GSSG favouring the spontaneous reaction of protein 
thiols with GSSG, resulting in an increase in the rate of glutathionylation and the 
glutathionylated protein pool [16, 101].  The ER provides an intracellular compartment 
for the post translational processing of proteins with the help of chaperone proteins that 
prevent the aggregation of misfolded proteins, thus maintaining them in a stable and 
active form [101, 102]. PDI, the most abundant chaperone protein in the ER, is a 
member of the thioredoxin superfamily and plays an indispensable role in trafficking 
proteins and maintaining protein folding and stability through the formation of intra- 
and/or inter-molecular disulphide bonds [100, 102, 103]. The protein was characterized 
with five distinct domains, a, a’, b, b’ and c of which the first two comprise the 
thioredoxin fold nesting two cysteine residues each [102].  The cysteine residue pairs 
form two separate active sites and play an important role in protein folding and 
formation of disulphides (refer review [102]). As a consequence, cysteine modifications 
have been shown to disrupt protein stability and result in increased turnover of 
misfolded proteins, characteristic of neurodegenerative diseases such as Alzheimer’s 
and Parkinson’s diseases [104, 105].  The activity of PDI is thus kept in check by ER 
oxidase-1, which maintains the thiols in an oxidized state. Apart from protein 
chaperoning, PDI has been shown to physically associate with the estrogen receptor 
(ERα) and form a part of the complex comprising of ERα, Hsp70, Hsp60 [106]. 
Townsend et al. have further demonstrated that glutathionylation of PDI by PABA/NO 
(a glutathionylation inducing agent) inhibits its activity in cancer cells resulting in the 
activation of the ‘unfolded protein response’ (UPR) pro-apoptotic pathway, leading to 
cell death [107].  
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1.4.4 Glutathione transferase Pi 
The GSTP gene is located on chromosome 11 and spans approximately 3kb in length. 
Polymorphic variants of GSTP have been implicated in differential susceptibility and 
drug response in cancer though a definite link is yet to be established (reviewed in 
[108]). Glutathionylation by GSTP mimics the typical nucleophilic reaction between the 
electrophilic substrates and the thiolate anion of GSH, previously deprotonated by the 
active tyrosine residue [20, 109]. This function is based on the catalytic activity of 
enzyme and is influenced by auto-S-glutathionylation of GSTP itself on two critical 
residues, Cys 47 and cys101 [110]. Glutathionylation of GSTP causes structural 
changes in the monomeric subunit which in turn alters the tertiary and quaternary 
structure of the dimer [20]. The structural changes induced by glutathionylation in 
GSTP can potentially influence protein-protein interactions of GSTP. The two cysteine 
residues Cys 47 and Cys 101 have been previously demonstrated to be involved in the 
physical interaction of GSTP with c-Jun N-terminal kinase (JNK), regulating 
downstream signalling events in cancer [20, 111]. Hence it is possible that the 
glutathionylation of GSTP may abolish signalling activated by its interaction with JNK, 
providing a potential target for the development of GSTP-SSG specific drugs to 
modulate the activity of GSTP in cancer.   
Under physiological conditions, the thiolate anion of GSH reacts with exposed protein 
cysteinyl thiols thereby undergoing GST-catalysed glutathionylation. However, exposed 
cysteines may also interact with GSH or GSSG, depending on the redox state of the 
immediate environment to undergo spontaneous glutathionylation [22, 111]. 
Independent of its direct glutathionylation activity, GSTP can indirectly contribute to 
global protein glutathionylation via its GST-like activity by catalysing the metabolism 
of a diazeniumdiolate-based prodrug to an activated glutathionylating agent PABA-NO  
which can simultaneously induce both S-nitrosylation and excessive glutathionylation 
of proteins in cells [111-113].  
The structural conservation of the canonical GST thioredoxin fold and the common 
ability to conjugate electrophilic substrates with GSH suggests that other members of 
the GST family may catalyse the glutathionylation cycle but apart from GSTM1-1 and 
GSTP, other GSTs have not yet been shown to catalyse glutathionylation reactions.   
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1.4.5 Sulfiredoxin 
Sulfiredoxin (Srx) was one of the first enzymes shown to specifically catalyse the 
reversal of protein glutathionylation i.e. deglutathionylation [29]. Sulfiredoxin was first 
identified in Saccharomyces cerevisiae as a protein that was induced as part of the 
antioxidant responses activated against increased oxidative stress [114]. It is understood 
that the specificity of sulfiredoxin in deglutathionylating proteins is due to the 
availability of only one cysteine residue in its active site, unlike most glutaredoxins that 
contain a CXXC domain at their active site [25, 29]. Sulfiredoxin is the only enzyme 
that has been shown to catalyse the reversal of oxidation of proteins from the sulfinic 
form to the further reversible sulfenic form. The sulfinic form of oxidized thiols was 
previously considered irreversible until sulfiredoxin was found to reverse the over-
oxidation of peroxiredoxins (Prdxs) to an active thiol [114]. Prdxs are antioxidants 
induced in response to the increased generation of hydrogen peroxide in cells [35, 115]. 
The family of Prdxs consists of 6 members of which Prdx I-IV contain a single cysteine 
residue at their active site while Prdx V and VI have two cysteines [115]. The reversal 
of over-oxidation of Prdxs occurs via the formation of two intermediates: first Prdx-
SO2H is converted to the sulfenic form (Prdx-SOH) by sulfriredoxin. As previously 
mentioned, the sulfenic form of protein thiols can be easily glutathionylated by GSSG 
and subsequently deglutathionylated by Srx/Grx, restoring the catalytic activity of Prdxs 
[33]. Alternatively, in the case of Prdxs, the sulfenic form of oxidized Prdx is reduced 
by the Thioredoxin/Thioredoxin reductase system. This cycle proceeds in cells to 
maintain the catalytic cysteines in Prdx in a reduced state. However, when Prdx gets 
over oxidized to the sulfinic form, Srx reverses the oxidation and Trx/TR and recycles 
Prdx back to the active form [34, 35, 114]. Interestingly, GSTP can also activate Prdx 
VI by glutathionylation of Cys 47 specifically [111].  
Sulfiredoxin contains a single cysteine residue (Cys 99) in the C-terminal domain, 
which appears to be conserved with the ‘non-conserved’ C-terminal cysteine residue in 
Grx5 [29]. Findlay et al. have further demonstrated that the deglutathionylating activity 
of Srx is mediated via Cys 99 and mutating the residue abolishes this activity [29]. 
Interestingly, a glutathionylated Srx intermediate could not be identified in the 
disulphide exchange reaction catalysed by Srx, suggesting that Cys 99 did not form a 
mixed disulphide with glutathione during the reaction. This was unexpected as the 
crystal structure of Srx confirms the active site region as a FGGCHR [116] but the 
absence of a typical mixed disulphide intermediate at Cys 99 suggests the possibility of 
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an unknown intermediate or atypical mechanism by which Srx deglutathionylates 
proteins. Srx was further demonstrated to modulate protein function in cells under 
oxidative stress [25, 117]. The current list of proteins deglutathionylated by Srx 
includes actin and PTP1B [29]. The physiological relevance of actin deglutathionylation 
in cytoskeletal remodelling was also elucidated further confirming the functional 
implications of the stringent regulatory switch offered by enzyme catalysed reversal of 
glutathionylation. Apart from the deglutathionylation activity, Cys 99 appears to be 
involved in the inhibition of glutathionylation reactions as well [29, 117]. The physical 
interaction between Srx and the target protein interfered with the spontaneous 
glutathionylation of actin and PTP1B by PABA/NO, thus acting as a target-specific 
inhibitor of glutathionylation [29]. 
1.5 Protein specificity of enzymes catalysing the glutathionylation cycle 
The target specificity of enzymes catalysing the glutathionylation cycle is very evident 
from the restricted overlap among their targets [61, 63, 64, 72, 118, 119]. The 
parameters defining the specificity of enzymes for glutathionylating and 
deglutathionylating proteins are not fully understood although comparison of the 
reaction mechanism and kinetics with different protein targets have revealed factors that 
may influence protein binding and glutathione exchange between the enzyme and 
target:  
1.5.1 Basicity of amino acids adjacent or in close proximity to the target thiol   
The occurrence of positively charged residues in close proximity to cysteine thiols in 
proteins have been demonstrated to promote the formation of reactive thiolates by 
lowering the pKa of the cysteine thiol [120, 121]. The pKa of cysteine thiols under 
normal physiological conditions is maintained at 8.5 [121]. Classic examples of proteins 
that have been shown to be modified by glutathionylation and have either a histidine or 
a serine residue near-by in the quaternary protein structure include PTPB1 (pKa 4.7-5.4) 
[122], creatinine kinase (pKa 5.5) [123-125], GAPDH (pKa 5.5) [76, 126], Prdx (pKa 
4.6) [70, 127]and protein disulphide isomerase (PDI) (pKa 6.7) [100, 103, 128].  
1.5.2 Solvent exposure of target thiols and conformational flexibility of enzymes 
The ability of enzymes such as Grxs, Trxs and sulfiredoxin to catalyse the 
glutathionylation and deglutathionylation respectively also relies on the exposure of the 
target thiol on the surface of the protein [57, 121].  Steric hindrance may prevent the 
cysteine thiol from interacting with the active site of the enzyme in order to initiate the 
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disulphide exchange [63, 129]. On the contrary, although computational modelling 
predictions on Cyclophilin A place Cys 52 and Cys 161 (out of 4 cysteine residues) on 
the surface of the protein making them more susceptible to redox modifications, Cys 52 
and Cys 62 but not Cys 161 were found to be significantly glutathionylated in T-
lymphocytes [130].  This suggests that target specificity cannot be attributed to solvent 
exposure alone and is dependent on multiple (yet to be fully characterized) parameters.  
The structural conformation of the enzyme may also dictate the ability of the target 
protein to ‘dock’ into the crevice accommodating the active site of the enzyme to enable 
transient physical interactions between the two proteins, enhancing the stability of the 
protein complex [121, 131]. 
1.5.3 Inter-protein electrostatic and ionic interactions 
Several studies have confirmed the participation of inter-protein electrostatic 
interactions, hydrogen bonds and Van der Waals bonds to contribute to target specificity 
observed in enzymes catalysing the glutathionylation cycle [120, 131, 132]. Mechanistic 
studies have provided valuable insight into the enzyme specific interactions that 
modulate the physical proximity and stability of target proteins that in turn determine 
the glutathionylating/deglutathionyting ability of the enzyme [120, 132]. One of the 
studies cited above demonstrated that the electrostatic energy change occurring due to 
the formation of new bonds during the interaction between two proteins can affect the 
stability of the transient intermediate complex formed between the target and the 
enzyme and the susceptibility of the target thiol to glutathionylation [132]. As described 
above, of the four free cysteines in cyclophilin A, Cys 52 and Cys 62 were 
glutathionylated in T-lymphocytes [130]. This finding correlated well with the energy 
change involved in the thiolate formation and reaction with glutathione as well. The 
energy change was measured to be the least for Cys 52 and the highest for Cys 161 
(cys52 < Cys 62 < Cys 115 < Cys 161), favouring the reaction of modification of Cys 
52 and Cys 62 [130].    
The energy change is additive for the formation of new bonds and alterations of existing 
bonds (causing enzyme conformational changes) in order to accommodate interacting 
proteins and disulphide exchanges [63, 131]. Some of the interactions that may 
contribute to the total energy change and stability are summarized below [119, 120, 
131-133]:  
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 Non-specific backbone-to-backbone hydrogen bonds between the enzyme and 
the target protein. 
  Interactions between γ-Glu of GSH or PSSG: The stabilizing effect exerted by 
the carboxylate group of the γ-Glu is significantly higher than the effect of the 
charged amino group.  
  The aliphatic linker of the γ-Glu component contributes to the stability. 
 Van der Waals interactions between the two interacting proteins contribute to 
specificity of the enzyme for the interacting protein. For example, the specificity 
of the glutathionylation reaction between NF-κB and Trx is attributed to the 12 
hydrophobic bonds and 9 electrostatic bonds formed between the two proteins.  
1.6 Biological significance of Glutathionylation 
1.6.1 Metabolism 
Two key enzymes participating in energy metabolism pathways that are modified by 
glutathionylation are Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and -
ketoglutarate dehydrogenase complex (KGDHC) (reviewed in [27, 134]. GAPDH, a 
glycolytic enzyme was shown to be inactivated by glutathionylation in an in vitro 
system. Incubating the protein with hydrogen peroxide further enhanced the extent of 
inactivation. Mitochondrial KGDHC in rat liver was found to be inactivated by 
glutathionylation on exposure to hydrogen peroxide. It was also shown that the 
glutathionylation-dependent inhibition was reversed by glutaredoxin [135]. Other 
metabolic enzymes such as aldolase, triose phosphate isomerase and alcohol 
dehydrogenase have also been reported to be regulated by glutathionylation in yeast 
Saccharomyces cerevisiae in response to oxidative stress [136]. 
1.6.2 Apoptosis 
Post translational modification of proteins including transcription factors, histones and 
intermediary signalling molecules has been shown to interfere with the cell proliferation 
by the activation of apoptotic pathways. A classic example is the disruption of the cell 
cycle via the glutathionylation of PTP1B and Mitogen-activated protein kinase kinase 
kinase 1 (MAP3K1/MEKK1) in response to oxidative stress. PTP1B and MEKK1 have 
been shown to undergo glutathionylation at specific cysteines, which inactivates the 
enzymes causing adverse downstream effects [27, 29]. The thiol modification interferes 
with ATP binding which in turn affects the ability of the kinases to phosphorylate their 
target substrates.  
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Investigations of the glutathionylation of transcription factors and cell signalling 
molecules such as NF-κB, TNF-, p53, GTPase, p21 Ras and Caspase-3 by 
glutathionylation have revealed inhibitory effects on the cell cycle and on the activation 
of apoptotic signalling in response to oxidative stress and cytotoxic agents [27, 137].  
1.6.3 Regulation of calcium ion channels 
The two main calcium channels in muscles are prime targets for glutathionylation under 
oxidative stress. Sarcoplasmic reticulum calcium ATPase (SERCA) and Ryanodine 
receptors (RyR) located in the muscle sarcoplasmic reticulum are highly sensitive to the 
reducing environment generated in the SR even under normal physiological conditions 
[27]. Glutathionylation of these calcium channels adversely affects their activity during 
stressed conditions such as myocardial ischemia resulting in irregular intracellular 
uptake and release of calcium ions and an overall increase in cellular calcium levels 
[138-140].  The reversibility of glutathionylation dependent inhibition of function was 
also demonstrated by these studies  
1.6.4 Redox regulation of epigenetic DNA modifications 
A recently published study identified glutathionylation as an indirect mechanism of 
DNA manipulation via histone modification [141]. The study demonstrated the 
significance of glutathionylation in drug response by establishing a link between histone 
glutathionylation and reversal of resistance to Doxorubicin (Dx) in MCF7/Dx, a 
Doxorubicin-resistant breast cancer cell line. This is the first study to identify 
glutathionylation as a mechanism of histone modification that indirectly introduces a 
novel theory: Is GSTO1-1 translocated into the nucleus to modify nuclear proteins? 
1.6.5 Cytoskeletal remodelling 
Actin is found in abundance in almost all cell types and is heavily glutathionylated 
under normal conditions [27, 69]. The glutathionylation of actin plays a significant role 
in cytoskeletal organization that occurs during cell division and cell adhesion. 
Remodelling involves the polymerization of actin into filaments and the disassembly of 
actin-myosin complexes during adhesion, both of which are modulated by 
glutathionylation (reviewed in [27, 134].  The thiol modification of specific cysteine 
residues was also found to regulate the contractile activity of actin in the cardiac muscle 
during ischemic attacks.  Paradoxically, oxidative stress induced by artificial agents in 
vitro was found to deglutathionylate actin in A-431 cancer cells affecting actin 
polymerization during cell division [69]. 
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1.6.6 Inflammation 
Many diseases are modified by inflammation and glutathionylation appears to modify 
the function of many proteins involved in inflammatory pathways. The functional role 
that glutathionylation plays in several diseases exacerbated by inflammation such as 
diabetes, Alzheimer’s disease, cardiovascular diseases, atherosclerosis and cancer is 
well elucidated [27, 53, 75, 142-146]. The anti-microbial activity of reactive species 
generated excessively in response to the presence of pathogens is well-documented 
[147-150]. The cytosolic source of ROS in phagocytic cells such as macrophages has 
been attributed to the activity of the family of NADPH oxidases [149, 150]. The 
functional implications of ROS mediated glutathionylation of proteins involved in 
inflammatory responses may be the missing link between oxidative stress and 
inflammation. A few examples of the modulation of inflammation by glutathionylation 
of specific proteins are presented below: 
a. Regulation of chemotaxis: The myeloid related proteins S100A8 and S100A9 are 
calcium-binding proteins that belong to the S100 family of pro-inflammatory proteins 
[151, 152]. They are abundantly expressed in phagocytic cells such as neutrophils and 
monocytes. Both proteins are considered as markers of acute inflammation and are 
secreted extracellularly during pro-inflammatory responses [153]. The pro-
inflammatory activity of neutrophils stimulated by S100A8/A9 is initiated by the 
association of S100A8 and S100A9 and subsequent polymerization with actin in 
response to increased calcium levels [153]. This in turn enhances the adhesion and 
chemotaxis ability of neutrophils. The oxidative burst occurring in activated neutrophils 
is sufficient to induce the glutathionylation and inhibition of S100A9 [154]. The 
complex calprotectin, formed by the association of S100A8/A9, is required for the 
adhesion of neutrophils to fibronectin on activation. The increased ROS has been shown 
to induce the glutathionylation of S100A9 alone which in turn prevents the adhesion of 
neutrophils to endothelial cells by inhibiting the oxidation and oligomerization of 
S100A8/A9 in response to increased ROS. On the other hand, induction of glutaredoxin 
by inflammatory stimuli has been reported by several studies [21, 61, 62, 64, 75] which 
suggests that glutaredoxins are required to maintain the redox state of proteins under 
different inflammatory stimuli. More recently, Bowers et. al (2012) have demonstrated 
the inhibitory effect of Sulfiredoxin-mediated glutathionylation of S100A4 resulting in 
the disruption of the interaction of S100A4 with cytoskeletal component non-muscle 
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myosin (NMIIA) [155]. The inability of S100A4 to interact with NMIIA was shown to 
impact cytoskeletal remodelling and consequently cell adhesion and migration. 
ROS produced in immune cells is also responsible for the increased glutathionylation 
measured by this study and in previously published studies. NOX4-mediated ROS 
caused an increase in the global levels of protein glutathionylation in monocytes treated 
with a combination of LDL and high concentrations of D-glucose [156]. The study 
identified actin as a target of ROS induced glutathionylation which in turn acts as a 
priming agent accelerating chemotaxis in metabolically stressed monocytes, suggesting 
a novel role for actin glutathionylation in metabolic disorders associated with increased 
atherogenesis [156, 157]. MAP kinase phosphatase-1 (MKP-1), another key protein 
involved in monocyte migration, is similarly glutathionylated in response to 
intracellular ROS [74]. Glutathionylation of both actin and MKP-1 enhance adhesion 
and migration of monocytes in response to metabolic stress. The ratio of F-actin to G-
actin was also reduced by metabolic stress in unstimulated monocytes, an effect that 
was further enhanced by MCP-1 stimulation as a consequence of increased 
glutathionylation of actin [74, 157].  
b. TNFα signalling in macrophages: Activation and differentiation of the murine 
monocytic M1 cell line by IL-6 has been shown to induce expression levels of 
glutaredoxin which correlated with increased phagocytosis in the cell line [158]. A 
recent study published by Salzano et al. elegantly demonstrated the glutathionylation 
and consequent secretion of peroxiredoxin by activated macrophages [159]. 
Glutathionylation was shown to be essential for the secretion of Prdx which in turn 
induced the secretion of TNFα in the macrophages.  Prdx was co-released along with 
thioredoxin, raising the speculation that this system was in place to maintain the 
oxidation/reduction of cell surface receptors such as the Toll like receptors (TLRs). The 
recruitment and activation of several intermediates in the TLR signalling pathways in 
immune cells have been shown to be influenced by the redox state of the signalling 
proteins [61, 118, 129, 160]. TLRs mediate pro- and anti-inflammatory responses on 
activation via signalling cascades that require the recruitment and association of 
intermediate proteins, most of which are shared among the members of the TLR family 
(13 in mammals) [161-163].  
c. Inhibition of NF-κB dependent transcription of inflammatory genes: Inflammatory 
responses mediated by TLRs result in the activation of the master regulator of 
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inflammatory genes, NF-κB by phosphorylation of its subunits p65 and p50 and 
subsequent nuclear translocation of the subunits in order to activate the transcription of 
inflammatory genes such as IL-6, TNFα, IL-1β, NADPH oxidase,etc [164-167]. The 
glutathionylation of NF-κB p50 subunit was shown to inhibit DNA binding by NF-κB 
[119]. The glutathionylation of upstream IKK complex subunit IKKβ has also been 
shown to modulate its ability to phosphorylate NF-κB in lung epithelial cells, which 
was reversible by glutaredoxin [118].  
d. Modulation of TLR4 signalling: The downstream recruitment and activation of TNF 
receptor-associated factor 6 (TRAF6) is essential for LPS stimulated signalling via 
TLR4/IL-1R in macrophages and B-cells [168]. On LPS stimulation, TRAF6 undergoes 
K63-linked auto-polyubiquitination which is required for the downstream protein-
protein interactions leading to the activation of NF-κB [61]. Under physiological 
conditions, TRAF6 remains glutathionylated and inactive. When stimulated with LPS, 
TRAF6 undergoes glutaredoxin-1 catalysed deglutathionylation and subsequent auto-
polyubiquitination and activation. However, the identity of the cysteine(s) was not 
further investigated.  
e. Doxorubicin induced protein glutathionylation: Treatment of human monocyte-
derived macrophages with the anti-cancer drug doxorubicin resulted in an increase in 
global glutathionylation levels before causing cell death [169]. Knocking down 
glutaredoxin aggravated cell death in the macrophages, suggesting that the regulation of 
deglutathionylation by glutaredoxins is necessary to maintain the increased 
glutathionylation levels in response to doxorubicin [169].  Interestingly, macrophage 
dysfunction was reported in adriamycin treated mice though the glutathionylation 
profile in affected tissues was not investigated [170].  
f. Regulation of NOD-like receptor family pyrin domain containing 3 (NLRP3) 
inflammasome complex activity: The redox protein thioredoxin interacting protein 
(TXNIP) was shown to disassociate from thioredoxin and directly interact with NLRP3, 
activating the formation of the NLRP3 inflammasome complex though subsequent 
studies could not validate this finding further [171]. Caspase 1, a component of the 
NLRP3 inflammasome complex and a cysteine protease responsible for the proteolytic 
activation of IL-1β is inactivated by glutathionylation induced by excessive ROS on 
LPS stimulation [160]. Since NLRP3 activation plays a prominent role in obesity 
induced inflammation and insulin resistance [172], the modulation of Caspase-1 
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glutathionylation may provide a novel therapeutic avenue for potential anti-
inflammatory drugs. The direct functional implications of protein glutathionylation on 
different proteins and inflammatory pathways has been extensively reviewed previously 
[142]. A more detailed discussion of previously published findings that are directly 
relevant to this study is presented in Chapter 9.  
 
1.7 Clinical avenues for drug development 
Nov-002 is a mimetic of GSSG in a complex with cisplatin designed to manipulate the 
redox homeostasis in cancer cells by targeting the endogenous GSSG/GSH pool and 
glutathione transferases [173]. Nov-002 is primarily designed for the treatment of non-
small cell lung cancer (NSCLC) [174, 175]. Initial rounds of clinical trials revealed the 
unanticipated effect of Nov-002 on the bone marrow [175, 176]. Preliminary trials 
showcased improved tolerance of anti-cancer drugs when administered in combination 
with Nov-002 [174] but in a study which recruited 903 patients with non-small cell lung 
cancer in 12 countries, Nov-002 along with standard chemotherapy failed to improve 
overall survival rates. 
TLK199, a peptidomimetic inhibitor of GSTP was found to cause unexpected 
myeloproliferation in rodents [110]. GSTP, apart from its detoxification activity, 
partakes in protein-protein interactions. The drug induced myeloproliferation was later 
identified to be due to the interaction of GSTP with pro-apoptotic protein, c-Jun N-
terminal kinase (JNK) [110, 111].  
 
1.8 Glutathione transferases (GSTs) 
Glutathione transferases (EC 2.5.1.18) are members of a superfamily of detoxification 
enzymes that predominantly catalyse Phase II conjugation reactions (reviewed in [108, 
177-180]). Although some GSTs were known to occur, a Carcinogen binding protein 
‘ligandin’ was studied independently as an all-substrate binding protein, owing to its 
ability to bind to various non-substrate ligands including steroids, bilirubin and heme 
[181-184]. The two proteins were later shown to be identical [185-193]. GSTs were 
then revealed to encompass a superfamily of proteins with demonstrated substrate 
specificities and detoxification independent activities [177-180, 194-197].  
The predominant functions of most, if not all GSTs, centre on their potential to 
recognize and bind glutathione in their active centres. GSTs constitute approximately 
10% of the cellular protein pool in rat liver cytosol. GSTs have been extensively studied 
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for their catalytic role in the detoxification of electrophilic compounds and in the 
removal of endogenously produced free radicals (reactive oxygen and nitrogen species) 
via their glutathione peroxidase activity [195, 198].  GSTs conjugate non-polar 
compounds including drugs, pesticides and other xenobiotics carrying electrophilic 
centres (carbon, nitrogen, sulphur) to glutathione, forming water-soluble GSH-
conjugates that are either readily transported out of the cell via membrane bound MRP 
efflux pumps or further metabolised to mercapturic acids and excreted in the kidney. 
Over the years, advances in GST research have revealed a multitude of substrates 
specific to individual GST classes (refer [195] and our recent review [180] for a detailed 
description). While some GSTs catalyse the cis-trans isomerization reactions in the 
synthesis of steroid hormones, prostaglandins and conversion of maleylacetoacetate 
(MAA) to fumarylacetoacetate (FAA), others play a regulatory role in switching on cell 
signalling pathways [89, 110, 199-204]. A relatively new class of GSTs called Chloride 
Intracellular channel proteins discovered due to sequence and structural similarity with 
GSTs were found to embed into membranes, forming and modulating membrane-bound 
ion channels [138, 202, 205, 206]. While GSTs were shown to modulate Ryanodine 
receptors in vitro, the finding that GSTM2-2 is a potent inhibitor of the cardiac 
ryanodine receptor offers therapeutic avenues to reduce or reverse abnormal channel 
activity in cardiovascular conditions [199, 207-209]. The Omega class GSTs, 
considered an atypical class, were shown to exhibit significant thiol transferase and 
dehydroascorbate reductase activity owing to their active site cysteine and have been 
implicated in neurodegenerative diseases and cancer [113, 210-217].  
 
1.8.1 Evolution of GSTs 
Human cytosolic GSTs (cGSTs) comprise nine classes listed in Table 1.1, that have 
been categorized on the basis of their sequence similarity and to some extent their 
common substrate specificities. cGSTs share approx. 40% sequence similarity within a 
class and over 25% similarity among classes [194, 218]. 
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Protein Class 
Chromosome 
location 
Gene 
GSTA1-1 – GSTA5-5 Alpha (A) 6p12.2 GSTA1-GSTA5 
GSTM1-1 – GSTM5-5 Mu (M) 1p13 GSTM1-GSTM5 
GSTP1-1 Pi (P) 11q13 GSTP1 
GSTZ1-1 Zeta (Z) 14q24.3 GSTZ1 
GSTO1-1 – GSTO2-2 Omega (O) 10q24.3 GSTO1-GSTO2 
GSTT1-1 – GSTT2-2 Theta (T) 22q11.2 GSTT1-GSTT2 
GSTS1-1 Sigma (S) 4q22.3 GSTS1 
CLIC1-CLIC5 
Chloride 
Intracellular 
Channel 
6p21.33 
Xq28 
(CLIC2) 
CLIC1-CLIC5 
GDAP 
Ganglioside induced 
differentiation-
associated protein 
8q21.11 
GDAP1 
 
 
1.8.2 Functions of GSTs 
a. Drug metabolism 
GSTs have been extensively studied for their catalytic role in detoxification of 
xenobiotic compounds including but not limited to anti-cancer drugs and for their role 
in the removal of endogenously produced free radicals via their glutathione peroxidase 
activity (reviewed in [108, 180, 195, 219, 220]). Members of the superfamily of 
enzymes catalyse the conjugation of glutathione to exogenous and endogenous 
electrophilic substrates (Figure 1.6). Apart from their well-established functions, many 
GSTs have specific functions exclusive to their class and to individual members.  
 
Table 1.1: Classification of human glutathione transferases  
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b. Prostaglandin and steroid hormone synthesis 
Testosterone and progesterone are two steroid hormones synthesized from a common 
precursor, 3β-hydroxy-5-pregnene-20-one (cholesterol) via a series of isomerization and 
oxidation reactions. The isomerization of intermediate 3-keto-Δ5-steroid metabolites 
was predicted to be catalysed by 3 β-hydroxy steroid dehydrogenase though in vitro 
studies suggest that GSTA3-3, expressed specifically in steroidogenic tissues such as 
the testes, adrenal glands and liver, exhibits significantly higher isomerization activity 
compared to the former [221].  
Several cytosolic GSTs including GSTA1-1, GSTA2-2, GSTM2-2, GSTM3-3 and 
members of the microsomal class (MGST1, prostaglandin E synthase (PGE2 synthase)) 
have been associated with prostaglandin metabolism [196, 201, 203]. The growth 
inhibitory properties of Prostaglandin A2 (PGA2) was found to be independent of the 
cellular glutathione in murine L-1210 cells [222] while contradicting data by Atsmon et 
al. suggest the cellular glutathione dependent regulation of the anti-proliferative 
property of prostaglandin J2 (PGJ2) in Chinese hamster ovary and hepatoma cells [223, 
224]. The stereo-selective conjugation of PGA2 and PGJ2 with GSH is differentially 
catalysed by GSTA1-1 (R-GSH conjugate selective), GSTA2-2, GSTM1a-1a and 
GSTP1-1 (S-GSH conjugate selective), [203]. A direct consequence of the GST-
dependent prostaglandin metabolism may be associated with the high proliferative 
Figure 1.6: Glutathione conjugation reaction catalysed by glutathione transferases 
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property of tumour cells. Over expression of GSTs is common in tumours, especially 
GSTP1-1 and the subsequent increased conjugation of PGA2 and J2 by GSTs may 
stimulate proliferation.  
Microsomal PGE2 synthase was primarily identified as the predominant enzyme 
catalysing the synthesis of PGE2 from precursor PGH2. However, GSTM2-2 and 
GSTM3-3 (expressed in the brain) have been identified as cytosolic PGE2 synthases, 
capable of catalysing the formation of PGE2 from PGH2 [201]. This finding could 
potentially bear functional relevance with respect to the regulation of brain dependent 
activities including temperature control [201].   
GSH-dependent Prostaglandin D2 synthase (GPDS), identified as the only member of 
the sigma class of GSTs in vertebrates has been shown to possess a unique structural 
‘cleft’ at its active site responsible for its catalysis of the isomerisation of prostaglandin 
H2 (PGH2) to prostaglandin D2 (PGD2) [196, 225]. GST involvement has also been 
reported further downstream in the formation of 15d-PGJ2 and its elimination via 
conjugation with GSH [203].   
c. Tyrosine/Phenylalanine degradation pathway 
GSTZ1-1, identical to maleylacetoacetate isomerase catalyses isomerization of 
maleylacetoacetate (MAA) to fumarylacetoacetate in the tyrosine catabolism pathway 
[204]. Catalysis by GSTZ1-1/MAAI is inhibited by the isomers, maleyloacetoacetate 
and fumarylacetoacetate via a feedback loop mechanism [204, 226]. Additionally, an 
exogenous mechanism based suicide inhibitor of GSTZ1-1 was found in dichloroacetate 
(DCA), a common contaminant in drinking water that is metabolized to glyoxylate by 
GSTZ1-1 [226-228].  At high levels DCA is a reported carcinogen in rodents but it is 
not considered to be carcinogenic in humans and is used currently in the treatment of 
lactic acidosis [227, 229]. Several studies report the anti-cancer and pro-apoptotic 
properties of DCA and thus characterizing the metabolism of the drug is of prime 
importance [230-233]. The functional implications of GSTZ1-1 have been previously 
reviewed in [177, 178]. 
Although these animals experience constitutive oxidative stress marked with depletion 
of the cellular GSH pool and lower GSH synthesis capacity Gstz1 knockout mice 
(Gstz1
-/-
) were shown to have no acute health issues indicating a non-enzymatic bypass 
in the tyrosine degradation pathway, [204, 219, 234]. The knockout mice were shown to 
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follow a phenotype consistent with the accumulation of toxic intermediary metabolites, 
however no detrimental effects like those reported with deficiencies of other upstream 
and downstream enzymes in the tyrosine catabolism pathway [204, 219, 234]. 
Deficiency of GSTZ1-1 was also shown to upregulate the expression of other GSTs 
including GSTP1/2 and GSTM via the activation of the oxidative stress responsive 
Keap/Nrf2 transcriptional regulation [219]. Gstz
-/-
 mice undergo constitutive oxidative 
stress which was further exacerbated along with the induction of severe leucopenia 
when treated with dietary phenylalanine [219, 235]. GSTZ1-1 inactivation in normal 
mice with DCA resulted in the accumulation of the intermediate MAA though failed to 
elicit any significant leucopenia in response to dietary phenylalanine [235].  
d. Signal transduction 
Several GSTs have been shown to be differentially expressed in tumours including non 
small cell lung (NSCLC), ovarian and prostate [110, 200, 236]. High levels of GSTP 
have often been shown to correlate with the heightened drug resistance observed in 
ovarian, NSCLC, breast, colon and lymphomas [237]. Although initial reports 
suggested the detoxification of anti-cancer drugs by GSTP to be solely responsible for 
the conferred resistance, several lines of evidence indicate otherwise. GSTP is a potent 
inhibitor of signalling molecules such as Jun Kinase (JNK), Apoptosis signal-regulating 
kinase 1 (ASK1) and recently reported TRAF2 via conjugation independent protein-
protein interactions [20, 22, 238-240]. In particular, many drugs for which GSTP 
mediated resistance has been invoked are in fact poor substrates for glutathione 
conjugation by GSTP. However, the ability of GSTP to regulate kinase pathways such 
as the Jun-Kinase pathway, indirectly manipulating survival and/or apoptotic signals has 
been hypothesized to be responsible for the observed drug resistance [238]. Under 
physiological conditions, a portion of GSTP exists bound to JNK, thus keeping basal 
levels of JNK in check (Figure 1.7). On sensing excess ROS generation following drug 
administration, GSTP1 dissociates from JNK and accumulates in the form of oligomers 
in the cytosol. The release of JNK triggers a cascade of signalling events starting with 
the activation of Jun-c via phosphorylation leading to proliferation or apoptosis. This 
would justify the correlation observed between increased GSTP expression in 
proliferative tissues such as tumours and survival.  Up-regulation of GSTP in tumours 
would result in the over-sequestration of JNK subsequently altering apoptotic signalling 
pathways and conferring resistance to drug induced cell death. A recent study further 
demonstrated the physiological downstream effects of GSTP1-1 aided inhibition of Jun-
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K on the onset and progression of neurodegeneration in the neurotoxin-based MPTP 
model of Parkinson’s disease [241]. Gstp1/2-/- mice treated with MPTP were found to 
be more susceptible to the neurotoxin resulting in the early onset of degeneration of 
dopaminergic neurons and striatal fibres. The regulation of the tumour necrosis factor-
F- signalling pathway via the activation of TRAF2-enhanced apoptosis signal 
regulating kinase-1 (ASK-1) [113, 242] provides another example of the regulatory 
interactions between GSTP and cell signalling pathways. As illustrated in Figure 1.7, 
GSTP interacts with TRAF2, inhibiting the subsequent activation of JNK and p38 
induced apoptotic signalling. Additionally, GSTP hinders the interaction of TRAF2 
with ASK1, impeding TRAF2-ASK-1 induced downstream pro-apoptotic signalling 
(Figure 1.7).  
GSTA1-1 is another GST shown to regulate apoptotic signalling pathways via direct 
protein-protein interaction with JNK [243, 244]. GSTA1-1 over expression was shown 
to attenuate the Doxorubicin dependent depletion of glutathione in H69 (a small cell 
lung cancer cell line), reducing the extent of lipid peroxidation [244]. Overexpression of 
GSTA1-1 significantly decreased the number of cells undergoing apoptosis via the 
inhibition of JNK-dependent c-Jun phosphorylation, caspase-3 activation and by 
maintaining Bcl-2 expression levels. The ability of GSTM1-1 in carrying out similar 
regulatory functions has been shown previously. The association of GSTM1-1 with 
ASK1 is critical in maintaining the basal levels of downstream phosphorylation targets 
including stress responsive protein kinase p38 (Figure 1.8). Stress triggers such as heat 
shock promoted the dissociation of GSTM1-1 from ASK1, resulting in the activation of 
ASK1 and the phosphorylation-dependent activation of p38 [245]. On the contrary, a 
recent study reported the suppression of JNK phosphorylation, a mechanism common to 
Gstp1/2
-/-
 mice, and the subsequent inhibition of downstream pro-apoptotic targets in 
GSTM1-1 knockout mice though the exact mechanism is not well elucidated [240, 246]. 
Unlike Gstp1/2
-/-
 mice, constitutive phosphorylation/activation of ASK1 downstream 
target, MKK4 was undetectable in both wild type and Gstm
-/-
 mice [240]. However, on 
treatment with Acetaminophen (APAP), phosphorylated MKK4 and downstream target 
JNK were induced in the wildtype mice alone. The absence of JNK activation is 
suggestive of the inability of ASK1 to activate intermediary MKK4 in Gstm
-/-
 mice 
though the link between inhibition of JNK activity and APAP induced hepatotoxicity is 
speculative. The role of cytosolic GSTs in the regulation of cell signalling kinases is 
clearly of major significance and requires further investigation.  
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Figure 1.7: The signalling role of GSTP: Under normal non-stressed conditions, 
JNK and Jun-c are sequestered in an inactive complex with GSTP. Exposure of the 
cell to a range of stresses can change the redox potential in the cell causing the 
dissociation of the complex and oligomerization of GSTP. JNK can then be 
phosphorylated, subsequently leading to the activation of downstream kinases.  
Similar interactions between GSTP and TRAF2 inhibit the downstream actions of   
JNK, p38-MAPK and ASK1.  
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Figure 1.8: The signalling role of GSTM1: GSTM1 and thioredoxin (Trx) can 
reversibly bind to ASK1 and in the presence of oxidative stress modulate its 
oligomerization and autophosphorylation.  Phosphorylation of ASK1 leads to further 
downstream kinase phosphorylation and activation leading to cellular proliferation 
or apoptosis depending on the strength and duration of the oxidative stress.  
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e. Calcium channels 
The regulatory impact on the family of Ryanodine receptors (RyR) is a well-
documented property of GSTs and has been extensively reviewed recently [247]. 
Ryanodine receptors are the major calcium release channels located on the 
endoplasmic/sarcoplasmic reticulum in muscles. Calcium plays a critical role in cell 
signalling pathways as a secondary messenger and in cellular processes such as the 
excitation-contraction coupling required for muscle contraction and relaxation [248]. 
Intracellular calcium reserves are mainly located in the SR/ER and are constantly 
released into the cytoplasm via the membrane bound RyRs, thus maintaining the E-C 
coupling. Disrupting the activity of RyRs results in an imbalance in calcium efflux into 
the cytosol, destabilizing the membrane potential, resulting in the uncoupling of muscle 
excitation from contraction and eventually leading to cardiovascular dysfunction or 
hyperthermia. Deregulation of cardiac RyR (RyR2) is considered a major risk factor for 
developing cardiovascular disorders and therapies targeting the modulation of RyR2 are 
currently in demand [249, 250]. The GSTs, tested so far have opposing effects on the 
cardiac (RyR2) and skeletal ryanodine receptors (RyR1). GSTM2-2 is a potent inhibitor 
of RyR2 while having minimal effect on RyR1, making GSTM2-2 a viable lead for 
drug development towards the treatment of arrhythmias and heart conditions presenting 
with excessive RyR2 activity [208, 209]. Extensive studies on GSTM2-2 have identified 
helix-6 in the C-terminus to be important for its inhibitory action [208, 251].  
GSTO1-1 was found to inhibit RyR2 and activate RyR1 in a concentration dependent 
manner while CLIC2 exhibited inhibitory effects on both RyR1 and RyR2 [202, 205]. 
Detailed interaction studies revealed that GSTO1-1 binds transiently to RyRs via its 
active site cysteine residue (Cys 32). A cysteinealanine mutation (C32A) abolished its 
modulatory effects while the weakness/transience of binding was demonstrated with 
washouts wherein the cytoplasm representative solution was replenished with fresh salt 
solution minus GSTO1-1, attenuating RyR-GSTO1-1 interaction [205]. Interestingly, 
the modulatory effect of CLIC2 was found to be redox sensitive. Altering the redox 
environment on either the cytoplasmic/sarcoplasmic or both by the inclusion of 
GSH/GSSG in varying concentrations resulted in the reversal of RyR2 modulation in 
lipid bilayer experiments [138]. CLIC2 was found to exhibit an inhibitory effect on 
RyR2 under reducing conditions (30:1 GSH:GSSG) while activating the receptor in 
oxidizing environments. On applying a redox potential mimicking physiological 
conditions, CLIC2 dependent channel modulation was found to be insignificant 
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compared to the higher rates measured in similar redox conditions minus CLIC2.  The 
redox-dependent modulation of RyR by other GSTs offers an interesting avenue yet to 
be explored.  
1.9 Significance of GSTs 
1.9.1 In cancer 
The two major drawbacks encountered with most anti-cancer therapies are acquired 
drug resistance and relapse. Acquired drug resistance may be attributed to several 
factors including upregulation of multidrug resistance proteins, drug metabolizing 
enzymes such as Cytochrome P450s, GSTs and inefficient intracellular uptake of 
administered drugs. The association of GSTs with acquired resistance may be sourced 
back to their two distinct activities - the classic conjugation reaction of xenobiotics with 
GSH and/or through the regulation of apoptotic signalling pathways discussed earlier. 
GSTP1/2 has consistently been associated with tumor progression and drug response. 
GSTP expression levels were found to be significantly upregulated in most tumor 
models and in vivo tumour tissues [236, 237, 239, 240, 252]. Conversely, reduced 
expression of GSTP1 in prostate tumors is considered a marker for tumor progression. 
However, the poor substrate affinity of GSTP for most anti-cancer drugs fails to account 
for the observed over expression with drug resistance in both tumors and cancer cell 
lines selected for resistance. Over expression of GSTP and MGST1, a member of the 
MAPEG family, have been detected in cancer cell lines resistant to cisplatin, 1,3-bis(2-
chloroethyl)-1-nitrosourea (BCNU), Cyclophosphamide, Chlorambucil and Melphalan 
[113, 220, 253-255]. GSTT1-1 and GSTA1-1 have been linked to increased intrinsic 
resistance in vitro. GSTT1-1 and GSTA1-1 exhibit high substrate affinities for BCNU 
and chlorambucil respectively, which may explain their resistance dependent over 
expression [256, 257]. GSTO1-1 was shown to be over expressed in a mouse lymphoma 
cell line that was resistant to multiple chemotherapeutic agents [258]. A similar study 
on an ovarian cancer cell line suggested the association of acquired resistance to 
platinum based anticancer drugs with over expression of GSTO1-1 [259]. Furthermore 
the artificial over expression of GSTO1-1 was shown to confer resistance to cisplatin 
induced cytotoxicity in HeLa cells in a concentration dependent manner [260]. Due to 
the inefficient metabolism of exogenous substrates by GSTO1-1, the possibility of 
GSTO1-1 driven cisplatin metabolism was ruled out. Alternately, aberrations in cell 
survival and apoptotic pathways were investigated which identified the activation of 
Akt and ERK1/2 dependent survival signalling cascades and the inhibition of JNK 
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phosphorylation dependent apoptotic signalling in GSTO1-1 transfectants, albeit a 
direct link was not demonstrated [260]. 
 
1.9.2 In neurodegenerative diseases 
The over expression of GSTO1-1 and its allelic polymorphic variants have been 
implicated in the age of onset and progression of neurodegenerative disorders such as 
Alzheimer’s and Parkinson’s diseases but no direct mechanism for these associations 
has been identified [210-212, 214, 215]. More recently, Kim et al. identified ATP 
synthase β subunit as an in vivo interacting partner of GSTO1-1 in a Drosophila model 
of Parkinson’s Disease (loss of function mutation in the parkin gene), capable of 
modulating membrane bound ATP synthase activity [261].  
  
The ability to recognize glutathione and interact with diverse substrates place 
glutathione transferases central to the regulation of redox sensitive metabolic pathways 
and cellular processes including oxidative stress response, intrinsic drug resistance, 
regulation of kinases in apoptotic signalling and protection of proteins susceptible to 
oxidation via glutathionylation.  
 
1.10 Glutathione transferase Omega 1 
Glutathione Transferase Omega is an atypical GST with minimal functional 
resemblance with the other members of the superfamily [179, 197, 262]. The gene is 
located adjacent to GSTO2 on Chromosome 10q24.3 and spans 1.5kb in length. 
GSTO1-1 was identified as a GST a decade ago due to its close sequence and structural 
similarity with the family and its ability, though minimal, to catalyse classic 
detoxification reactions with common GST substrates. Over the years, several atypical 
functions have been discovered (listed in Table 1.2), which will be discussed in detail in 
the sections to follow. Immunohistochemical studies identified GSTO1-1 in a range of 
diverse tissues with varied expression levels [263].  Though a surprisingly high 
expression level was observed in the heart and liver, the functional implications of the 
tissue-specific distribution are not fully understood. The study also reported the 
interesting subcellular localization of GSTO1-1 in the nucleus and nuclear membrane in 
several tissues. The significance of this unusual nuclear translocation is yet to be 
investigated.  
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The GSTO1-1 dependent regulation of IL-1β resulting from either the direct post 
translational modification of IL-1β or interaction with the inflammasome ASC complex 
offers a potential target pathway to study the deglutathionylating activity of GSTO1-1 
[264, 265]. More recently, Kim et al. identified ATP synthase β subunit as an in vivo 
target of GSTO1-1 in a Drosophila model of Parkinson’s Disease (loss of function 
mutation in the parkin gene) [261]. The transgenic fly model constitutively down-
regulates the expression of GSTO1-1 and glutathionylated form of ATP synthase β 
subunit. Over expression of GSTO1-1 in the parkin mutants was shown to increase 
glutathionylation of ATP Synthase and partially restore enzyme activity. Though the 
study suggests the catalytic role of Drosophila GSTO1-1 in glutathionylation, we 
propose that the deglutathionylating activity of GSTO1-1 may also be physiologically 
significant. 
1.10.1 Atypical functions of GSTO1-1 
GSTO1-1 was previously shown to catalyse the reduction of dehydroascorbate and 
exhibits low thioltransferase activity [262, 266]. These reactions are not catalysed by 
other GSTs but are characteristic of glutaredoxins. The functions unique to GSTO1-1 
are listed in Table 1.2. Recent studies have demonstrated the significance of GSTO1-1 
expression in cell defence mechanisms [260, 264, 267]. A study by Laliberte et al. 
identified GSTO1-1 as a target of Cytokine Release Inhibitory Drugs (CRIDs) and 
hence implicating GSTO1-1 in mechanisms activating proinflammatory Interleukin 1β 
in monocytes [264]. The exact role of GSTO1-1 in this process is yet to be determined 
though a recent study in 2011 identified a novel interaction of GSTO1-1 with ASC 
(Apoptosis associated speck-like protein containing a CARD), a component of the 
inflammasome complex required for the activation of IL-1β production indicating the 
probability of an indirect effect of GSTO1-1 on IL-1β via protein-protein interactions 
within the activation complex [265].  
There are several lines of evidence implicating GSTO1-1 in drug resistance in cell lines 
although no mechanism has been established [258, 259, 268]. Another study 
successfully linked GSTO1-1 over-expression with increased resistance to Cisplatin in 
HeLa cells [260]. On a different note, the redox sensitive regulation of cardiac 
Ryanodine receptor (RyR2) was reported by Dulhunty et al. [269]. Though the 
regulation of ryanodine receptors by GSTs is well established, the presence of cysteine 
at the active site of GSTO1-1 as opposed to Tyr/Ser increasingly questions the exact 
mechanism of RyR regulation by GSTO1-1. The redox sensitivity of GSTO1-1 
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dependent regulation of RyR would be an interesting option to explore with respect to 
determining the ‘mechanism of action’ of GSTO1-1.  
Due to its structural similarity to glutaredoxin and its inability to recognize and strongly 
bind to typical GST substrates, we believe that its primary function is yet to be defined. 
Based on recent findings, my project proposes that GSTO1-1 may regulate a variety of 
proteins irrespective of their function via a common mechanism. The relevance of this 
hypothesis to my project is further elaborated in the following sections. 
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Cell/Tissue/Animal 
model 
Functional implications Reference 
Monocytes Activation of IL-1β [264],[265] 
T47-D breast cancer cells, 
rat hepatic cytosol 
Reduction of  
S- (phenacyl)glutathiones 
[270, 271] 
HeLa Resistance to Cisplatin [260] 
Humans Delay in onset of neurodegenerative 
diseases such as Parkinson’s and 
Alzheimer’s diseases 
GSTO1-1 is implicated in Chronic 
obstructive pulmonary disease. Lower 
levels of GSTO1-1 reported in COPD 
patients when compared to non-
smokers. 
[214-216, 
272] [213] 
Calcium channels in lipid 
bilayers 
Regulation of cardiac Ryanodine 
receptor RyR2 
[269] 
Caenorhabditis elegans Participates in cellular response to 
oxidative stress   
[267] 
BALB/c and C57BL/6 
mice 
Up-regulation on induction of allergic 
airway disease. Antioxidant properties 
speculated as cause of up-regulation 
[273] 
Gsto1 knockout mice 
(Gsto1
-/-
) 
Reduction of Monomethylarsenate, 
Dimethylarsenic acid in the 
biotransformation of inorganic arsenic 
[274, 275] 
 
 
 
Table 1.2: Functional significance of Glutathione transferase Omega 
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1.10.2 GSTO1-1 and Glutathionylation 
The crystal structure of GSTO1-1 is suggestive of a novel role of GSTO1-1 in 
glutathionylation, atypical of the superfamily. GSTO1-1 possesses the typical GST fold 
comprising of the N-terminal ‘thioredoxin’ resembling domain embedding the GSH 
binding site and the C-terminal helical domain [262]. As mentioned earlier, most GSTs 
possess a tyrosine or serine residue at their active site, responsible for catalysing 
conjugation reactions between GSH and electrophilic substrates. The active site residue 
in GSTO1-1 was identified as cysteine (Cys 32) flanked by proline and phenylalanine 
uncharacteristic of other mammalian GSTs [262]. On detailed dissection of the crystal 
structure, the active cysteine (Cys 32) was found to form a disulphide bond with GSH, a 
feature that is characteristic of glutaredoxin. Additionally, the GSH binding site is 
interestingly positioned in a wide crevice that can potentially accommodate large 
substrates such as proteins, suggesting potential interactions with molecules apart from 
GSH [197].  
Due to the structural diversity at the substrate-binding site among the members of the 
GST superfamily and their ability to bind to GSH, it was hypothesized that the enzymes 
may be involved in protein-protein interactions leading to downstream effects. The 
enzymatic glutathionylation of proteins in vitro by GSTP1-1 was recently demonstrated 
by Townsend et al. using actin as an in vitro substrate [20]. However, it is yet to be 
determined whether other GSTs participate in the glutathionylation cycle.  
This section attempts to summarize the literature on GSTO1-1 and justify the relevance 
of this information to the main objective of my project. There is increasing evidence for 
the physiological significance of GSTO1-1 in cellular defence mechanisms. Most GSTs 
are up-regulated by oxidative stress but the uniqueness of the structure of GSTO1-1 
with respect to its active site suggests a novel role for this enzyme in physiological and 
oxidative stressed environments. The close structural resemblance of GSTO1-1 with 
Glutaredoxin, summarized in Table 1.3 supports the possibility that GSTO1-1 may 
catalyse glutaredoxin like activities.  
Previous data from our laboratory confirm the thioltransferase activity of GSTO1-1 with 
chemical substrates such as 2-Hydroxyethyl disulphide (HEDS) [275]. Preliminary data 
from my project take this one step further and demonstrates the deglutathionylation of a 
glutathionylated cysteine residue in an 8-mer peptide and GSTO1-1 in vitro. This 
observation provides experimental evidence supporting a novel catalytic role of 
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GSTO1-1 in the deglutathionylation of proteins. In 2006, Sulfiredoxin was identified as 
a novel regulator of redox sensitive protein modification with the ability to 
deglutathionylate proteins [29]. Although the protein shares structural resemblance to 
the glutaredoxin family of enzymes, the catalytic cys-99 responsible for the 
thioltransferase activity is not conserved between the protein and Grx members. The 
cys-99 residue is instead in alignment with the non-conserved cysteine residue in Grx5 
which is known to possess deglutathionylating activity. In the case of GSTO1-1, Cys 32 
is conserved with the catalytic cysteine in Grx, a finding favouring the hypothesis 
underlying this study. Moreover, sulfiredoxin over-expression was demonstrated to 
regulate cell proliferation and drug response in vitro via the manipulation of proteins 
involved in regulating the cell cycle [25]. This study has encouraged me to question the 
possibility that GSTO1-1 may play a role in cell cycle modulation and drug resistance 
given that deglutathionylation is a common mechanism with the potential to influence 
global cell signalling.  
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Structural/functional 
characteristics 
Glutaredoxin GSTO1-1 
Thioredoxin fold-like structure + + 
Active site cysteine residue Two catalytic cysteine 
residues 
One catalytic cysteine 
residue conserved with 
glutaredoxin 
Glutathionylation activity Catalyses both 
glutathionylation and 
deglutathionylation 
To be characterized 
(Recently published study 
indicates demonstrates the 
glutathionylating activity 
of GSTO1-1 in 
Drosophila while data 
from our lab suggest 
deglutathionylation by 
GSTO1-1) 
Thioltransferase activity ++ + 
Dehydroascorbate reductase 
activity 
++ + 
Ability to accommodate large 
substrates such as proteins in the 
active site 
++ ++ 
 
Table 1.3: Comparison of the characteristic features of glutaredoxins and GSTO1-1 
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1.11 Inflammation 
Innate immunity is considered as the first line of defence against invading pathogens in 
mammalian cells. Immune cells mediating innate immune responses such as 
macrophages, neutrophils and dendritic cells express pathogen recognition receptors on 
their surface (PRRs) that recognize bacterial components and DNA, collectively called 
Pathogen Associated Molecular Patterns (PAMPs) [161, 276]. Based on their structural 
characteristics and ligand specificity, PRRs may be further classified into three distinct 
classes of receptors: cytosolic C-type lectin receptors, membrane bound Toll like 
receptors (TLR) and cytosolic NOD (nucleotide-binding oligomerization domain) like 
receptors [276]. Of the 11 TLRs identified across mammalian cells, TLR4 is highly 
expressed in macrophages and mediates inflammatory responses when in contact with 
bacterial cell wall component, lipopolysaccharide (LPS) or nickel metal ions [277].   
In macrophages, activation of TLR4 by LPS has been shown to recruit downstream 
signalling proteins and induce the generation of reactive oxygen species (ROS) and pro-
inflammatory cytokines such as IL-1β (Figure 1.9) [162, 278-281]. In addition to their 
bactericidal activity, their signalling role and their impact on the expression of pro-
inflammatory cytokines, the ROS generated by the TLR4 pathway have also been 
shown to cause tissue damage and are central to the progression and pathology of many 
inflammatory diseases [280]. TLR signalling is regulated at various levels to maintain a 
tightly monitored inflammatory response against pathogen infection. Regulatory 
mechanisms at the transcriptional level by microRNAs and at the proteomic level by 
post-translational modifications of proteins involved have been shown to play important 
roles in the activation and maintenance of TLR signalling [161, 163]. Redox 
modifications of proteins partaking in TLR4 signalling have been discussed in detail in 
Chapter 9. 
The secretion of IL-1β requires the activation of two parallel pathways (Figure 1.9): 
TLR4-dependent activation of transcription of pro-IL-1β and recruitment of the NLRP3 
inflammasome. Transcription of pro-IL-1β is switched on by NF-κB which requires the 
activation of a cascade of intermediate signalling molecules on TLR4 activation by 
lipopolysaccharide (LPS) [278, 282-284]. A simultaneous potassium efflux into the cell 
signals the recruitment of the NLRP3 inflammasome complex comprising NLRP3, ASC 
and Procaspase-1. Procaspase1 is cleaved to its active form, Caspase-1 which 
subsequently cleaves pro-IL-1β into mature IL-1β.  
Chapter 1 
43 
 
The role played by ROS in the parallel activation of the NLRP3 inflammasome is still 
not clear and there is considerable controversy about if and how ROS acts as a direct 
stimulus for NLRP3 activation [161, 283]. Cytosolic ROS generated by the activity of 
NADPH oxidases was previously shown to activate the recruitment and formation of 
the NLRP3 complex [285]. This directed curiosity towards the possible redox 
modifications that proteins within and downstream of the NLRP3 inflammasome 
complex may be undergoing in the presence of ROS. However, subsequent studies on 
macrophages derived from NADPH oxidase deficient mice demonstrated normal 
NLRP3 function, indicating that NADPH oxidase dependent ROS may not be the 
source of ROS-mediated activation of NLRP3 [285, 286].  
Following these observations, focus was drawn to the generation of mitochondrial ROS 
and the role it plays in priming NLRP3. It is now clear that mitochondrial ROS can act 
as a stimulus for NLRP3 activation and the subsequent secretion of IL-1β in the 
presence of an appropriate TLR stimulus (LPS) [284, 287-289]. A recent study has 
further extended the consequences of mitochondrial ROS to other TLRs such as TLR3.  
It is yet to be fully understood whether ROS directly primes NLRP3 alone or whether it 
modulates proteins downstream of the multiple pathways activated during inflammatory 
responses in macrophages. One of the downstream effects activated in macrophages is 
their ability to phagocytose invading microbes, which has been considered as a 
reasonable marker to investigate the extent of TLR signalling inhibition by synthetic 
drugs [290, 291]. In addition, the role of antioxidants in NLRP3 inflammasome function 
has also been investigated, suggesting the need for a fine balance between the 
generation of oxidants and the expression of counteracting antioxidants in order to 
maintain inflammatory responses [149, 160, 292]. As described in section 1.7.6, 
macrophages deficient in superoxide dismutase 1 (SOD1) were found to have increased 
ROS and low inflammasome activity due to the inactivation of caspase 1 by the rapid 
oxidation of susceptible cysteines which is prevented in SOD1 expressing cells by 
glutathionylation [160]. The effects of redox catalysts such as the glutaredoxins have 
also been shown to modulate the phagocytic efficiency of neutrophils, and redox post 
translational modifications of proteins as one of the key regulatory mechanisms in place 
in phagocytic immune cells [293].  
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1.12 Investigating the biological role of GSTO1-1 
At the start of these studies it was known that GSTO1-1 catalysed reactions that are 
similar to those catalysed by the glutaredoxins and it was suspected that it may 
contribute to protein glutathionylation.  In addition, there was evidence suggesting that 
GSTO1-1 had a role in the release of IL-1β.  Genetic variation in GSTO1-1 had also 
been associated with a range of unrelated clinical disorders such as Alzhemier’s disease, 
COPD, Parkinson’s disease and cancer suggesting that GSTO1-1 may be mediating its 
effects through a common process that contributes to the pathology and progress of 
multiple disorders. With this prior knowledge the following hypothesis and aims were 
proposed.  
Hypothesis 
 
GSTO1-1 regulates proteins and their biological functions by catalysing the 
glutathionylation cycle and modulates proteins involved in inflammatory signalling in 
macrophages. 
 
Aims 
 To investigate glutathionylation and/or deglutathionylation reactions catalysed 
by GSTO1-1  
 To identify protein targets of GSTO1-1 catalysed glutathionylation or 
deglutathionylation 
 To determine whether GSTO1-1 is a redox modulator of pro-inflammatory 
responses in macrophages 
The results obtained from these experiments led to the development of further aims: 
 To expand the development of GSTO1-1 inhibitors as anti-inflammatory agents 
in vitro 
 To investigate the effect of GSTO1-1 deficiency on the development of the 
glycolytic phenotype of TLR4 activated macrophages 
 To investigate mechanism(s) by which GSTO1-1 mediates pro-inflammatory 
signalling mediated via TLR4  
 
 
Chapter 2 
46 
 
CHAPTER 2 
Materials and methods 
2.1 Commonly Used Materials 
Commonly used chemicals are listed in Appendix A1. All chemicals are of analytical 
grade and were purchased from Sigma Aldrich unless specified otherwise. All 
restriction enzymes used were purchased from New England Biolabs (NEB).  
Culture media, sterile PBS, antibiotics, trypsin and glutamine were obtained from Life 
Technologies (Gibco). Culture media, buffers and enzymes are listed in Appendix A2-4. 
Chemicals used for treatment of mammalian cell lines were dissolved in cell culture 
grade DMSO (Sigma Aldrich). All cell lines were previously purchased from the 
American Type Culture Collection (ATCC) and maintained as per supplier’s 
recommendations.  
 
2.2 Bacterial Strains and Plasmids 
All plasmids were maintained and manipulated in bacterial strain E.coli DH5α and were 
streaked out on Luria broth/Ampicillin (LB/Amp) plates and grown overnight in LB 
media supplemented with a 100 μg/ml ampicillin at 37°C. Clones were stored in 75% 
glycerol stocks at -70°C. For protein expression and purification purposes, respective 
clones were transformed into bacterial strain BL-21 and grown under ampicillin 
selection. 
 
2.3. Plasmid DNA Preparation 
Plasmid DNA was isolated from E.coli cells using a miniprep kit (Qiagen Plasmid 
Purification Mini-Kit, Qiagen Pvt. Ltd., Australia). Cells were harvested and plasmids 
were extracted by alkaline lysis. Cells were re-suspended and lysed in 250 μl of sodium 
hydroxide containing Reagent P1 followed by protein denaturation with 250 μl of 
Reagent P2 containing SDS. The alkaline suspension was neutralized with 350 μl 
sodium acetate (Reagent P3). The precipitate was then separated from the supernatant 
by centrifuging the samples at 13000 x g for 10 minutes. The clear supernatant was 
transferred into Qiagen spin columns. After centrifugation at 13000 x g for 1 minute, 
DNA was retained on the spin column membrane which was then repeatedly washed 
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with Ethanol. The membrane was incubated in 50 μl DNase free sterile water for a 
minute prior to elution by centrifugation.   
2.4 DNA Manipulation 
2.4.1 Restriction Digestion 
Plasmid DNA (250-400ng) was double digested with restriction enzymes as per NEB 
instructions. The digestion reaction was set up in a suitable buffer, common to both 
restriction endonucleases. The reaction volume was made up with water to a total of 10 
μl for all digestions. The reactions were incubated at 37°C for two hours. Final 
concentrations of enzymes, buffers and BSA were maintained at 1/10
th
 the total volume. 
 
2.4.2 DNA Sequencing 
DNA Sequencing was performed on a 3730xl DNA automated DNA Analyzer (Applied 
Biosystems) at the Biomolecular Resource Facility (BRF), JCSMR.  The analyzer 
utilizes a high throughput capillary electrophoresis system to detect and analyze 
fluorescently labelled DNA sequences that were generated using the Chain Termination 
principle using fluorescently labelled dideoxynucleotides (ddNTPs). A typical 20 μl 
reaction mix contained 2 μl of ABI PRISM Big Dye Terminator mix, 3 μl of the 
respective ABI Big Dye Terminator 5X sequencing buffer, 3.2pmol of primer and 
300ng of plasmid DNA.  The terminator mix contains fluorescently labelled ddNTPs 
with unlabelled ddNTPs which were incorporated into the DNA fragment during PCR 
amplification. A clean up with Ethanol/Sodium Acetate is required to remove residual 
unincorporated terminator dye which may interfere with the capillary electrophoresis 
procedure (Biomolecular Resource Facility DNA Sequencing Protocol).  The 
sequencing sample is washed with 70% Ethanol twice to get rid of residual nucleotides 
and vacuum-dried.  
Fluorescently tagged DNA fragments are run on an acrylamide gel, separating them 
based on size. The fluorescent tags on each of the four ddNTPs are of different emission 
wavelengths. A laser positioned at the bottom of the gel excites the fluorescent tag on 
each fragment and generates a list of nucleotides in the order of the fragment size. The 
nucleotides are then read off based on the wavelength of the fluorescence emitted. 
 
2.4.3 Polymerase Chain Reaction (PCR) 
a. Primer Design 
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Primers were designed using NCBI Blast and Amplify 3X. Primer length was restricted 
to between 18-30 bps with a GC content ≤ 50% for all PCR reactions. Annealing 
temperatures of primer pairs were in close proximity to one another. Primers were 
preferably designed to end with a 3′ guanine or cytosine.  
b. Cycle conditions 
Cycle conditions were altered depending on the DNA template and the primer melting 
temperature (Tm). A single cycle denatured the DNA template at 95°C followed by 
annealing of primers at the appropriate temperature which was generally the same as the 
lowest melting temperature of the primer pair. Extension of DNA strands by Taq 
Polymerase proceeded at 70°-72C°. The three steps were repeated 30-35 times and 
completed with a single round of extension for 5 minutes at 70°-72°C.  
 
2.4.4 DNA Ligation 
Ligation of insert with vector was carried out by T4 DNA Ligase. In the case of ligation 
into pGEMT, the insert was tagged with a single adenosine at both ends. An A-tailing 
reaction mix consisted of 0.6 μl of Taq Polymerase, 1 μl of 2 mM dATP, 0.4 μl MgCl2, 
1 μl of ABI Buffer IV and 7 μl of the PCR product. The reaction was incubated at 70°C 
for 20 minutes. The reaction was stopped and the PCR product was purified using a 
PCR purification kit (Promega). 150ng of insert DNA was incubated with 50ng of 
vector and 1 unit of T4 DNA Ligase in a buffered reaction (total volume 10 μl) 
containing 1 μl of 10X T4 DNA Ligase Buffer overnight at 4°C.  Insert to vector ratio 
was maintained at 3:1 for all ligation reactions. 
 
2.4.5 Transformation of plasmids into bacterial cells 
a. Preparation of competent E.coli cells  
A primary culture of E.coli in 5 ml of LB media was set up overnight at 37°C in a 
shaker. A secondary culture was set up by inoculating 400 ml of LB media with 2 ml of 
the primary culture. Cells were incubated until the absorbance at 600 nm reached 0.5-
0.9. Half of the culture was aspirated and replenished with fresh LB media. The culture 
was further incubated till the O.D. of 0.6 was reached. The cells were centrifuged at 
4000 x g for 10 minutes at 4°C and the pellet was re-suspended in 40 ml of TfB I buffer 
(refer recipe in Appendix A5). Centrifugation was repeated and the cells were re-
suspended in 40 ml of TfB II buffer (refer recipe in Appendix A5). Cells were then 
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aliquoted (100 μl) into sterile 1 ml microcentrifuge tubes and snap-frozen on dry ice 
prior to storage at -70°C.   
b. Transformation of plasmids  
Ligation reactions were transformed into 100 μl aliquots of competent cells and 
incubated on ice for 30 minutes. Cells were heat shocked at 42°C for 90 seconds and 
immediately allowed to recover on ice for 60 seconds. The cells were then incubated in 
500 μl of LB media without antibiotics for 40 minutes. Transformed cells were then 
plated onto LB plates containing ampicillin and incubated overnight at 37°C. 
 
2.4.6 Nucleic Acid Quantification 
Nucleic acid concentration and purity was determined using a spectrophotometer 
(Nanodrop Technology, Biolab). Concentration was measured in terms of the 
corresponding optical density (O.D.) at a wavelength of 260 nm. Purity of DNA/RNA 
was estimated by calculating 260/280. A ratio of approximately 1.8 is considered pure 
for double stranded DNA.   
 
2.4.7 Agarose Gel Electrophoresis 
Restriction enzyme digested plasmids, PCR amplification products and colony crack 
PCR results were analysed by agarose gel electrophoresis. Gels varied from 0.8-1.5% in 
agarose concentration. Agarose was dissolved in 1X TBE Buffer (refer recipe in 
Appendix A5) by gradual heating. The solution was allowed to cool to 50°-60°C before 
adding 0.02% GelRed, a DNA binding dye that allows visualization of DNA by UV 
illumination. DNA samples were diluted with sucrose loading dye in a 4:1 ratio prior to 
loading. All gels were run in the 1X TBE buffer used to prepare the gel. 
 
2.5 Protein expression and purification  
Histidine tagged hGSTO1-1 allelic variants, hGSTO2-2, hGSTK1-1 and CLIC 2 were 
expressed from cDNA constructs in the bacterial expression plasmid pQE30 and 
purified as described previously using nickel affinity chromatography [294]. A starting 
culture of 5 ml LB broth supplemented with 100 μg/ml of ampicillin (see Appendix A5 
for recipe) was inoculated with BL-21 cells expressing the desired plasmid and 
incubated overnight at 37°C with gentle agitation. The starting culture was added to 500 
ml of LB broth supplemented with 100 μg/ml of ampicillin and grown at 37°C till the 
absorbance at 600 nm reaches approximately 0.6-0.7. Protein expression was induced 
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with 250 μl of 100 mM IPTG and the culture was incubated for 4 hours at 37°C with 
shaking. Cells were harvested by centrifugation at 3000 x g for 20 minutes at 4°C and 
lysed in 25 ml Buffer A (50 mM sodium phosphate buffer pH 7.5, 300 mM NaCl, 10% 
glycerol) containing 1 mM AEBSF and 80 μg/ml lysozyme. Cells were lysed by 5 x 30 
second bursts of sonication. The lysate was extracted by centrifugation at 15000 x g for 
20 minutes at 4°C. The clarified lysate was mixed with equilibrated Nickel agarose 
beads overnight at 4°C.  Nickel bound proteins were washed thoroughly and eluted 
using 50-500 mM of Imidazole. Eluted fractions were run on an SDS PAGE gel and 
fractions containing the purified protein were pooled. The pooled fractions were 
dialyzed into Buffer A overnight at 4°C and then concentrated using protein 
concentrators (Vivaspin 10KDa cut-off). The concentrated protein was dialyzed into 20 
mM tris pH 8.0, 1 mM DTT and 10% glycerol and stored at -20°C.   
 
2.6 Proteomics assays 
2.6.1 Protein quantification 
Protein concentration in cell lysates, tissue homogenates and of recombinant purified 
proteins was determined using a Bicinchoninic acid assay (BCA) protein estimation kit 
as per the manufacturer’s instructions (Pierce catalogue # 23225).  
 
2.6.2 Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 a. Preparing and running a polyacrylamide gel 
SDS-PAGE generally preceded Western blots in all experiments. All buffers were 
prepared prior to use from stock solutions. Buffer compositions are mentioned in 
Appendix A5. Polyacrylamide gels were prepared in a Biorad gel apparatus as per 
manufacturer’s instructions. The gel plates, plate holders and combs were rinsed 
thoroughly and wiped with 80% Ethanol to remove gel residues. Resolving gel of the 
desired percentage was poured into the gel apparatus and allowed to set at room 
temperature. This was followed by filling the top one-fourth of the gel apparatus with 
the stacking gel (4%).  The comb was gently placed in the stacking gel and allowed to 
set.  
b. Protein sample preparation 
Proteins were extracted from cell lines. Cells were spun down and re-suspended in PBS. 
Cells were lysed by means of an electric pestle and centrifuged at 16000 x g for 10 
minutes at 4°C. The lysate supernatant was transferred into fresh tubes and protein 
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concentration was determined.  Lysates were kept on ice throughout the protocol. 100 
μg of protein was mixed with SDS-Loading dye in a 2:1 dilution and boiled for 5 
minutes.  The protein samples were spun down and loaded onto the SDS- 
polyacrylamide gel.  
c. Running SDS-PAGE gels 
Polyacrylamide gels were run in Biorad electrophoresis chambers. The gels were run at 
150V for approximately one hour. Invitrogen Pre-stained Benchmark ladder (10 μl) was 
loaded alongside the samples. On completion of a successful run, the proteins were 
stained with Coomassie brilliant blue stain for an hour followed by destaining the gel 
40% methanol, 10% glacial acetic acid overnight.   
 
2.6.3 Immunoblotting 
For blotting purposes, an SDS-PAGE gel was transferred onto a nitrocellulose 
membrane and sandwiched between a set of pre-soaked three filter papers and a porous 
mat on either side [295]. The sandwich was firmly placed in a blotting cassette and 
electro-transferred at a constant voltage of 100V for an hour at room temperature. The 
membrane was blocked in either 5% skim milk or 5% bovine serum albumin (as 
recommended by specific antibody suppliers) for one hour at room temperature. 
Incubations with primary and secondary antibodies varied and have been described in 
Appendix A8. All secondary antibodies used in this project were HRP-tagged and 
chemiluminescence signal was detected using ECL Rapid detection system (GE 
Healthcare) on a Fujifilm Chemiluminescence Imager. 
 
2.7 Mammalian Cell Culture 
Human cancer cell line T47-D was obtained previously from ATCC and maintained as 
per supplier’s recommendations. Cells were grown in RPMI media supplemented with 
10% FBS, 0.1%PSN and 2 mM Glutamine. Cells stably transfected with GSTO1-1 
coding plasmids were maintained under Geneticin selection at a concentration of 350 
μg/ml. Mouse macrophage cell line J774.1A wildtype and lentiviral transfected cells 
were kind gifts from Prof. Luke O’Neill and Dr Rebecca Coll (Trinity College, Dublin). 
Wildtype J774.1A cells were grown in DMEM supplemented with 10% FBS, 0.1% PSN 
and 2 mM glutamine. Lentiviral transfected cells were maintained in the same media, 
under Puromycin selection at a concentration of 3 μg/ml.  Epstein–Barr virus-
transformed human lymphoblastoid cell lines (LCLs) generated from anonymous Red 
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Cross Blood Bank donors were a gift from Dr. Juleen Cavanaugh (Australian National 
University) and were cultured in RPMI 1640, 15% foetal bovine serum, 2 mM l-
glutamine, 100 IU/ml penicillin and 0.01 mg/ml streptomycin. All cell lines were 
maintained at 5% CO2 and 37°C except for the lymphoblastoid cells which were 
cultured at 10 % CO2 and 37°C. 
 
2.8 In vitro assays 
2.8.1 Cell viability assay 
Total cell number was measured quantitatively using neutral red assays. Cells were 
seeded at ~50% confluency into 96 well plates and treated for desired periods at 37°C, 
5% CO2. Cells were then washed in PBS and incubated with neutral red stain (33 
μg/well in media) for 3 hours at 37°C, 5% CO2 followed by a wash in PBS to remove 
dead cells. Viable (stained) cells were lysed in a 25% acetic acid: 75% methanol 
solution and absorbance was read at 540 nm using a plate reader (SpectraMax 190, 
Molecular Devices). 
 
2.8.2 Peptide synthesis 
The peptide used in this study (SQLWCLSN) was synthesized by the Biomolecular 
Resource Facility (BRF), JCSMR, ANU. The synthesized peptide was dissolved in 0.1 
M ammonium acetate, pH 8.0 and glutathionylated by incubation with a 10 fold molar 
excess of oxidised glutathione for 24 hours at room temperature with constant stirring. 
The peptide was then diluted in sterile water (3X) prior to freeze drying and purification 
by HPLC prior to use. 
 
2.8.3 Tryptophan quenching assay 
The deglutathionylation assay was based on a previously described procedure that 
recorded the change in tryptophan fluorescence as glutathione is removed from a model 
peptide [87]. Fluorescence was recorded at an excitation wavelength of 280 nm and an 
emission wavelength of 356 nm at room temperature over a time period of 10-30 
minutes. For the deglutathionylation reaction, the reaction mix contained McIlvaine’s 
buffer (2 M sodium hydrogen phosphate, 1 M citric acid pH 7.0), 1 mM GSH, 50 μΜ 
NADPH, 0.25 U Glutathione reductase (GR), 1 mM EDTA, 0-20 μM peptide, 1.4 μg 
GSTO1-1. GR and GSTO1-1 were diluted in McIlvaine’s buffer containing 1 μg/μl 
BSA. GSH affinity was similarly measured by varying GSH concentrations from 0-2 
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mM, maintaining protein concentration constant at 1.4 μg and substrate concentration at 
5 μM. Deglutathionylation activities of human GSTO2-2, CLIC2 and GSTK were tested 
up to an enzyme concentration of 6 μg. All measurements were recorded in triplicate.  
Glutathionylation of the peptide was measured as described previously [87] with a 
modification. The reaction mix was made in McIlvaine’s buffer (described above) with 
5 mM GSSG, 1 mM EDTA, 5 μM peptide, 6 μg enzyme, 2 mM t-butylhydroxyperoxide 
and 10 μg of GSTA2-2 were added to the reaction to recycle the GSH to GSSG. 
 
2.9 Quantification of cellular glutathione pool 
The assay was carried out as described previously [296]. For oxidized glutathione, 100 
μl of sample or GSSG standard were treated with 10% 2-vinylpyridine for one hour 
followed by pH neutralization with 6% triethanolamine. For reduced glutathione, 100 μl 
of sample or GSH standard were assayed directly. Samples were incubated with pre-
mixed DTNB (0.67 mg/ml) and glutathione reductase (250 μg/ml) for 30 sec - 1 minute 
as per protocol and mixed with NADPH (0.67 mg/ml) and the reaction rate was 
immediately measured at 412 nm using a microplate reader (SpectraMax 190, 
Molecular Devices). 
 
2.10 Immunoprecipitation 
T47-D cells were treated in culture with 50 mM N-ethylmaleimide (NEM) for 30 
minutes followed by lysis in non-reducing buffer (20 mM  tris  pH 8.0, 137 mM  NaCl,  
1%  NP-40,  2 mM  EDTA,  10 mM  NEM,  2 mM  AEBSF  protease inhibitor). 1 mg of 
total cell lysate protein was used per sample as measured by BCA protein estimation. 
Immunoprecipitation was carried out using Pierce crosslinking immunoprecipitation kit. 
Cellular GSH was removed by precipitating the proteins with 5 times the volume 
acetone overnight at -20°C. Precipitated proteins were resuspended in lysis buffer as per 
manufacturer’s instructions. Immunoprecipitated proteins were separated on 12% SDS-
PAGE and immunoblotted as above.  
 
2.11 Real time RT-PCR 
Total RNA was extracted from cells and tissues in trizol as per manufacturer’s 
instructions (Invitrogen). Trizol-lysed samples were incubated for 5 minutes at room 
temperature and passed repeatedly through a 25 gauge syringe to enhance cell lysis. 200 
μl of chloroform was added to each sample and the tube was shaken vigorously for 30 
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seconds. The samples were centrifuged at 15000 x g for 15 minutes at 4°C and the top 
clear layer was transferred to a fresh tube followed by the addition of 600 μl of 70% 
ethanol. The samples were then transferred to RNA spin columns and RNA was isolated 
as per manufacturer’s instructions (Qiagen RNA extraction kit). The extracted RNA was 
treated with DNase to remove genomic DNA contamination (Ambion DNAse kit) and 
cDNA was synthesized with an Invitrogen First strand cDNA synthesis kit. Real time 
PCR was carried out on an ABI 7900HT thermocycler and relative transcript levels 
were calculated by the ΔΔCt method using GAPDH as an internal control to which all 
transcripts were normalized. 
 
2.12 Statistical analysis 
Data were expressed as the mean ± standard error and analysed using Prism 4 
(Graphpad software Inc.). Statistical significance was calculated by standard t-tests. All 
experiments were performed in triplicate unless otherwise stated. 
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CHAPTER 3 
Developing a novel fluorescence based micro-titre 
plate assay to quantify protein glutathionylation 
3.1 Introduction 
Glutathione (L-γ-glutamyl-L-cysteinylglycine) is a tripeptide found in abundance intra-
cellularly and has been extensively studied for its diverse functions, ranging from 
cellular defence mechanisms to cell signalling and metabolism [297]. The most 
important role of glutathione is in the maintenance and regulation of the redox state of a 
cell. Occurring freely in either a reduced (GSH) or oxidized (GSSG) state, glutathione 
concentrations play a critical role in maintaining cell homeostasis. An imbalance in the 
cellular GSH:GSSG ratio can destabilize the redox environment leading to excessive 
generation of free radicals, disruption of protein function, dysregulation of redox-
sensitive signalling pathways and eventually cell death [140, 141, 268, 298, 299]. 
Typical functions of glutathione in redox homeostasis include the conjugation of 
electrophilic compounds including xenobiotics and detoxification of free radicals 
generated during oxidative stress. Many of these reactions are catalysed by members of 
the superfamily of enzymes known as Glutathione Transferases (GSTs) [195, 300, 301]. 
Redox regulation involves mechanisms that confer reversible post translational 
modifications on proteins to temporarily to tolerate changes in the immediate redox 
environment [4, 5].  
Post-translational modifications can alter both the functional and structural aspects of 
proteins. This project investigating the biological roles of GSTO1-1 will focus on one 
such protein modification known as glutathionylation wherein thiol (-SH) groups in 
proteins are protected from irreversible oxidation by the addition of glutathione via 
disulphide bonds. The reaction may be spontaneous or can be catalysed by members of 
the Glutaredoxin (Grx) family of thioltransferases [21]. Under physiological conditions, 
glutathione is the most prevalent cellular thiol occurring both freely and bound to 
proteins in the form of mixed disulphides. On oxidative insult, redox sensitive protein 
thiol groups become glutathionylated via the formation of generally reversible 
disulphide bonds with cellular glutathione (capping cysteine residues), thus shielding 
them from irreversible oxidation to sulfonic acids [10, 27, 68]. Therefore, 
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glutathionylation may be seen as a defence mechanism to protect proteins from 
oxidative stress induced irreversible damage. Though glutathionylation is mainly 
considered as an oxidative stress triggered protein modification, reversible 
glutathionylation in the absence of oxidative stress has been shown to have an impact 
on the functions of proteins including the contractile activity of actin and the 
phosphatase activity of Protein Tyrosine Phosphatase 1B (PTP1B) [29, 69]. The current 
list of proteins that are structurally and functionally modified by glutathionylation, 
collectively known as the ‘Disulphide proteome’, is available at 
http://csb.cse.yzu.edu.tw/dbGSH/  [49].  
In recent years there has been increasing interest in the role of glutathionylation in a 
wide range of cellular processes including, energy metabolism, signalling and apoptosis, 
cell cycle regulation, ion channel modulation, calcium homeostasis, regulation of 
cytoskeletal structures, protein folding and gene regulation ( reviewed in [25, 67, 141]). 
As a result of its impact on cellular processes, aberrant glutathionylation has been 
implicated in the pathology of a number of clinically significant diseases including 
Alzheimer’s disease, Type 2 diabetes, cystic fibrosis, cataracts and cancer [20, 22, 25, 
67, 117, 121, 129, 143, 145].   
Because of the increasing recognition of the biological and clinical importance of 
glutathionylation, a range of techniques have been developed to identify, and locate 
glutathionylated proteins and to determine the level of glutathionylation. This section 
aims to briefly describe currently available techniques, their merits, inadequacies and 
most importantly emphasizes the need for a quantitative glutathionylation assay. 
3.1.1 Immunoassays with anti-glutathione 
Immunoassays targeting protein bound glutathione are the most prevalent methods used 
to determine protein glutathionylation. The technique has been used to qualitatively 
measure global glutathionylation by separating proteins on a polyacrylamide gel, 
transferring them onto a nitrocellulose membrane and probing transferred proteins with 
an anti-glutathione antibody [29, 302, 303]. A modification to the method is the use of 
glutathione-based ELISA assays where proteins are probed in 96-well plates using the 
same principle. The technique offers you the option of quantitatively estimating the 
amount of glutathione bound to proteins. 
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3.1.2 
  35
S radioactive labelling of proteins 
One of the oldest and most commonly employed techniques to detect glutathionylation 
is the use of 
35
S radioactively labelled glutathione which effectively identifies 
glutathionylated proteins in an isolated system [304]. The tagged proteins can be located 
by autoradiography and identified either by probing with protein-specific antibodies or 
mass spectroscopy [302]. Though the technique provides information about the 
localization and abundance of glutathionylated proteins, it proves to be a tedious 
approach involving radiation. Additionally, this approach is confined to in vitro 
labelling and may give rise to experimental artefacts owing to metabolic labelling.   
3.1.3 Mass spectroscopy 
Another frequently used proteomic approach involves extensive mass spectroscopic 
measurements [137, 305-307]. Mass spectroscopy efficiently picks up individual 
glutathionylated cysteine residues in proteins by detecting the mass of the extra bound 
‘–SG’ [302]. Though it offers an accurate method to identify glutathionylated proteins, 
the technique has its limitations. For one, it is neither a quantitative nor economic 
approach to be considered for preliminary experimentation as the technique requires 
extensive sample processing which may not be an option for initial data collection. 
Also, it cannot be used to identify unknown glutathionylated protein targets. Developing 
a quantitative method for the identification of glutathionylated proteins will provide 
new insights about the physiological consequences of oxidative protein modifications. 
3.1.4 Glutathione transferase Overlay 
Cheng et al. employed a biotin tagged Glutathione transferase overlay method to detect 
glutathionylated proteins in vitro [308]. Proteins were separated on a polyacrylamide 
gel and electrophoretically transferred to a Hybond P-membrane. The transferred 
proteins were probed with biotin tagged GST which binds specifically to the glutathione 
moieties. Though the method introduces a novel idea of targeting glutathionylated 
proteins with GSTs, it is not particularly quantitative and it is not clear whether it 
detects all glutathionylated cysteines.   
3.1.5 Biotin labelling of glutathionylated proteins 
The concept of protein tagging and biotinylation has been in use for many years to study 
various cellular processes. Tagging proteins or compounds interacting with target 
proteins has led to the revelation of a number of proteins undergoing glutathionylation. 
Several modifications adapting the principle of tagging have been established over the 
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years. The technique involves the treatment of whole cells with a blocking agent that 
binds irreversibly to protein thiol groups. The glutathionylated protein sites are then 
enzymatically reduced followed by labelling with thiol-specific biotinimide [309]. The 
biotin tag can be detected and traced via a labelled avidin conjugated agent 
(agarose/sepharose bound avidin or fluorescence tagged avidin), making the technique 
an alternative to standard immunoblotting with protein specific or GSH specific 
antibody [306, 309]. Biotin tagged proteins isolated by affinity chromatography with 
sepharose bound avidin are identified by separating the protein pool on a 2-DE gel and 
analysing individual proteins by high through-put techniques like MALDI/TOF [306]. 
A recent study developed a membrane permeable biotinylated analogue of glutathione 
which could be tracked by Annexin II [310].  Biotin-tagging of N-ethylmaleimide, 
which specifically binds to sulfhydryl groups, has led to the identification of 
glutathionylated proteins. A major drawback to this technique is the lack of accurate 
quantitation of the extent of glutathionylation.  
3.1.6 Measuring the enzymatic rate of glutathionylation/deglutathionylation 
The kinetics of the catalytic glutathionylation/deglutathionylation activity of 
glutaredoxin was measured by Peltoniemi et al. using an 8 residue long peptide 
designed to incorporate a single cysteine residue adjacent to tryptophan 
(XXXWCXXX) [88]. tryptophan, an aromatic amino acid fluoresces on excitation at 
280 nm. The technique is based on the principle of tryptophan fluorescence quenching. 
Any change in the immediate environment of tryptophan would alter the fluorescence. 
For example, when glutaredoxin glutathionylates the adjacent cysteine residue, 
tryptophan fluorescence is quenched in a time dependent manner. Alternately, the 
peptide was artificially glutathionylated to measure the deglutathionylation activity of 
glutaredoxin. On addition of free GSH to the mix, Grx was found to deglutathionylate 
the peptide, resulting in a time dependent increase in tryptophan fluorescence. The 
technique is well suited to test the activity of potential 
glutathionylating/deglutathionylating candidate enzymes such as GSTs. 
3.1.7 Fluorescence microtitre-based quantitative assay 
Recently a new quantitative technique was described that used recombinant 
glutaredoxin-3 to reduce protein –glutathione mixed disulphides and capillary gel 
electrophoresis to detect and measure the eluted GSH [311].  While the method is 
sensitive and provides a valuable advance in accurate quantification, it relies on the 
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limited availability of recombinant glutaredoxin-3 and requires a relatively slow 
capillary electrophoresis fractionation step. The current techniques are highly complex, 
require intensive optimization and are restricted in the sample numbers that can be 
measured. In order to better understand the effect of glutathionylation on cellular 
processes, a more efficient and quantitative approach is needed to analyse 
glutathionylated proteins in an in vitro setting.  
This chapter describes a new, highly specific and quantitative assay for the 
determination of total protein glutathionylation in cell lysates and tissue homogenates 
by exploiting the specificity of NDA (2,3-napthalenedicarboxaldehyde) for GSH and its 
precursor γ-glutamylcysteine. In this assay, GSH is eluted from the glutathionylated 
protein with tris(2-carboxyethyl)phosphine (TCEP) and specifically detected after 
reaction with NDA [312]. The assay can be undertaken in a 96 well plate format, uses 
commercially available reagents and only requires a fluorescence plate reader.   
3.2 Materials and Methods 
3.2.1 Preparation of purified glutathionylated BSA 
Glutathionylated  bovine  serum  albumin  (BSA)  was  prepared  by treating   the  
protein  with  10 mM  reduced  glutathione  and  200 mM hydrogen peroxide for 30 
minutes at 37°C. The glutathionylated protein was recovered by precipitation with 10 
times the sample volume of ice cold acetone for two hours at -20°C and was 
resuspended in 20 mM Tris pH 8.   
3.2.2 Cell culture 
Cells (T47-D, HeLa, HEK 293) were purchased from ATCC and were maintained at 
37°C, 5% CO2 in RPMI-1640 media (DMEM for HEK 293 cells) supplemented with 
10% FBS and 1% glutamine as recommended by ATCC. Cells were maintained at 37°C 
in a humidified incubator at 5% CO2. Cells were plated at a high density of 5x10
5
 cells 
grown to 80% confluency in 6-well plates and treated with 0.5 mM hydrogen peroxide 
in sterile phosphate buffered saline (PBS) for 60 minutes at 37°C  in serum free media 
followed by lysis in non-reducing lysis buffer as described below.  
3.2.3 Animals  
Balb/c male mice (aged 8-10 weeks) were maintained at the ANU Biosciences facility 
under controlled animal room conditions. The animals were fed regular animal diet and 
water ad libitum.  
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3.2.4 Drug administration 
Doxorubicin was diluted in sterile saline and administered intra-peritoneally at a dose of 
20 mg/kg. Control animals were injected with equal volume of saline. Animals were 
regularly monitored and sacrificed at 24 hours. Organs including heart, liver, lungs, 
brain, kidneys, testes and spleen were harvested immediately in sterile PBS and 
homogenized in a non-reducing buffer (20 mM  Tris  pH 8.0, 137 mM  NaCl,  1%  NP-
40,  2 mM  EDTA,  10 mM  NEM,  2 mM  AEBSF  protease inhibitor) using a Dounce 
homogenizer. No significant weight loss was observed in treated mice during this 
experiment. 
3.2.5 Sample preparation 
The steps involved in this assay are shown schematically in Figure 3.1.  In this assay of 
determining protein   glutathionylation,  free  thiols  (predominantly  GSH)  are  blocked  
by  the inclusion  of  10 mM  NEM  in  the  tissue-homogenizing  buffer  (20 mM  Tris  
pH 8.0, 137 mM  NaCl,  1%  NP-40,  2 mM  EDTA,  10 mM  NEM,  2 mM  AEBSF  
protease inhibitor). Tissue homogenates were centrifuged at 20000xg for 20 minutes 
and the protein concentration of the supernatant was determined by Lowry protein 
estimation [22]. For a typical assay, a sample of tissue extract containing 100 μg of 
protein was precipitated with twice the volume  of  ice  cold  acetone  at  -20°C  for  60  
minutes  to  remove  the  alkylated cellular GSH, free thiols and excess NEM. After 
centrifugation at 20000 x g for 15 minutes, the supernatant was discarded and the 
precipitated proteins were washed again in ice cold acetone and then re suspended in 40 
μl of 0.5 mM Tris-HCL containing 0.1% Triton X-100 at room temperature.  
3.2.6 Protein-SSG reduction 
The reducing agent TCEP was added to the protein solution at a final concentration of 5 
mM to break the P-SSG bonds and elute the protein bound GSH (10 μl 25 mM TCEP at 
room temperature for 30 minutes).  The deglutathionylated protein was then precipitated 
by the addition of 25 μl 200 mM sulfosalicylic acid. After incubation on ice for 30 
minutes, the precipitated protein was removed by repeating the centrifugation step. 
3.2.7 Quantification of GSH 
Previous studies have shown that at a high pH NDA reacts specifically with GSH to 
form a highly  fluorescent  cyclic  derivative [313].  Consequently, GSH in the 
supernatant was reacted with NDA and the fluorescence quantified by comparison with 
authentic GSH standards that were run in parallel for each experiment.  Specifically, 20 
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μl of supernatant was combined with 180 μl of NDA derivatization mix for 30 min in 
the dark at room temperature.  The fluorescence was determined in an Optima 
FLUOstar Fluorescence plate reader with an excitation wavelength of 485 nm and an 
emission wave length of 520 nm. The NDA reaction mix was prepared immediately 
before use by combining 1 ml 10 mM NDA in dimethyl sulfoxide, 7 ml 50 mM tris pH 
10, and 1 ml of 0.5 m NaOH with gentle mixing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Step-wise description of the assay developed to determine total protein 
glutathionylation 
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3.3 Results  
3.3.1 Optimization of NDA-based fluorescence assay 
To develop and validate the method, commercially available Bovine Serum Albumin 
was artificially glutathionylated (BSA-SSG). Western blotting with an anti-glutathione 
antibody confirmed that BSA was strongly glutathionylated by treatment with 
glutathione and hydrogen peroxide (Figure 3.2A).  The excess glutathione was removed 
by precipitating the glutathionylated albumin with ice cold acetone. Initial experiments 
using 10 μg of BSA-SSG showed that >95% of the mixed disulphide was reduced by 2 
mM TCEP (Figure 3.2B).  In subsequent experiments, 5 mM TCEP was used to ensure 
the reduction had gone to completion. In additional optimization experiments, the 
quantification of GSH derived from BSA-SSG by incubation with TCEP was found to 
be linear over a range from 0.05- 1.0 mg/ml BSA (Figure 3.2C). This assay determined 
the quantity of glutathione bound to BSA-SSG to be 54.3  3.8 nmoles of GSH/mg 
protein compared with 2.3  3.7 nmoles of GSH/mg protein obtained for normal BSA 
(Figure 3.2D). To confirm that the method measures reversible glutathionylation, the 
BSA-SSG was pre-treated with dithiothreitol (DTT). This treatment diminished the 
level of glutathionylation to background levels. The results were calculated as nmoles 
GSH/mg protein by reference to a standard curve generated with authentic GSH (Figure 
3.2E). 
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Figure 3.2: Optimization of the glutathionylation assay. (A) shows the 
glutathionylation level detected in recombinant BSA (control) and glutathionylated 
BSA (BSA-SSG)  probed with an anti-glutathione antibody. (B) shows the 
quantitative measure of NDA-GSH derived fluorescence from BSA-SSG with 
increasing concentrations of TCEP. (C) shows the linearity of the fluorescence 
measurements with increasing concentrations of BSA-SSG ( ) and un-
glutathionylated control BSA (   ). (D) shows the specificity of the assay for protein 
bound glutathione  by measuring fluorescence levels of BSA-SSG pre and post 
treatment with DTT. (E) A typical standard curve obtained with authentic GSH. 
Chapter 3 
64 
 
 3.3.2 The effect of oxidative stress on cellular glutathionylation  
The level of total glutathionylation was determined in human lymphoblastoid cell lines 
before and after treatment with the glutathionylating agent GSNO. As shown in Figure 
3.3A, the basal level of glutathionylation in untreated cells was found to be 0.9 ± 0.45 
nmoles/mg protein, which is well within the detection range estimated for this assay 
(Figure 3.2C). In contrast, one hour after treatment with 1 mM GSNO, the 
glutathionylation levels had risen to 16.6 ± 2.5 nmoles/mg protein. The experiment was 
repeated on separate days to indicate the repeatability of the assay and the cellular 
response. The level of total glutathionylation was determined in several cell lines and 
significantly higher levels were found in HEK293 cells compared to T47D and HeLa 
cells (p<0.001). However, treatment with 0.5 mM hydrogen peroxide caused a 
significant (p<0.001) increase in the level of glutathionylation in all cell lines (Figure 
3.3B) (Table 3.1) which is similar to thefindings previously reported [302]. 
 
Figure 3.3: Determination of protein glutathionylation in cells 
(A) Reproducibility of the assay was determined by measuring the total 
glutathionylation levels in lymphoblastoid cell lines before and after treatment with 
1 mM GSNO on two consecutive days. The mean of individual data points is 
shown. (B) The assay was exploited to measure glutathionylation levels in basal 
and oxidative stress conditions in multiple cell lines. The assay consistently 
detected an increase in total glutathionylation levels in cells treated with hydrogen 
peroxide across all three cell lines. 
 
A B 
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3.3.3 Quantification of global glutathionylation in mouse tissues 
Fresh liver, lung, kidney, heart, brain, spleen, testes and skeletal muscle from normal 
male BALB/c mice were extracted and glutathionylation was measured. The levels of 
glutathionylation were found to range from 1-2.5 nmoles GSH/mg protein for each 
tissue except for significantly higher (p<0.001) levels in skeletal muscle (Figure 3.4). 
Treatment of mice with the anti-cancer drug doxorubicin (20 mg/kg IP injection) caused 
an increase in glutathionylation in most tissues but notably caused a highly significant 
decrease in the glutathionylation of proteins in skeletal muscle which is still not fully 
understood. Since doxorubicin has been shown to induce oxidative stress [314-316], it 
was considered a suitable agent to evaluate and compare glutathionylation levels post 
doxorubicin treatment. 
Figure 3.4: Protein glutathionylation levels were measured in mouse tissues pre- 
and post- treatment with doxorubicin for 24 hours. Data represents mean ± 
standard error; n=6 
 
 
Table 3.1: Quantification of protein bound glutathione in cell lines  
 
 
nmoles GSH/mg of protein
Cell line Untreated H2O2 treated
HEK 293 7.57 ± 0.01 13.33 ± 0.05
T47-D 0.18 ± 0.18 13.61 ± 0.12
HeLa 0.33 ± 0.22 8.22 ± 0.19
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3.4 Discussion  
Glutathionylation may be spontaneous or can be catalysed by members of the 
Glutaredoxin (Grx) family of thioltransferases and GSTP [20, 21]. Under physiological 
conditions, glutathione is the most prevalent thiol occurring both freely and bound to 
proteins in the form of mixed disulphides. On oxidative insult, redox sensitive protein 
thiol groups become glutathionylated via the formation of generally reversible 
disulphide bonds with cellular glutathione (capping cysteine residues), shielding them 
from irreversible oxidation [10, 67, 68]. Thus, glutathionylation may be considered as a 
‘hallmark’ to characterize the response to oxidative stress. Though glutathionylation is 
mainly considered as an oxidative stress triggered protein modification, reversible 
glutathionylation in the absence of oxidative stress has been shown to have an impact 
on the functions of proteins including the contractile activity of actin and the 
phosphatase activity of Protein Tyrosine Phosphatase1B (PTP1B) [29, 69].  
While many methods for the detection of protein glutathionylation have been described, 
most are qualitative and at best only semi quantitative. The new method described here 
for the quantification of protein glutathionylation has several advantages. It is rapid and 
can be applied to many different tissues and large sample numbers. Unlike a previously 
described method that uses difficult to obtain or expensive enzymes for the reduction of 
the Protein-SSG mixed disulphides (P-SSG) [311], this new assay uses commercially 
available reagents and a standard fluorescence plate reader. The technique can be 
applied to whole cell lysates and tissue homogenates and has been proven sensitive 
enough to measure the amount of glutathione bound to proteins in cells under 
physiological conditions. The specificity and reproducibility of the assay to measure 
protein bound glutathione alone is due to (a) the high specificity of NDA for glutathione 
and (b) removal of the cellular glutathione pool in the lysate by acetone precipitation.  
The assay was tested in vitro with three different cell lines and was found to be sensitive 
enough to quantitate the increase in total glutathionylation in response to hydrogen 
peroxide induced oxidative stress. The reproducibility of the assay was determined by 
measuring the total protein glutathionylation levels in lymphoblastoid cells from 
different passages on different days. Both the basal and induced glutathionylation levels 
were remarkably similar, confirming that the assay can be employed routinely to detect 
protein glutathionylation levels in biological samples. The assay was further employed 
to establish values for the basal level of glutathionylation in vivo in the absence of 
oxidative stress. The levels of protein bound glutathione measured in the brain of mice 
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(1.7  0.23 nmoles/mg) by the present assay compared well with the range of 1-12 
nmoles/mg observed in various areas of the brain in a previous study [311]. Basal levels 
of glutathionylation have previously been shown to be necessary not only to protect 
protein thiols under oxidative stress conditions but also to maintain the activity of 
proteins such as PTP1B under normal physiological conditions [27, 61, 76, 141]. 
This method gains its specificity for GSH from the selective capacity of NDA in 
alkaline conditions to form a novel highly fluorescent cyclic derivative. The formation 
of a similar derivative is also possible with γ-glutamylcysteine, an immediate precursor 
in the synthesis of GSH [313]. γ-glutamylcysteine concentrations are normally low in 
cells as it is rapidly consumed in the synthesis of GSH by glutathione synthetase. In the 
case of glutathione synthetase deficiency when high levels of γ-glutamylcysteine might 
be expected to accumulate, it is converted to 5-oxoproline and cysteine by γ-glutamyl-
cyclotransferase [317]. Thus it seems unlikely that elevated levels of γ-glutamylcysteine 
ever occur in normal cells. However if the levels of γ-glutamylcysteine were elevated it 
would be expected that it would behave like GSH in the glutathionylation process and 
would be indistinguishable in this assay. O-phthalaldehyde (OPA) has previously been 
shown to interact with glutathione in a similar manner generating a fluorescent adduct. 
However, the substrate has several limitations including the slow rate of adduct 
formation, low fluorescence yield and non-specific interactions with histidine residues 
[318]. Another limitation of the assay would be the inability to identify individual 
cysteine residues modified by glutathionylation. In the present study a novel assay has 
been developed that allows accurate quantification of changes in the level of protein 
glutathionylation in response to oxidative stress in complex biological samples 
including cells and tissues as described in the following chapters.   
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CHAPTER 4 
 Glutathione transferase Omega 1 (GSTO1-1) 
catalyses the glutathionylation cycle 
4.1 Introduction 
The process of protein glutathionylation provides a primary line of defence against 
irreversible protein damage caused by oxidative stress. Glutathionylation is defined as a 
post translational modification of protein thiol groups by the formation of mixed 
disulphides with glutathione [27]. On oxidative insult, redox sensitive protein thiol 
groups are glutathionylated (capping cysteine residues), thus shielding them from 
irreversible oxidative damage. This reaction may occur spontaneously, but growing 
evidence suggests the catalytic involvement of the Glutaredoxin (Grx) family 
thioltransferases [21, 69]. Additionally, glutathionylation reactions may also be reversed 
via deglutathionylation i.e. removal of protein bound glutathione. Glutaredoxins and 
sulfiredoxin are known to catalyse the deglutathionylation of proteins and thus protect 
protein thiols from oxidation to the oxidized sulfenic acid and sulfinic acid forms [21, 
29, 67, 304, 319]. Thus, protein thiol groups can be transiently capped with glutathione 
until the redox balance is restored, at which time proteins can be enzymatically 
deglutathionylated. This makes glutathione an indispensable player in the regulation of 
cellular redox homeostasis. Aside from its well characterised role in oxidative stress, 
reversible glutathionylation in the absence of oxidative stress has also been shown to 
affect protein function. Glutathionylation has an impact on the regulation of the cell 
cycle, apoptosis and inflammation [67, 110, 113, 320], as well as the contractile activity 
of actin and the phosphatase activity of Protein Tyrosine Phosphatase1B (PTPB1) [29, 
69]. Therefore, the mechanisms and enzymatic mediators involved in the 
glutathionylation cycle are of great interest under both oxidative and non-oxidative 
conditions.  
A role for GSTO1-1 in the glutathionylation cycle is not unexpected given it is an 
atypical GST, with minimal functional resemblance to other members of the GST 
superfamily [179, 197, 262]. Most GSTs possess a tyrosine or serine residue at their 
active site, responsible for catalysing conjugation reactions between GSH and 
electrophilic substrates. However, the active site residue in GSTO1-1 was identified as 
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cysteine (Cys-32), flanked by proline and phenylalanine, uncharacteristic of other 
mammalian GSTs [262]. Previous data from our laboratory have confirmed the 
glutaredoxin-like thioltransferase activity of GSTO1-1 with chemical substrates such as 
2-Hydroxyethyl disulphide (HEDS) [275]. Overall, the crystal structure of GSTO1-1 is 
suggestive of a novel role for GSTO1-1 in the glutathionylation cycle as the active site 
is open and could accommodate large substrates such as proteins. In this chapter the 
capacity of GSTO1-1 to contribute to protein glutathionylation and deglutathionylation 
reactions has been investigated.  
 
4.2 Materials and methods 
4.2.1 Cell culture 
Cells lines were purchased from ATCC and were maintained at 37°C, 5% CO2 in RPMI 
media supplemented with 10% fetal bovine serum. T47-D cells were previously stably 
transfected with a Gsto1 encoding pCDNA3 plasmid [321]. Stable expression was 
confirmed by immunoblotting with rabbit anti-human GSTO1-1 antibody.  The human 
lymphoblastoid cell lines expressing Gsto1 variants were a gift from Dr Juleen 
Cavanaugh.  
4.2.2 Preparation of S-nitrosoglutathione 
S-nitrosoglutathione was synthesized as described previously [263]. An equimolar 
amount of reduced glutathione was mixed with sodium nitrite and the pH was adjusted 
to 1.5 with concentrated HCl. The reaction was allowed to proceed at room temperature 
for 5 minutes followed by neutralization of the synthesized GSNO with 5 M NaOH. The 
concentration of GSNO was estimated by measuring absorbance at 544 nm and 332 nm 
on a Cary UV Spectrophotometer using extinction coefficients of 15 M
-1
cm
-1
 and 750 
M
-1
cm
-1
 respectively. 
4.2.3 Total protein glutathionylation assay 
Protein glutathionylation was determined by a previously described method [322] (see 
Chapter 3) Cells were lysed in a non-reducing buffer (0.5M tris, 300 mM NaCl, 1% NP-
40, 50 mM N-ethylmaleimide (NEM), 2 mM AEBSF) and the protein concentration 
was determined using a BCA protein estimation kit according to manufacturer’s 
instructions (Pierce, Illinois, U.S.A). Cellular proteins (100 μg) were precipitated in ice 
cold acetone at -20°C for over two hours. Precipitated proteins were collected by 
centrifugation at 20000 x g for 15 minutes and re-suspended in 0.1% Triton X-100 and 
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reduced with 5 mM tris(2-carboxyethyl)phosphine (TCEP) for 30 minutes at room 
temperature. Reduced proteins were precipitated with 200 mM salicylic acid and 
centrifuged at 20000 x g for 15 minutes. The eluted GSH in the supernatant was assayed 
with 2,3-naphthalenedicarboxyaldehyde (NDA) and compared with a standard curve. 
The assay was carried out in duplicate in five independent experiments. 
4.2.4 Enzyme assays  
a. Dehydroascorbate reductase assay 
Reactions were carried out as previously described [323]. Dehydroascorbate was 
prepared fresh on the day and used within 3 hours. A typical reaction mix contained 200 
mM sodium phosphate, pH 6.85, 3 mM GSH and 1.5 mM dehydroascorbate. The 
reaction was initiated by adding 1 μg of purified protein and the rate of reaction was 
recorded at 265 nm at 30°C.  The specific activity of the enzymes was calculated with 
an extinction coefficient of 14.7 mM
−1
cm
−1
. Background rates (sample buffer only) 
were subtracted from the enzyme catalysed reaction rates. 
b. Glutathione transferase assay 
Reactions were carried out in 0.1 M sodium phosphate buffer pH 6.5 with 1 mM GSH 
and 1 mM freshly made 1-chloro-2,4-dinitrobenzene (CDNB). The conjugation reaction 
was initiated by adding 5 μg of enzyme and recorded at 340 nm at 30 °C for 10 minutes 
[324]. Specific activity was calculated with an extinction coefficient of 9.6 mM
-1
cm
-1
. 
c. Glutathionylation via thiyl radical formation 
The assay was carried out as previously described [325]. The Fe(II)ADP complex was 
prepared by incubating 20 mM FeCl2 and 100 mM ADP for at least an hour prior to use. 
The final reaction mix was made up in 0.1 M sodium potassium phosphate buffer and 
contained 0.2 mM NADPH, 0.5 mM GSH, 2 U/ml glutathione reductase and 50 μM 
hydrogen peroxide. The reaction was initiated with premixed 0.5 mM FeCl2 and 2.5 
mM ADP and recorded spectrophotometrically at 340 nm. 
4.2.5 Mass spectrometry 
Immunoprecipitation was performed as described in Chapter 2. Glutathionylated 
proteins were vacuum dried and re- suspended in 7 M Urea, 2 M thiourea, 20 mM tris, 
4% CHAPS. Samples were then incubated in DTT (final conc. 100 mM) for 1 hour 
followed by iodoacetamide (final conc. 15 mM) for 1 hr in the dark and run on a 12% 
SDS-PAGE. The gel was stained in Coomassie blue R-250 overnight and bands absent 
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in the T47-D/GSTO1-1 lysates were excised from the T47-D/pCDNA3 lysate. 1D 
nanoLC ESI MS/MS was carried out at the Australian Proteome Analysis Facility 
(APAF). Data generated were submitted to Mascot (Matrix Science Ltd, London, UK). 
Listed proteins were identified with a significance threshold of p<0.02 with Mascot cut-
off of 34.  
4.2.6 G-actin/F-actin assay 
Cells were plated in 6-well plates and treated with 1 mM S-nitrosoglutathione as 
described above. Cells were washed twice with PBS and lysed in 1% Triton X-100. The 
detergent soluble supernatant (containing globular actin) was collected and the pellet 
(containing filamentous actin) was washed in PBS and re-suspended in 1X SDS sample 
loading buffer [326]. Proteins were run on SDS-PAGE and immunoblotted. Actin was 
detected after incubation with anti-actin (abcam) and the ratio of G/F actin was 
determined by densitometry. Glutathionylated actin was detected by immunoblotting 
with anti-glutathione antibody. 
4.2.7 Phalloidin staining 
Cells were plated on coverslips (5 x 10
4
 cells) and treated with GSNO as described. For 
immunostaining, the cells were washed with PBS to remove unattached cells and fixed 
in 3.7% paraformaldehyde (in PBS) for 15 minutes at room temperature. The cells were 
washed in PBS three times and permeabilized in 0.1% Triton X-100 for 10 minutes at 
room temperature. Permeabilized cells were washed in PBS and incubated with 50 
μg/ml Phalloidin-FITC stain for 1 hour at room temperature in the dark. Samples were 
washed extensively in PBS and mounted on glass slides with mounting medium with 
Dapi (Vectashield). Fluorescence was recorded using a confocal microscope (Leica 
SP5). 
4.3 Results 
4.3.1 In vitro deglutathionylation by GSTO1-1  
To determine if the omega class GSTs participate in the glutathionylation cycle we 
adapted a peptide based tryptophan fluorescence quenching assay that has been 
previously used to measure the deglutathionylation activity of glutaredoxin [88]. A 
synthetic peptide incorporating a single cysteine residue adjacent to a tryptophan 
residue ’SQLWCLSN’ was artificially glutathionylated at the cysteine residue 
(SQLWC
-[SG]
LSN)  and used as a substrate. Deglutathionylation by GSTO1-1 was then 
measured by monitoring the change in fluorescence emitted by tryptophan as GSH was 
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removed from the neighbouring cysteine. Figure 4.1 shows the significant increase in 
fluorescence in the presence of GSTO1-1 but not with the active site cysteine 32 mutant 
(C32A).  It is interesting to note that the closely related GSTO2-2 isozyme did not 
exhibit any deglutathionylation activity.  Two additional GSTs were included in the 
study that could potentially catalyse deglutathionylation reactions. Chloride intracellular 
channel 2 protein (CLIC-2) is a member of the cytosolic GST structural family and like 
the Omega class GSTs has a cysteine residue in its active site.   Despite the presence of 
an active cysteine residue, no deglutathionylation activity was detected with CLIC2.  
The Kappa class of glutathione transferases is expressed in mitochondria and is 
structurally and evolutionarily distinct from the cytosolic GSTs like GSTO1-1. GSTK1-
11-1 is structurally related to the prokaryotic disulphide bond forming proteins and can 
also be considered as a potentially active participant in the gluathionylation cycle.  
However, recombinant human GSTK1-11-1 did not catalyse the deglutathionylation of 
the glutathionylated peptide (Figure 4.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1   GSTO1-1 catalyses the deglutathionylation of a peptide substrate.  
The increase in tryptophan fluorescence indicates the rate of peptide (SQLWC
-
[SG]
LSN) deglutathionylation by hGSTO1-1 in the presence of GSH. Among the 
GSTs tested, only GSTO1-1 showed deglutathionylating activity. Though GSTO2-2 
and CLIC2 have a cysteine residue at the active site, they failed to elicit similar 
fluorescence spectra with the glutathionylated peptide. Deglutathionylating activity 
by GSTO1-1 was abolished by mutating the active cysteine residue (C32A). The 
graph represents the average of three traces. 
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4.3.2 Determination of kinetic parameters of the deglutathionylation reaction  
The tryptophan fluorescence quenching assay was employed to further characterize the 
GSTO1-1 catalysed deglutathionylation reaction. Previous studies have identified 
several polymorphic variants of GSTO1-1 that could potentially vary in their substrate 
affinity and have an impact on the regulation of glutathionylation levels [179, 197, 262].  
The specific activity and other kinetic parameters were calculated from V/[S] plots in 
Figure 4.2 (Table 4.1).  The D140 variant had significantly lower deglutathionylation 
activity and this difference mainly reflected a lower kcat . To confirm that this difference 
was not due to differential degradation of the enzymes during their preparation, we 
compared their thioltransferase and dehydroascorbate reductase activities (Table 4.1). 
These activities were found to be equivalent in agreement with previous studies from 
this laboratory [197].  A deletion in  E155 has previously been demonstrated to be 
highly unstable and is usually genetically linked to a polymorphism E208K [321]. In 
this case, recombinant protein with the single K208 substitution was prepared.  This 
enzyme had a significantly lower specific activity when compared to wildtype GSTO1-
1. As indicated above, GSTO2-2 had no deglutathionylation activity. However, as 
shown in Table 4.1, the preparation was not degraded as it exhibited normal 
thioltransferase activity and the expected high level of dehydroascorbate reductase 
activity.  Previous studies of CLIC-2 have failed to identify any significant enzyme 
activity so it is not possible to confirm that this protein preparation has not been 
degraded.  We confirmed the viability of the GSTK1-11-1 protein by measuring its 
glutathione conjugating activity with 1-chloro-2,4-dinitrobenzene. This activity was 
readily measurable but lower than the specific activity we have previously reported 
[327]. 
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Figure 4.2: Kinetics of GSTO1-1 catalysed deglutathionylation in vitro: V/ [S] 
plots 
(A) Increase in the rate of deglutathionylation by GSTO1-1 and its allelic variants 
with increasing substrate (peptide) concentrations; (B) Increase in the rate of 
deglutathionylation by GSTO1-1 with increasing GSH concentrations.  
  
A
  
B
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Enzyme Km Peptide  
(μM) 
kcat 
Peptide 
(s
-1
) 
kcat/Km 
Peptide 
(μM-1 s-1) 
KmGSH 
(mM) 
Deglutathionylatio
n specific activity 
(nmoles/mg of 
protein/min) 
Thiol transferase 
specific activity 
(μmoles/mg of 
protein/min) 
Dehydroascorbate 
reductase specific 
activity (μmoles/mg 
of protein/min) 
A140/E208/C32 7.9 ± 0.97 2.8 ± 0.28 0.3 0.4 ± 0.09 83.4 ± 4.4 1.0 ± 0.02 0.1 ± 0.03 
D140/E208/C32   3.4 ± 0.5 1.3 ± 0.15 0.4 0.4 ± 0.12 48.6 ± 2.9 0.9 ± 0.03 0.2 ± 0.04 
A140/K208/C32 2.6 ± 0.49 0.4 ± 0.07 0.1 0.3 ± 0.05 17.8 ± 2.53 1.0 ± 0.03 0.1 ± 0.04 
A140/E208/A32 - - - - nd nd 0.6 ± 0.09 
GSTO2-2 - - - - nd 1.2 ± 0.02 12.9 ± 0.88 
GSTK1-1
 
- - - - nd nd nd 
        
Table 4.1. Characterization of the kinetic parameters of GSTO1-1 catalysed deglutathionylation in vitro. 
 The allelic variants of GSTO1-1 exhibit significantly different deglutathionylation reaction kinetics. Km: Michaelis constant; Kcat: turnover 
number; Kcat/Km: enzyme efficiency 
*nd: not detected 
 
Chapter 4 
76 
 
4.3.3 pH dependence of deglutathionylation by GSTO1-1  
The dependence of the reaction rate on pH was determined by recording reaction rates 
in the presence of buffers of varying pHs (4-9). The reaction conditions were found to 
be optimum at pH 7 with significantly lower rates at both extremes (Figure 4.3).  
 
 
 
4.3.4 Over expression of GSTO1-1 caused global abatement of protein 
glutathionylation 
T47-D cells are naturally deficient in GSTO1-1 and can be used to evaluate the role of 
GSTO1-1 in the glutathionylation cycle [321]. Stable expression of GSTO1-1 in T47-D 
cells was checked prior to use of cells for experiments by immunoblotting (Figure 
4.4A). Whole cell lysates from T47-D cells expressing GSTO1-1 and T47-D expressing 
the empty vector control were separated on a non-reducing gel and probed with an anti-
glutathione antibody. In T47-D empty vector transfectants global glutathionylation 
levels were 2.2 ± 0.49 nmoles GSH/ mg of protein. In contrast 0.9 ± 0.18 nmoles 
GSH/mg of protein was detected in the GSTO1-1 stable transfectants (Figure 4.4B). A 
significant decrease in the extent of glutathionylation of proteins as well as a decrease in 
the number of glutathionylated proteins was seen in the GSTO1-1 stable transfectants 
(Figure 4.4C). The data suggest that the expression of GSTO1-1 was responsible for the 
deglutathionylation of at least half the glutathionylated proteins, resulting in low 
glutathionylation levels. 
 
 
 
Figure 4.3: pH dependence of deglutathionylation by GSTO1-1 
Chapter 4 
77 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.5 Identification of targets of GSTO1-1 using mass spectrometry  
Glutathionylated proteins that were reproducibly observed to be deglutathionylated in 
T47-D/GSTO1-1 cells were identified by mass spectrometry. Glutathionylated proteins 
were immunoprecipitated and separated on a SDS PAGE. Three protein bands present 
in the T47-D/pCDNA3 cells but absent in the GSTO1-1 expressing cells were excised 
from the gel, trypsin digested and subjected to mass spectrometry. Four proteins were 
identified as potential targets of GSTO1-1 catalysed deglutathionylation (Figure 4.5) 
Figure 4.4: Expression of GSTO1-1 causes the deglutathionylation of proteins in T47-
D breast cancer cells.  
(A) Parental T47-D cells transfected with empty vector are deficient in GSTO1-1 (left 
lane). The cells were stably transfected with pCDNA3 C32A GSTO1-1 mutant (middle 
lane) and pCDNA3 GSTO1-1 (right lane). (B) The expression of GSTO1-1 resulted in a 
significant decrease in the total protein glutathionylation levels. This decrease was seen 
only in cells expressing wildtype GSTO1-1 and not in the cells expressing C32A 
GSTO1-1. The C32A GSTO1-1 transfected cells had protein glutathionylation levels 
comparable to the empty vector transfected cells. (C) Total glutathionylated proteins in 
empty vector and GSTO1-1 transfected cells were qualitatively detected with an anti-
glutathione antibody (left panel).  Proteins showing a marked decrease in 
glutathionylation are indicated by arrows. To confirm that the antibody was detecting 
protein bound glutathione, cell lysates were incubated with DTT and analysed as above. 
The lower right panel (C) shows that treatment of cellular proteins with dithiothreitol 
removed the chemiluminescence signal i.e. protein bound glutathione. The upper panel 
shows glutaredoxin 1 (Grx1) expression in T47-D cells transfected with the empty 
pCDNA3 vector and lower expression in T47-D cells expressing GSTO1-1.  
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(Table 4.2) including β-actin, Heat shock protein 70 (HSP70), Heat shock protein 7C 
(HSP7C) and Prolactin inducible protein (PIP).  
 
 
 
 
 
 
 
 
 
Since β-actin is a well-researched target of glutathionylation [27, 29, 69], the role of 
GSTO1-1 in its deglutathionylation in T47-D cells was validated.  β-actin was 
immunoprecipitated from T47-D cells expressing GSTO1-1 and T47-D cells expressing 
the empty vector control and probed with anti-glutathione to determine its 
Table 4.2   Proteins deglutathionylated by GSTO1-1 identified by mass spectrometry 
(Mass Hunter) 
 
Figure 4.5: Sample preparation for mass spectrometry on glutathionylated proteins. 
Glutathionylated proteins were immunoprecipitated with anti-glutathione and 
separated on a 12% SDS PAGE gel and stained with Coommassie blue. Proteins 
indicated by the arrows were excised and analysed by mass spectrometry.  
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glutathionylation state. As shown in Figure 4.6A, glutathionylated β-actin was detected 
in T47-D/pCDNA3 cells but not in T47-D/GSTO1-1 cells. The equal pull down of β-
actin from both cell types was confirmed by probing the membrane with an anti-actin 
antibody (middle panel). To further validate the deglutathionylation of β-actin by 
GSTO1-1, glutathionylated proteins were immunoprecipitated from the T47-D cells and 
the pull down of β-actin was detected with an anti-actin antibody. As shown in the 
lower panel of Figure 4.6A, β-actin was glutathionylated only in T47-D /pCDNA3 cells 
and not in GSTO1-1 expressing cells, confirming that GSTO1-1 is required for the 
deglutathionylation of β-actin. 
4.3.6 Physiological implications of GSTO1-1 mediated deglutathionylation of β-actin 
The glutathionylation state of actin previously has been demonstrated to influence the 
ability of the protein to switch from the monomeric globular state (G-) to a filamentous 
state (F-) which contributes to the cytoskeletal modelling of cells [29]. Hence, the 
conformational state of actin was evaluated in T47-D/GSTO1-1 cells. As seen in Figure 
4.6B, the ratio of G- to F-actin was considerably higher in T47-D/pCDNA3 cells when 
compared to the ratio in GSTO1-1 expressing T47-D cells. Notably, G-actin was more 
abundant in T47D/pCDNA3 cells contributing to the shift in the ratio of G-/F-actin. 
This finding correlates with published literature [29, 69] which states that globular actin 
is heavily glutathionylated and needs to be deglutathionylated in order to switch to the 
filamentous form which forms the cytoskeleton.  To further understand the modulation 
of cytoskeletal structuring in the cells, actin was stained with FITC labelled phalloidin 
(actin-specific dye). Over-expression of GSTO1-1 in T47-D cells was seen to increase 
the proportion of filamentous actin (Figure 4.6C) which was reversed in GSNO treated 
cells. Since GSNO is a glutathionylating agent, it is possible that the deglutathionylation 
of actin was ‘over-ridden’ by the increased oxidative stress.  
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Figure 4.6: GSTO1-1 dependent deglutathionylation modulates the cytoskeletal 
structure by altering the G-/F-actin ratio. 
(A) β-actin was validated as a target of GSTO1-1 dependent deglutathionylation by 
immunoprecipitation. β-actin was immunoprecipitated with an anti- β-actin antibody 
followed by immunoblotting with anti-P-SSG (top panel). Glutathionylated actin 
was detected in the control cells deficient in GSTO1-1 while no glutathionylated β-
actin was detected in the GSTO1-1 over- expressing cells. Immunoprecipitation of β-
actin in both samples was confirmed by probing with anti- β-actin (middle panel). 
Glutathionylated proteins were immunoprecipitated with anti-P-SSG and probed 
with anti- β-actin (lower panel). (B) Globular and filamentous β-actin were extracted 
from T47-D cells expressing GSTO1-1 and T47-D cells expressing the empty vector 
control and probed with anti-β-actin. Expression of GSTO1-1 in T47-D cells 
decreased the G-/F-actin ratio as a consequence of deglutathionylation of actin. Data 
represent the average of densitometry performed in three independent experiments. 
C) Fluorescence microscopy revealed increased filamentous actin (green) in the 
GSTO1-1 expressing cells. Treatment of cells with GSNO resulted in increased 
glutathionylation and the reversal of filamentous actin to globular actin in GSTO1-1 
expressing cells. The nucleus is stained blue with DAPI. 
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4.3.7 In vitro glutathionylation by GSTO1-1  
The glutathionylating activity of GSTO1-1, GSTO2-2, CLIC2 and GSTK1-11-1 was 
tested using the deglutathionylated form of the SQLWCLSN peptide in the presence of 
high GSSG concentrations. Although the spontaneous glutathionylation rate was high in 
this experiment (no enzyme control reaction, Figure 4.7), the rate of glutathionylation 
only increased marginally in the presence of the GSTO1-1, GSTO2-2 and CLIC 2. In 
contrast GSTK1-11-1 did not affect the reaction rate. Although GSTO1-1 GSTO2-2 and 
CLIC 2 appear to catalyse the glutathionylation of the peptide under these conditions 
the absolute rate was insignificant when compared to the deglutathionylating activity of 
GSTO1-1 (Figure 4.1).  
 
 
 
 
 
 
4.3.8 Treatment with GSNO increased global glutathionylation in a time dependent 
manner 
S-nitrosoglutathione (GSNO) has previously been shown to be a suitable agent to 
induce protein glutathionylation in cells with minimal oxidative damage [314]. GSNO 
was preferred over GSSG in this system as GSSG reacts very slowly with PSH [57]. 
The degradation of GSNO is dependent on the action of alcohol dehydrogenase class III 
and can generate several intermediates (Figure 4.8).  In the presence of high glutathione 
concentrations the formation of GSSG is favoured [328]; while low GSH levels favours 
Figure 4.7: GSTO1-1, GSTO2-2 and CLIC2 catalysed the glutathionylation of the 
peptide SQLWCLSN at a poor rate in vitro. The graph represents the average of 
three traces. 
 
 
Chapter 4 
82 
 
the formation of glutathione disulphide-S-oxide (GS(O)SG). Both GSSG and GS(O)SG  
are capable of glutathionylating proteins directly. Though the S-N bond in GSNO has a 
slight polarity with a partial negative charge on sulphur and a partial positive charge on 
nitrogen, there is evidence indicating that protein thiolates react with the partially 
negatively charged sulphur atom and are glutathionylated and not nitrosylated [28, 58, 
126, 329]. This may occur either by direct interaction of P-SSG with GSH or through 
the denitrosylation of PSNO by GSH.  
 
 
 
Figure 4.8: Pathways for the GSH dependent metabolism of GSNO.  GSNO 
can be taken up into cells by transnitrosation with cysteine and the L system 
amino acid transporter [3]. GSTO1-1 could catalyse any of the intermediate 
steps in the metabolism of GSNO by either catalysing the formation of 
glutathione disulphide from S-(N-hydroxyamino)glutathione (GS-NH-OH) or 
the formation of  glutathione disulphide-S-oxide (GS(O)SG from glutathione 
sulfinamide (GS(O)NH2) or the glutathionylation of proteins (P-SSG) by 
GS(O)SG (shown in grey). 
 
Chapter 4 
83 
 
The susceptibility of proteins to glutathionylation versus nitrosylation has been shown 
to be dependent on various parameters including the polarity of adjacent residues [126]. 
Protein thiolates adjacent to basic residues such as histidine are more susceptible to 
glutathionylation. GSNO-induced glutathionylation was shown to be transient in the 
presence of GSH as an initial increase in total P-SSG was followed by a gradual drop in 
levels [28, 57, 58, 126, 330]. This was previously attributed to the spontaneous 
deglutathionylation of P-SSG to PSH.  
 
In this study T47-D transfectants were treated with 1 mM GSNO to determine whether 
GSTO1-1 expression influences the extent of glutathionylation and the rate of 
deglutathionylation. Glutathionylation was enhanced significantly by GSNO in both 
T47-D cells expressing GSTO1-1 and T47-D expressing the empty vector control 
(Figure 4.9A & B). The cells expressing active GSTO1-1 were found to be more 
sensitive to GSNO treatment indicated by their higher total glutathionylation levels 
within 30 minutes (Figure 4.9B) compared with cells not expressing GSTO1-1 or cells 
expressing the catalytically inactive GSTO1-1 C32A mutant. We expected the 
expression of GSTO1-1 in T47-D cells would accelerate the rate of deglutathionylation 
once glutathionylation reached peak levels. T47-D cells over expressing GSTO1-1 
demonstrated a marginally higher deglutathionylation rate as compared to the control 
pCDNA3 transfected cells which suggests that GSTO1-1 may be catalysing the 
deglutathionylation of proteins and thus helping proteins recover their physiological 
structure and resume normal cellular function. To investigate the mechanism of the 
increased glutathionylation in GSTO1-1 expressing cells after GSNO exposure, the 
endogenous GSSG levels were measured. The GSTO1-1 expressing cells had 
significantly higher levels of free GSSG that could contribute to the increased 
glutathionylation of proteins in these cells (Figure 4.9C). This suggests that GSTO1-1 
may catalyse an intermediate step in the formation of GSSG in the metabolism of 
GSNO in cells (Figure 4.8).  
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Figure 4.9: GSNO induced protein glutathionylation is dependent on GSTO1-1  
(A) Increase in protein glutathionylation after treatment of cells with 1 mM S-nitrosoglutathione (GSNO) is significantly higher in T47-D cells expressing 
active GSTO1-1 than in GSTO1-1 deficient cells transfected with the empty pCDNA3 vector or the C32A mutant enzyme. The data points represent the 
mean  SEM of 3 replicates. (B) Protein glutathionylation increased post treatment with nitrosoglutathione (GSNO) in all cells but the level of 
glutathionylation was significantly higher in T47-D cells expressing active GSTO1-1 than in cells transfected with the empty pCDNA3 vector 
or the C32A mutant protein (C) Protein glutathionylation was measured qualitatively in cells treated with GSNO.  (D) The levels of GSSG 
were significantly higher in T47-D cells expressing GSTO1-1 in 30 minutes, correlating with the increase observed in protein 
glutathionylation. The data points represent the mean  SEM of 3 replicates 
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4.3.9 Glutathione thiyl radicals as a GSTO1-1 substrate.  
Glutaredoxin (Grx) has been shown to react with glutathione thiyl (GS•) radicals, 
forming a GRx-SSG• disulphide anion radical intermediate and transfers the (GS•) to 
protein thiols or glutathione resulting in the formation of glutathionylated proteins or 
GSSG. The ability of GSTO1-1 to react with thiyl radicals was tested by incubating 
purified GSTO1-1 variants with (GS•). Both allelic variants of GSTO1-1 catalysed the 
formation of GSSG from the thiyl radical. However, the rate of formation of GSSG by 
D140 GSTO1-1 was significantly higher than the A140 variant (Figure 4.10A).  
Furthermore, comparing the total glutathionylation levels in lymphoblastoid cells 
expressing the two allelic variants revealed that cells expressing the D140 variant had 
slightly higher levels of glutathionylated proteins (Figure 4.10B). This was expected as 
the deglutathionylation activity of the D140 variant was shown to be significantly lower 
than the A140 wildtype protein in vitro. On GSNO treatment, both cell types showed a 
similar peaking in total protein glutathionylation followed by a time dependent drop as 
GSNO is metabolised in the cell. Notably, the difference in total glutathionylation levels 
was evident between the two variants even in the presence of GSNO, though it was not 
statistically significant (Figure 4.10B).   
 
Figure 4.10: Glutathionylation of proteins by GSTO1-1 and its allelic variants 
(A) GSTO1-1 catalyses the formation of GSSG from glutathione thiyl radicals. The 
D140 allelic variant exhibited a higher rate of GSSG formation when compared to the 
wildtype A140 GSTO1-1. (B) The total protein glutathionylation levels were 
consistently higher in D140 GSTO1-1 expressing lymphoblastoid cells even after 
treatment with GSNO.  
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4.4 Discussion 
The impact of post-translational modifications such as phosphorylation and 
glutathionylation on protein structure and function are of great significance. 
Phosphorylation has been extensively studied for its role in the regulation of signalling 
cascades via the modulation of tyrosine kinases. In comparison, glutathionylation is 
relatively less explored though increasing evidence suggests a growing curiosity in the 
mechanism and role of protein thiol modification with glutathione [27, 68, 305]. 
Glutathionylation is the reversible modification of proteins by the addition of a 
glutathione moiety to thiols exposed on the protein surface. Protein thiols are sensitive 
to the immediate redox environment and a slight imbalance in redox homeostasis may 
result in their irreversible oxidation to a sulfonic acid form which may be detrimental to 
proteins [4]. Glutathionylation may be considered as a primary line of defence raised 
against oxidative stress and hence the reversal of this thiol modification is equally 
essential for a cell to recover protein function when rescued from an unfavourable 
environment. Though glutathionylation is strongly associated with oxidative stress, 
there are several lines of evidence confirming the occurrence of glutathionylation in 
normal physiological conditions, acting as a switch regulating protein activity [69, 76, 
143]. The reversal of glutathionylation is largely dependent on catalysts, a list that is 
predominantly restricted to glutaredoxins, thioredoxins and sulfiredoxin [29, 31, 319]. 
Glutaredoxins are enzymes that rely on their active site cysteine residues to catalyse the 
glutathionylation and deglutathionylation of proteins [21, 26, 61-65, 76, 87]. Due to the 
occurrence of two active site cysteines in a conserved CXXC motif, glutaredoxins are 
capable of glutathionylating proteins via a monothiol mechanism and 
deglutathionylating via a dithiol mechanism [63]. Glutaredoxins can also catalyse 
disulphide exchange between the two active cysteines, which forms an intermediate step 
in the dithiol mechanism. Sulfiredoxins have a single cysteine residue and hence 
catalyse deglutathionylation reactions via a monothiol mechanism [29, 331].  
Members of the Glutathione transferase family have been well characterized with 
excellent ability to catalyse the conjugation of glutathione with a range of xenobiotics 
[194, 195].  A relatively new hypothesis proposed previously questioned the possibility 
of extending GST-catalysed glutathione conjugation reactions to protein substrates 
[332]. Though GSTs have been shown to regulate signal transduction via direct protein-
protein interactions [208, 238, 242, 243, 245, 333], GSTP was the first member 
identified to catalyse protein glutathionylation. The mechanism of glutathionylation by 
GSTP was shown to be similar to that of typical GSH-conjugation reaction with 
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xenobiotics i.e. via lowering the pKa of GSH by the active site tyrosine residue [20, 
111]. Though other GSTs haven’t been extensively studied, a recent study demonstrated 
the in vitro ability of mammalian GSTM1 and GSTP1 to catalyse the glutathionylation 
of recombinant AMP- kinase (AMPKα) though the physiological implications were not 
fully elaborated [334].  
Previous studies have established the structural resemblance of the N-terminal domain 
of GSTO1-1 to the Grx family [197] with a conserved thioredoxin fold. On further 
analysis, we found that the active site cysteine in human GSTO1-1 aligns with the 
active site in human Grx1, supporting our findings that GSTO1-1 catalyses 
deglutathionylation of proteins similar to the glutaredoxins (Figure 4.11). Our data 
suggest that GSTO1-1 deglutathionylates proteins via a monothiol mechanism through 
cysteine-32.  The reaction proceeds by the following path where the model peptide 
represents a protein substrate and the enzyme is recycled by the action of GSH: 
 
GSTO1 32C
SH
 + SQLWC
SG
LSN    GSTO1 32CSG +    SQLWCSHLSN 
GSTO1 32C
SG
 + GSH       GSTO1 32CSH + GSSG 
 
Interestingly, GSTO2-2 (68% sequence similarity to GSTO1-1) and CLIC 2 also 
contain the thioredoxin fold and similar active site residues but do not exhibit 
deglutathionylation activity under the conditions used in this study. It must be noted that 
though GSTO2-2 and CLIC2 have cysteine residues in their active sites, GSTO2-2 does 
not catalyse the S-phenacylglutathione reductase activity of GSTO1-1 while CLIC2 
does not have any measurable catalytic activity. Thus, the inability of the two proteins 
to catalyse the glutathionylation cycle reactions is not without precedent.  
We have characterized the kinetics of GSTO1-1 catalysed deglutathionylation in vitro 
and further confirmed the physiological occurrence of the reaction in cells. 
Recombinant GSTO1-1 catalysed the removal of glutathione from an artificially 
glutathionylated peptide in the presence of GSH, which was quantified by measuring 
the decrease in fluorescence emitted by an adjacent tryptophan residue.  The emission 
spectrum of tryptophan is highly reflective of its immediate environment and an 
alteration to surrounding residues can modify its fluorescence emission. Thus, when 
glutathione is catalytically removed from the adjacent tyrosine residue in the  
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Figure 4.11: Structural similarities between the glutaredoxin family of 
oxidoreductases and GSTs 
(A) The structures of GSTO1, GSTO2, CLIC2 and Grx1 shown in cartoon form, 
are drawn from the coordinates in PDB files 1EEM, 3Q18, 2R4V and 1GRX 
respectively.  In the conserved thioredoxin fold domain β-sheet is shown in 
magenta and helices are shown in cyan. The C-terminal helical domain of 
GSTO1, GSTO2 and CLIC2 is shown in green.  (B) Residues conserved in the 
active site of the enzymes. (pink: fully conserved, yellow: very similar and blue: 
weakly similar).   
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SQLWCLSN peptide we measured an increase in tryptophan fluorescence which was 
normalized to the control (no enzyme) levels for the estimation of its specific activity. 
The specific activity of GSTO1-1 in deglutathionylation was estimated at 83.4 
nmoles/mg of protein/min. The initial rate of the reaction increased with increasing 
peptide concentration and fitted well to the Michaelis-Menten equation. The Km value 
obtained for GSTO1-1 was 7.9 ± 0.97 μM which is comparable to that reported for Grx 
(7.8 μM) [87]. An interesting finding this study revealed was the significant difference 
in deglutathionylating activity among the allelic variants of GSTO1-1. The polymorphic 
variant D140 exhibited deglutathionylation activity of almost half that of the more 
frequent (wildtype) A140 isoform. More significantly, the K208 variant was 
approximately five times less active than the most common E208 allelic variant. In 
Europeans the K208 allele is closely linked to a deletion of E155 which destabilizes the 
protein [335] and its effects would not be apparent in vivo.  Genetic variation at the 
GSTO1 locus has previously been linked to the age at onset of Alzheimer’s and 
Parkinson’s diseases however a direct functional mechanism has never been identified 
[210-212, 214, 272].  It is reasonable to speculate that differences in glutathionylation 
could play a role in the progression of the pathology of these diseases and this study has 
shown that there are significant differences in the deglutathionylation reaction kinetics 
between the common A140 and D140 allelic variants.  
In this study, the deglutathionylating activity of GSTO1-1 was evaluated in whole cells. 
T47-D breast cancer cells were considered ideal to determine the deglutathionylating 
activity of GSTO1-1 as these cells are devoid of endogenous GSTO1-1 expression due 
to their hemizygosity for Del E155 allele  that results in the expression of an unstable 
protein.[336]. Thus, T47-D stable transfectants expressing active GSTO1-1 or a 
catalytically inactive C32A mutant were employed to determine the effect of GSTO1-1 
on protein glutathionylation. Expression of GSTO1-1 resulted in an abatement of total 
protein glutathionylation which complemented the in vitro peptide studies. Further 
investigation into GSTO1-1 catalysed deglutathionylation in T47-D cells identified four 
protein targets including β-actin. This finding further supports the proposal that 
GSTO1-1 has target specificity and does not deglutathionylated all proteins at the same 
rate. Figure 4.12 depicts a proposed mechanism by which GSTO1-1 catalyses the 
deglutathionylation of proteins and gets recycled by cellular GSH or GSH provided in 
the in vitro reaction mix. Glutathionylation is known to modulate the activity of proteins 
in various metabolic and signalling pathways [27, 61, 66, 139, 141, 143, 160, 305, 337, 
338]. For instance, this study demonstrated that GSTO1-1 dependent 
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deglutathionylation of actin can modulate the structural modelling of T47-D cells 
(Figure 4.6). 
   
Figure 4.12: Model depicting the reaction pathway of deglutathionylation by 
GSTO1-1 
Glutathionylated protein thiols interact with GSTO1-1 in two steps: First the 
glutathionylated protein thiol (P-SSG) binds to the GSH binding site of 
GSTO1-1 via the –SSG group. The –SSG group is exchanged between 
cysteine 32 (Cys32-SH) (shown in yellow) and P-SSG. The glutathionylated 
Cys32-SSG is recycled by free GSH and is free to catalyse the 
deglutathionylation of the next protein substrate. 
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Thus, it is essential for enzymes catalysing the glutathionylation cycle such as 
glutaredoxins, sulfiredoxin, GSTP and GSTO1-1 to have substrate specificity to 
establish a reversible switch to differentially regulate specific pathways under different 
stress signals. The factors contributing to the observed target specificity of GSTO1-1 
are yet to be fully understood.  
The in vitro experiments performed to measure the potential glutathionylation activity 
(due to structural and sequence similarity with glutaredoxins) using the peptide 
‘SQLWCLSN’ failed to detect any significant activity catalysed by either GSTO1-1 or 
GSTO2-2. This may be due to several reasons. Fluorescence from the adjacent 
tryptophan residue was consistently decreasing in the control reaction even in the 
absence of GSTO indicating spontaneous glutathionylation in the presence of high 
GSSG concentrations. However it is also known that glutathionylation by GSSG is a 
relatively slow reaction [57] which may account for the absence of a higher reaction 
rate for the spontaneous reaction (Figure 4.6). Though glutathionylation is thought to be 
largely spontaneous, Grxs have been demonstrated to catalyse the reaction with target 
specificity [21, 26, 62, 63, 76, 87]. Apart from an enzyme’s affinity towards a protein 
target, the susceptibility of the target cysteine residue is also determined by its pKa 
value which in turn is influenced by the polarity of residues in its immediate 
environment, either adjacent to the cysteine or in close proximity due to the protein’s 
tertiary structure [30]. Cysteines surrounded by basic amino acids such as histidine have 
been reported to be more susceptible to glutathionylation by lowering the pKa of the 
cysteine residue [30, 126]. Since the peptide was 8 residues long, it cannot be argued 
that the peptide’s tertiary structure influenced the poor reaction rates measured. 
However the absence of suitable basic amino acids within the 8-mer may have 
contributed to the absence of a significant glutathionylation reaction in the presence of 
GSSG in the absence of GSTO1-1. Also, it is possible that the sequence of the peptide 
may not be appropriate for binding to GSTO1-1, hence preventing the interaction of the 
target thiol with the active site cysteine residue.  
GSTO1-1 was also demonstrated to produce GSSG from glutathione thiyl radicals that 
can in turn glutathionylate proteins. Interestingly, GSTO1-1 may be responsible for 
glutathionylation of proteins in cells treated with GSNO either by directly catalysing the 
glutathionylation of specific proteins or by increasing the GSSG levels which in turn 
glutathionylates proteins. The former could not be proven in this study but after GSNO 
treatment, GSSG levels were significantly higher in T47D cells expressing GSTO1-1 
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than in empty vector control cells. This study provides preliminary evidence that 
GSTO1-1 may catalyse intermediate reactions in the generation of GSSG from GSNO. 
Consequently GSTO1-1 may indirectly glutathionylate proteins via GSSG formation 
from glutathionylating agents such as GSNO or by reacting with glutathione thiyl 
radicals. It is yet to be fully investigated whether glutathionylation by GSTO1-1 has 
target specificity like Grxs which is affected by other parameters such as the tertiary 
structure of the protein.   
The known impact of glutathionylation on neurodegenerative diseases is not extensive 
though the activity of critical proteins such as Tau have been reported to be modulated 
by the oxidative state of their thiols (reviewed extensively in [339]). GSTO1-1 and its 
allelic variants have been implicated to influence the age at onset of inflammation 
associated neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases. 
Since the D140 GSTO1-1 variant was shown to exhibit lower deglutathionylation 
activity both in vitro and in lymphoblastoid cells, it is not unreasonable to speculate that 
GSTO1-1 and its differentially active allelic variants may modulate the function of 
proteins involved in neurodegeneration by catalysing their deglutathionylation.  
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CHAPTER 5 
Glutathione transferase Omega modulates TLR4 
dependent pro-inflammatory responses 
5.1 Introduction 
A study by Laliberte et al. identified GSTO1-1 as a target of Cytokine Release 
Inhibitory Drugs (CRIDs), implicating GSTO1-1 in pro-inflammatory pathways 
involved in the activation and processing of interleukin 1β in monocytes [264]. A recent 
study identified a novel interaction of GSTO1-1 with ASC (Apoptosis associated speck-
like protein containing a CARD), which is a component of the inflammasome complex 
required for the synthesis of mature IL-1β. These results indicate the probability of an 
indirect effect of GSTO1-1 on IL-1β via protein-protein interactions within the 
activation complex [265]. We have recently shown that GSTO1-1 has significant 
deglutathionylation activity like glutaredoxins, both in vitro and in cells [90](Chapter 
4).  Whether this activity has a role in the regulation of pro-inflammatory responses is 
yet to be determined.  
Inflammatory stimulants, such as bacterial endotoxin (Lipopolysaccharide, LPS) have 
been shown to induce reactive oxygen species (ROS) generation through the activation 
of Toll like receptor 4 (TLR4) by disturbing the balance between the activation of 
oxidants and suppression of antioxidants [149, 280, 340-343]. Though LPS induced 
inflammatory responses largely depend on the activation of TLR4 and recruitment of 
downstream signalling proteins, the immediate generation of TLR4 mediated ROS has 
been shown to have an impact on the expression of pro-inflammatory cytokines [279, 
340, 343, 344]. The generation of ROS after LPS stimulation has been shown to be 
dependent on the cytosolic NADPH oxidases [147, 340, 345, 346]. A recent study 
elucidated the role of NADPH oxidase 1 in LPS induced ROS generation which was 
significantly attenuated in Irak1
-/-
 mice [149]. In this chapter, the indispensable role of 
GSTO1-1 as a novel regulator of ROS-dependent pro-inflammatory responses in 
macrophages is described. Gsto1 knockdown cells were found to be non-responsive to 
LPS and failed to elicit pro-inflammatory responses including the expression of IL-1β, 
generation of ROS and the suppression of antioxidants. Since their first description, the 
Omega class GSTs have been investigated in relation to a number of biologically 
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significant pathways and clinical disorders including drug resistance [260], Alzheimer’s 
Disease [210, 211, 215, 216, 272], Parkinson’s disease [210, 215, 216, 261], vascular 
dementia and stroke [214], amyotrophic lateral sclerosis [217], the action of anti-
inflammatory drugs [264], the disposition of arsenic [274], susceptibility to chronic 
obstructive pulmonary disease (COPD) [213] and cancer [113, 260, 321]. This study 
introduces a novel finding that may help elucidate the role of GSTO1-1 in inflammatory 
disorders. 
 
5.2 Materials and methods 
5.2.1 Materials 
Ligands for TLR activation including LPS (E. coli O111:B4) for TLR4, PAM3CSK4 
for TLR1/2, Poly:I(C)  for TLR3, R848 for TLR7 and CpG for TLR9 were purchased 
from Invitrogen. The primers used in this study were purchased from Integrated DNA 
Technology (IDT). Primer sequences are listed in Appendix A6. ML175 was purchased 
from Vitas-M laboratory (Netherlands).  
5.2.2 Cell lines and treatments 
Murine J774.1A cells were stably transfected with Gsto1 targeting lentiviral shRNA and 
scrambled non-targeting shRNA as previously described [345] and maintained in 
DMEM media supplemented with 10% FBS, 3μg/ml puromycin and 2 mM Glutamine. 
Cells were treated with standard concentrations of 10 ng/ml LPS, 1 μg/ml PAM3CSK4, 
1 μg/ml R848, 25 μg/ml Poly:I(C)  and 1 μg/ml CpG unless otherwise stated.  Cells 
were treated with varied concentrations of ML175 (0.25 μM- 5 μM) for 2 hours prior to 
LPS stimulation. For measurement of cytokines, cells were stimulated with indicated 
ligands for 24 hours and supernatants were collected and frozen at -20°C for ELISAs. 
For the measurement of ROS and mRNA expression levels, cells were stimulated with 
LPS for 6 hours.  
5.2.3 Measurement of ROS 
Total intracellular ROS was determined with the fluorescent probe chloromethyl-2’,7’-
dichlorofluorescein diacetate (CM-H2DCFDA) (Invitrogen). J774.1A macrophages 
were seeded at a density of 1x10
5
 cells in a 6-well plate and treated with LPS 
(100ng/ml) for indicated time points. The cells were washed twice with PBS and 
incubated with 10 μM CM-H2DCFDA (in PBS) for 30 minutes at 37°C. The cells were 
again washed with PBS and formation of dichlorofluorescein was measured using a 
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fluorescence spectrophotometer (Fluostar Optima) at excitation/emission wavelengths 
of 488/525 nm. Raw fluorescence measurements were normalized to unstained cells.  
5.2.4 Enzyme assays 
a. Catalase: Reactions were carried out as described previously [347].  5 μg of total cell 
lysate was added to a reaction mix containing 50 mM phosphate buffer (pH 7.0), 50 
mM H2O2. The reaction was stopped with 1.25% sodium dichromate for 10 minutes. 
The reaction rate was measured at 240 nm at 37°C and the specific activity was 
calculated as moles of H2O2 consumed/mg of protein. Baseline samples were prepared 
by adding sodium dichromate to samples at time ‘zero’ and background rate was 
subtracted from the enzyme catalysed reaction rates. Protein concentration was 
estimated by a BCA protein estimation kit (Pierce).  
b. Glutathione peroxidase: 50 μg of total cell lysate was added to a reaction mix 
containing 50 mM phosphate buffer (pH 7.0), 1 mM GSH, 200 μM NADPH, 0.1 U 
glutathione reductase and 20 μM cumene hydroperoxide. The reaction rate was 
measured at 340 nm at 37°C and the specific activity was calculated based on an 
extinction coefficient of 6.22 mM
−1
cm
−1
. Background rates were subtracted from the 
enzyme catalysed reaction rates.  
c. Glutathione Reductase: 20 μg of cell lysate was added to a reaction mix containing 
0.1 M Tris/0.5 mM EDTA (pH 8.0), 0.2 mM NADPH and 3.3 mM GSSG. The reaction 
rate was measured at 340 nm at 37°C and the specific activity was calculated based on 
an extinction coefficient of 6.22 mM
−1
·cm
−1
. Background rates (sample buffer only) 
were subtracted from the enzyme catalysed reaction rates.  
d. 4-NPG reduction: GSTO1-1 specific activity was determined with S-(4-
nitrophenacyl)glutathione (4-NPG) as described previously [348]. Briefly, 5 mM 4-
NPG was incubated with 75 μg of cell lysate in 100 mM tris pH 8.0 and 10 mM β-
mercaptoethanol. The reduction of 4-NPG was measured spectrophotometrically at 305 
nm at 37°C and the specific activity was calculated based on an extinction coefficient of 
1.1 mM
−1
·cm
−1
. 
5.2.5 Immunostaining 
Cells were plated on coverslips (5 x 10
4
 cells), treated with LPS and immunostained as 
previously described [349]. Briefly, the coverslips were washed with PBS to remove 
unattached cells and fixed in 3.7% paraformaldehyde (in PBS) for 15 minutes at room 
temperature. The cells were washed in PBS three times and permeablized in blocking 
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buffer (1% Bovine serum albumin (BSA)/0.2% Triton-X100/PBS) for 30 minutes at 
room temperature. Permeabilized cells were washed in PBS and incubated in primary 
anti-p65 (Santacruz sc109) at a dilution of 1:100 for 2 hours at room temperature. Cells 
were thoroughly washed and incubated in secondary chicken anti-rabbit FITC tagged 
secondary antibody  (1:200) for one hour at room temperature in the dark. The 
coverslips were washed extensively in PBS, mounted on glass slides with Dapi 
containing mounting medium and fluorescence was recorded using a Leica SP5 
confocal microscope. The images were analysed using Leica LAS AF software. 
5.2.6 Immunoprecipitation 
Immunoprecipitation was carried out using Pierce crosslinking immunoprecipitation kit 
using an anti-IRAK4 antibody (Cell signalling). Immunoprecipitated proteins were 
separated on 12% SDS-PAGE and immunoblotted as described in Chapter 2. The 
nitrocellulose membrane was incubated with a mouse anti-phospho-serine and phospho-
threonine antibody. 
5.2.7 Real time RT-PCR 
Total RNA was extracted from cells in trizol (Invitrogen) and a Qiagen RNA extraction 
kit as previously described (refer Chapter 2 for detailed methods). Primer sequences are 
provided in Appendix A6. 
5.2.8 Phagocytosis assay 
Phagocytosis of fluorescently labelled dead E. coli (strain K-12) was measured as per 
manufacturer’s instructions (Vybrant phagocytosis kit, Life Technologies). J774.1A 
cells were seeded in 96-well plates at a density of 10
5
/well and allowed to adhere for 2 
hours at 37°C, 5% CO2. Media was removed and the cells were incubated in the 
fluorescent bioparticle suspension for 2 hours followed by immediate quenching with 
trypan blue. The supernatant was then aspirated and fluorescence was measured at an 
Ex/Em wavelength of 480/520 nm using a plate reader (Fluostar Optima). Net 
phagocytosis of GSTO1-1 knockdown cells was determined by subtracting the average 
fluorescence of media-only negative control wells and normalized to the average 
fluorescence of the non-silencing control J774.1A macrophages.  
5.2.9 Latex bead phagocytosis assay 
Yellow orange 3 micron Fluoresbrite carboxy latex microparticles (Polysciences) were 
incubated with 30 μg ml−1 LPS overnight at 4 °C in PBS. Beads were then washed 
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thoroughly in PBS to remove unbound LPS.  Cells cultured overnight on coverslips in 
12-well plates were incubated on ice for 10 minutes. Coated and uncoated (control) 
latex beads were added to the cells and allowed to settle on the cells for 10 minutes 
prior to incubation in warm culture media at 37°C for indicated time periods. Cells were 
fixed with 3.7% paraformaldehyde for 15 minutes at room temperature, permeabilized 
with 0.1% Triton-X100/0.2%BSA and stained with Phalloidin-FITC (Sigma) as per 
manufacturer’s instructions. The intracellular uptake of the beads was visualized by 
confocal microscopy (Leica SP5).Serial z-sections were recorded to confirm 
intracellular localization of the beads. The number of beads taken up by the cells was 
counted across 30 cells/coverslip. 
5.2.10 In vitro viability assay 
Total cell viability was determined with the help of neutral red staining as described in 
Chapter 2. Cells were seeded in 96-well plates at 50% confluency and treated with 
increasing concentrations of ML175 for indicated time periods. Cells were washed with 
PBS and lysed in 25% acetic acid:75% methanol. Absorbance was measured at 540 nm. 
5.2.11 Enzyme linked immunoassay (ELISA) 
IL-6 was quantified in cell culture supernatant using a murine IL-6 Duoset Elisa kit 
(R&D Biosystems). Cells were seeded at a density of 10
4
 cells/well (in triplicates) in 
clear bottom 96-well plates and incubated overnight. Post 24 hours of stimulation with 
TLR-specific ligands, the supernatant was collected and stored at -20°C until further 
use. Plates (Nunc Maxisorp flat bottom 96 well plates) were prepared by coating each 
well with 50 μl of 2 μg/ml in PBS of capture antibody (rat anti-mouse IL-6). The plates 
were incubated overnight at room temperature and washed three times with PBS to 
remove unbound antibody. Plates were then blocked in 150 μl of 1% BSA/PBS for at 
least 2 hours at room temperature and the wash step was repeated. 50 μl of cell culture 
supernatant was added to the wells in triplicates and incubated for 2 hours at room 
temperature or overnight at 4°C. Recombinant mIL-6 standards were prepared in PBS 
and added to wells in duplicates. The wells were washed in PBS thoroughly and 
incubated with the detection antibody (biotinylated goat anti- mouse IL-6) at a final 
concentration of 150ng/ml (50 μl/well) for 2 hours at room temperature. Plates were 
washed thoroughly and incubated with streptavidin-HRP for 20 minutes in the dark at 
room temperature. The wash step was repeated and HRP substrate (Millipore 
Immobilon western chemiluminescent HRP substrate) was added and incubated for 
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another 20 minutes in the dark. The reaction was stopped with 50 μl of 2N sulphuric 
acid and absorbance was measured at 450 nm using a plate reader (Optima Fluostar).  
5.3 Results 
5.3.1 GSTO1-1 expression profile in immune cells 
The expression profile of GSTO1-1 in immune cells was accessed through 
Immunological Genome Project (Immgen). The levels of GSTO1-1 were significantly 
higher in phagocytic immune cells such as macrophages, monocytes and neutrophils 
when compared to non-phagocytic immune cells (Figure 5.1A) whereas the expression 
of GSTO2-2 in these cells was relatively lower (Figure 5.1B), indicating that GSTO1-1 
may be involved in inflammatory responses in macrophages.  
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Figure 5.1A: Expression profiling of Gsto1 in mouse immune cells (Immgen 
www.immgen.org). Cell population description: DC: dendritic cells, Mo: Monocytes, 
MF: macrophages, NK: Natural Killer cells, T: T-cells, B.: B-cells. Detailed 
description of subset nomenclature is provided in Appendix A7, Figure 1C. 
The data represent relative fold differences in the expression levels (x-axis) of Gsto1 
in indicated cell types (Y-axis).  
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Figure 5.1B: Expression profiling of Gsto2 in mouse immune cells (Immgen 
www.immgen.org). Cell population description: DC: dendritic cells, Mo: Monocytes, 
MF: macrophages, NK: Natural Killer cells, T: T-cells, B.: B-cells. Detailed 
description of subset nomenclature is provided in Appendix A7, Figure 1C. 
The data represent relative fold differences in the expression levels of Gsto1 in 
indicated cell types (y-axis).   
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5.3.2 Knockdown and pharmacological inhibition of GSTO1-1 
The expression of GSTO1-1 was knocked down by lentiviral mediated shRNA and 
activity was blocked by chemical inhibitors in J774.1A macrophages. The Gsto1 
knockdown cell line generated by lentiviral shRNA transfection [345] showed >90% 
reduction in Gsto1 transcript levels (Figure 5.2A) and no reduction in Gsto2 (Figure 
5.2B). GSTO1-1 protein as measured by western blot, (Figure 5.2C) or by GSTO1-1 
activity measured with the specific substrate 4-nitrophenacylglutathione (Figure 5.2D) 
was also knocked down.  The 4-NPG assay was also used to evaluate the efficacy of 
two pharmacological inhibitors of GSTO1-1, CRID3 [264] (Cytokine release inhibitory 
drug 3) and ML175 (N-[3-(N-(2-chloroacetyl)-4-nitroanilino)propyl]-2,2,2-
trifluoroacetamide) [350].  CRID3 was found to have an IC50 of 99.5 μM (Figure 5.2E) 
that is notably higher than the IC50 of 22.8 nM obtained for ML175 (Figure 5.2F). To 
confirm the specificity of ML175, the effect of the compound was tested on the activity 
of purified GSTO2-2. As expected, increasing concentrations of ML175 had no effect 
on the dehydroascorbate reductase (DHAR) activity of GSTO2-2 (Figure 5.2G). ML175 
is a well-characterized compound with high specificity for GSTO1-1. However the 
cytotoxicity of the compound in macrophages specifically was evaluated to determine 
the optimal range of concentrations for further experiments in cells. Treating J774.1A 
macrophages with concentrations up to 5 μΜ for 6 hours did not result in cytotoxicity. 
However, treating cells with increasing concentrations for ≥ 24 hours resulted in a 
concentration dependent decrease in cell viability (Figure 5.2H). Based on the cell 
viability data, concentrations of 0.25-5 μM for no more than 6 hours were used in 
subsequent experiments with ML175.  
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5.3.3 The role of GSTO1-1 in TLR signalling in macrophages 
The requirement of GSTO1-1 in TLR signalling in macrophages was investigated by 
screening the activation of multiple murine TLRs with their respective ligands in 
J774.1A macrophages deficient in GSTO1-1 (lentiviral shRNA knockdown of GSTO1-
1) and non-silencing control cells (lentiviral scrambled shRNA). All TLRs screened 
were activated with their respective ligands and the amount of secreted, IL-6 cytokine 
was measured. TLR1/2, TLR3, TLR7 and TLR9 were functional in the Gsto1 
knockdown cells, secreting IL-6 to the same extent as the non-silencing control cells 
(Figure 5.3A-B,D-E). However pro-inflammatory signalling through TLR4 on LPS 
stimulation was found to be severely compromised in the GSTO1-1 deficient cells 
(Figure 5.3C). The effect of GSTO1-1 on TLR4 signalling was thus further investigated 
to determine whether GSTO1-1 modulated the redox state of protein(s) involved in the 
TLR4 cascade.  
 
Figure 5.2: Knockdown of GSTO1-1 by gene silencing and chemical inhibitors. 
(A)* Gsto1 mRNA levels knocked down by lentiviral transfection of shRNA 
targeting Gsto1. (B)* Specificity of the Gsto1 shRNA was confirmed by measuring 
unchanged levels of Gsto2 in transfected cells. (C)* Immunoblot showing the 
knockdown of Gsto1 in J774.1A cells by lentiviral transfection of shRNA targeting 
Gsto1 and a scrambled non-silencing control.(D) Gsto1 knockdown was confirmed 
by measuring the reduction of 4-NPG, a substrate specific to GSTO1-1. The efficacy 
of inhibition of the activity of GSTO1-1 by CRID3 (E) and ML175 (F) were 
determined by measuring the reduction of 4-NPG. (G) The DHAR activity of 
purified GSTO2-2 remained unaffected by ML175, confirming the specificity of 
ML175 as a GSTO1-1 inhibitor. (H) Doses over 5 μM of ML175 were observed to 
cause cell death in macrophages in 6 hours. ML175 concentrations were restricted to 
5 μM for 2-6 hours in all experiments.  
* Figures 5.2 A, B and C were provided by Dr. Rebecca Coll, Luke O’Neill lab, 
Trinity College Dublin. 
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Figure 5.3: Effect of GSTO1-1 deficiency on TLR activation in macrophages. 
TLR1/2, TLR3, TLR4, LR7 and TLR9 were activated with varying concentrations of 
their respective ligands in non-silencing control and Gsto1 knockdown cells. IL-6 
secretion on TLR1/2 (A), TLR3 (B), TLR7 (D) and TLR9 (E) activation was similar 
in both cell types and did not appear to be dependent on the expression of GSTO1-1. 
(C) GSTO1-1 knockdown cells failed to secrete IL-6 in response to LPS. Higher 
concentrations (100-200ng/ml) of LPS induced the secretion of IL-6 in the GSTO1-1 
deficient cells but to a significantly lower extent as compared to the non silencing 
control cells.  
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To determine whether the block in TLR4 signalling was dependent on the catalytic 
activity of GSTO1-1, wildtype J774.1A macrophages were treated with GSTO1-1 
inhibitor ML175 (Figure5.3). ML175 treated cells showed a dose dependent decrease in 
the secretion of IL-6 on LPS stimulation (Figure 5.4A). Pre-treatment of cells with 
ML175 did not alter cytokine secretion through the activation of TLR1/2 and TLR7 by 
PAM3CSK4 (Figure 5.4B) and R848 respectively (Figure 5.4C). 
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Figure 5.4: Effect of ML175 on TLRs: the specificity of ML175 was tested by screening the activation of TLR1/2, TLR4 and TLR7.  
(A) TLR4 mediated IL-6 secretion on LPS activation was significantly inhibited by increasing concentrations of ML175. IL-6 secretion 
activated through TLR1/2 (B) and TLR7 (C) remained unaffected in the presence of ML175. Hence, the inhibitory effect of ML175 is 
specific to TLR4 activated macrophages.  Cells were treated with increasing concentrations of ML175 two hours prior to stimulation with 
indicated TLR ligands (doses as described in Section 5.2.2). 
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5.3.4 GSTO1-1 is required for TLR4 mediated pro-inflammatory responses 
a. Interleukin 1β 
The transcription of pro-inflammatory cytokine IL-1β is activated on LPS stimulation 
via the TLR4/NF-κB pathway.  TLR4 activation with LPS induced the expression of 
pro-IL-1β, the uncleaved parental form of IL-1β (Figure 5.5A). The GSTO1-1 deficient 
macrophages failed to elicit this response, suggesting the unresponsiveness of the cells 
to LPS. To demonstrate that the effect of GSTO1-1 is mediated via its active site 
cysteine residue, J774.1A wildtype cells were pre-treated with catalytic inhibitor 
ML175. The cells mimicked the cytokine profile of Gsto1 knockdown cells and failed 
to induce the expression of pro-IL-1β (Figure 5.5B). Since the parental form of IL-1β is 
inhibited, this rules out the possibility that the NLRP3 inflammasome, which is 
responsible for the cleavage of pro-IL-1β to mature IL-1β, is the prime target of 
GSTO1-1.  
 
 
 
 
 
 
 
 
 
 
b. Interleukin 10 
Along with inducing the expression of pro-inflammatory cytokines, LPS induces 
multiple negative feedback pathways, one of which is the activation of IL-10. IL-10 
limits the expression of pro-inflammatory cytokines such as IL-1β and TNFα [351]. The 
expression of IL-10 was induced in non-silencing control cells but was largely absent in 
Gsto1 knockdown cells (Figure 5.6). The two cytokine profiles taken together suggest 
A B 
Figure 5.5: Unresponsiveness of GSTO1-1 deficient cells on LPS/TLR4 activation 
(A) Expression of pro-IL-1β was induced in non-silencing control J774.1A 
macrophages but not in cells deficient in GSTO1-1 when TLR4 signalling was 
activated with LPS. (B) Pre-treating wildtype J774.1A macrophages inhibited TLR4 
dependent pro-IL-1β expression in a dose dependent manner, suggesting that 
catalytically active GSTO1-1 is indispensable for the expression of parental IL-1β.   
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that LPS failed to elicit TLR4 signalling in cells deficient of GSTO1-1 and the effect of 
GSTO1-1 is mainly on the signalling required for NF-κB nuclear translocation which is 
a pre requisite for the expression of cytokines. 
 
 
 
 
 
c. Inducible Nitric oxide synthase (iNOS) and Cyclooxygenase 2 (COX2) 
Changes in the transcript levels of inflammatory markers that are influenced by 
oxidative stress were measured in GSTO1-1 deficient macrophages. Increase in ROS 
levels and/or a decrease in antioxidants such as glutathione have both previously been 
demonstrated to induce the expression of cyclooxygenase-2 and nitric oxide synthase-2 
in LPS treated macrophages. As expected, LPS treated macrophages deficient in 
GSTO1-1 showed a much reduced induction of COX2 (Figure 5.7A) and iNOS (Figure 
5.7B), possibly due to the lack of stimuli in the form of increased ROS/GSH ratio. 
When LPS activated macrophages were pre-treated with ML175, a potent inhibitor of 
GSTO1-1, the induction of COX2 and iNOS were significantly abolished (Figure 5.7C-
D).  
 
 
 
 
 
 
Figure 5.6: The expression of 1L-10 was induced in non-silencing control cells but 
not in Gsto1 knockdown cells. 
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Figure 5.7: Induction of transcript levels of pro-inflammatory markers on LPS 
stimulation is dependent on GSTO1-1 
LPS treated macrophages deficient in GSTO1-1 showed a significantly lower 
induction of transcript levels of pro-inflammatory markers such as COX2 (A) and 
iNOS (B).  (C-D) The induction of both COX2 and iNOS was abolished in LPS 
activated macrophages pre-treated with ML175, mimicking Gsto1 knockdown cells 
and suggesting the catalytic involvement of GSTO1-1 in LPS signalling.  
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5.3.5 GSTO1-1 mediates LPS induced ROS generation 
To determine the effect of GSTO1-1 on the levels of ROS when the TLR4 signalling 
pathway is activated, J774.1A Gsto1 knockdown cells and non-silencing control cells 
were treated with LPS.  As shown in Figure 5.8A there was a significant increase in 
ROS in a time dependent manner in the non-silencing control cells that was largely 
absent in the GSTO1-1 knock down cells.  In order to determine whether the effect of 
GSTO1-1 was specific to TLR4 activation, the cells were treated with Poly I:(C) that 
activates the TLR3 inflammatory cascade. The increase in ROS on TLR3 activation was 
found to be the same in both non-silencing control and Gsto1 knockdown cells (Figure 
5.8B).    
To evaluate the effect of GSTO1-1 inhibitor ML175 on cellular ROS, cells were treated 
with increasing concentration of ML175 followed by LPS.  ML175 significantly 
blocked the increase in ROS in non-silencing control cells on LPS treatment (Figure 
5.8C), mimicking the effect of genetic knockdown of GSTO1-1 in macrophages. 
However, ML175 did not influence the generation of ROS on TLR3 activation when 
cells were treated with PolyI(C) (Figure 5.8D).   
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Figure 5.8: GSTO1-1 mediates LPS induced ROS. 
A, Knocking down GSTO1-1 attenuates LPS induced TLR4 mediated ROS generation. B, 
GSTO1-1 dependent ROS generation is TLR4 specific and does not alter poly:I(C) induced 
TLR3 specific ROS. C, Inhibition of the catalytic activity of GSTO1-1 by ML175 
attenuated LPS induced ROS production in a dose dependent manner. Cells were pre-
treated with increasing concentrations of ML175 for one hour followed by LPS (100ng/ml) 
for 6 hours. D, Inhibition of the catalytic activity of GSTO1-1 by ML175 did not attenuate 
polyI:C induced ROS generation. Cells were pre-treated with increasing concentrations of 
ML175 for one hour followed by 10 μg/ml polyI:C for 6 hours. 
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5.3.6 GSTO1-1 mediates the induction of NADPH oxidase 1 (NOX1) after LPS 
stimulation 
Cytosolic ROS is predominantly generated by the family of NADPH oxidases with 
tissue specificity [147]. NOX1 and NOX2 are primarily expressed in macrophages. 
Since NOX2 is constitutively transcribed, the expression of NOX1 in LPS activated 
cells was determined [149]. The expression of NOX1 at both the transcription and 
protein level was significantly induced in LPS treated non-silencing control cells but 
largely attenuated in GSTO1-1 deficient cells (Figure 5.9A-B). Similar results were 
obtained with the inhibitors CRID3 and ML175 (Figure 5.9C and 5.9D). As expected, 
the effect of CRID3 on NOX1 was less pronounced than that of ML175 due to the 
relatively poor efficacy of CRID3 as GSTO1-1 inhibitor; hence ML175 was used in 
subsequent studies to investigate the role of GSTO1-1 in TLR4 signalling. 
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Figure 5.9: GSTO1-1 mediates ROS production via the activation of NADPH 
oxidase  
(A) Activation of NOX1 transcription by LPS is dependent on GSTO1-1 expression 
in J774.1A macrophages. (B) Induction of NOX1 protein expression was attenuated 
in Gsto1 knockdown cells, resulting in attenuated ROS generation. (C) CRID3 
decreased the LPS dependent induction of NOX1 transcripts to a moderate extent (at 
higher concentrations due to its poor efficacy) in wildtype J774.1A cells. (D) 
Inhibition of GSTO1-1 in J774.1A wild type cells by ML175 decreased the LPS 
induced activation of NOX1 transcript expression to control levels. 
 
 
Chapter 5 
114 
 
5.3.7 Glutathione homeostasis on LPS activation 
As a consequence to increased oxidative stress resulting from the increased cytosolic 
ROS, a significant shift in the GSH/GSSG ratio was measured in LPS stimulated 
J774.1A non silencing control cells (Figure 5.10). Interestingly, the GSH/GSSG ratio 
remained unaltered in Gsto1 knockdown cells, confirming undisturbed redox 
homeostasis in these cells under the same condition.  
 
 
 
5.3.8 The effect of GSTO1-1 knockdown on protein glutathionylation 
The deglutathionylation activity of GSTO1-1 has been extensively investigated in the 
previous chapter and in published data [90]. To further evaluate the redox state of 
proteins in Gsto1 deficient cells, the total glutathionylation level under basal conditions 
was determined. The total protein glutathionylation level in Gsto1 knockdown 
macrophages was significantly increased (Figure 5.11A). Treatment of J774.1A non-
silencing control cells with LPS caused a significant increase in glutathionylation, 
presumably as a result of the generation of ROS as the same increase did not occur in 
Gsto1-knock down cells that do not produce ROS.  To confirm that the catalytic active 
site of GSTO1-1 is required to mediate these effects, both non-silencing control and 
Gsto1 knockdown cells were treated with ML175 before eliciting pro-inflammatory 
responses with LPS. As shown in Figure 5.11B, ML175 pre-treatment reversed the up-
regulation of total protein glutathionylation on LPS stimulation in the non-silencing 
control cells in a dose dependent manner. However, ML175 did not have any effect on 
the Gsto1 knockdown cells. Interestingly, an increase in the glutathionylation levels in 
Figure 5.10: Glutathione levels in macrophages 
A significant drop in the GSH/GSSG ratio was measured in the non-silencing control 
cells in response to LPS induced ROS while the ratio remained unchanged in Gsto1 
knockdown cells.  
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Gsto1 knockdown cells at 0.5μM of ML175 was observed which could be due to 
increased cytotoxicity at higher doses. 
 
 
 
 
 
 
5.3.9 Anti-oxidant response to LPS stimulation 
The production of ROS in cells would normally be expected to perturb the redox 
balance and potentially induce increased expression of enzymes that generally protect 
against oxidative stress. However it has been previously demonstrated that in order to 
maintain an initial phase of increased ROS, LPS suppresses the antioxidant levels while 
simultaneously inducing ROS generating enzymes such as NOX1 and NOX4 [147, 149, 
346]. Therefore, the effect of LPS stimulation on the transcription and/or activity of 
catalase, glutathione peroxidase 3 (GPx3), glutamate cysteine ligase catalytic subunit 
(GCLc), glutamate cysteine ligase modulating subunit (GCLm) and glutathione 
reductase was evaluated. LPS stimulation of non-silencing control cells caused a 
significant decrease in the mRNA level of catalase, GPx3, GCLc, Heme oxygenase-1 
(HO-1) and NADPH quinone oxidoreductase-1 (NQO1) (Figure 5.12A-C,E-F).  In 
contrast the level of GCLm mRNA was unchanged by LPS stimulation (Figure 5.12D).  
Notably, knock down of GSTO1-1 by shRNA expression abolished the suppression of 
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Figure 5.11: Global protein glutathionylation in J774.1A macrophages 
(A) Protein glutathionylation was increased in GSTO1-1 knockdown cells compared to 
non-silencing control cells. When non-silencing control cells were treated with LPS, 
high ROS levels result in increased protein glutathionylation levels in but low levels of 
glutathionylation occur in GSTO1-1 knockdown cells that do not generate high ROS 
levels. (B) Treating non silencing control macrophages with ML175 abrogated LPS 
induced glutathionylation. ML175 treatment did not alter the glutathionylation levels 
in GSTO1-1 deficient cells. 
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catalase, GPx3, GCLc, HO-1 and NQO1 induced by LPS.  The knockdown of GSTO1-
1 caused a significant induction of GCLm that was unaffected by LPS stimulation. The 
activities of catalase, glutathione peroxidase and glutathione reductase were also 
determined (Figure 5.13A-C).  In J774.1A non-silencing control cells the activities of 
catalase and glutathione reductase were diminished by LPS treatment and this reduction 
in activity was abrogated in GSTO1-1 knock down cells (Figure 5.13A-B).  In contrast, 
glutathione peroxidase activity was not reduced by LPS treatment (Figure 5.13C).  This 
may be due to the fact that glutathione peroxidase activity is catalysed by multiple 
isozymes including some glutathione transferases and their genes may not be subject to 
the same transcriptional regulation as GPx3.  Alternatively, GPx3 may turnover slowly 
and a decrease in transcription may not be reflected in the protein level within six hours 
in this experiment.  
In order to confirm that the redox events unfolding in the absence of GSTO1-1 were due 
to its catalytic activity, a previously published inhibitor ML175 was tested on wildtype 
J774.1A macrophages. Similar results were obtained when GSTO1-1 was inhibited by 
the treatment of non-silencing J774.1A control cells with the GSTO1-1 inhibitor 
ML175 (Figure 5.14 A-E). The activation of ROS production and suppression of 
antioxidants on LPS stimulus was blocked significantly by ML175 in a dose dependent 
manner, mimicking the phenotype of GSTO1-1 knockdown cells. 
The results strongly suggest that ML175 is a potent inhibitor of GSTO1-1 both in vitro 
(IC50 in the nanomolar range) and in cells and that the inhibitory effect is mediated via 
the inhibition of the enzyme activity of GSTO1-1 (as shown in Figure 5.2F) 
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Figure 5.12: LPS modulates the oxidant/antioxidant axis by suppressing 
antioxidant activity to promote a pro-inflammatory oxidative burst in macrophages 
Suppression of Catalase (A); Gpx3 (B); GCLc (C); GCLm (D); HO-1 (E) and 
NQO1 (F) was abrogated significantly in Gsto1 knockdown cells.  
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Figure 5.13:  Suppression of antioxidants by LPS is abolished in GSTO1-1 deficient J774.1A macrophages 
The catalytic activities of catalase (A) and glutathione reductase (B) also showed a decrease in response to LPS in the non-silencing control cells 
but not in the GSTO1-1 deficient macrophages. (C) Gpx activity did not significantly change in both non-silencing and Gsto1 knockdown 
macrophages.   
Chapter 5 
119 
 
Figure 5.14: The LPS mediated suppression of anti-oxidant enzymes was blocked by inhibition of the catalytic activity of GSTO1-1 with ML175. 
Transcript levels of Catalase (A); GCLc (B); GCLm (C); HO-1 (D) and NQO1 (E) were measured in ML175 treated J774.1A macrophages. 
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To investigate the inability of Gsto1 knockdown cells to suppress the immediate 
antioxidant responses on TLR4 activation, the role of PPARγ, a key regulator of the 
Keap1/Nrf2 pathway was determined [352]. Phase 2 genes such as HO-1, NQO1, GCLc 
and GCLm have anti-oxidant response elements (ARE) and are induced in response to 
oxidative stress through the Keap1/Nrf2 pathway [352, 353].  As shown in Figure 
5.15A, the non-silencing control cells have low levels of expression of PPARγ and this 
is not significantly altered by LPS treatment.  In contrast, Gsto1 knockdown cells 
express high levels of PPARγ which would support the induction of genes such as 
GCLc and GCLm. The expression levels of PPARγ coactivator PGC1β also followed a 
similar trend in the Gsto1 knockdown cells. PGC1β levels were suppressed in LPS 
treated non silencing macrophages as previously reported [354]. However GSTO1-1 
deficient macrophages expressed significantly higher levels of the co-factor even in the 
absence of LPS indicating that the expression of GSTO1-1 mediates PPARγ expression 
and associated downstream effects albeit the exact mechanism is not known (Figure 
5.15B). PGC1β expression was considerably attenuated in response to LPS treatment in 
Gsto1 knockdown cells but was not completely abolished. The induction of PPARγ on 
treatment with GSTO1-1 inhibitor ML175 even in the presence of LPS confirmed the 
requirement of active GSTO1-1 in the maintenance of PPARγ in a suppressed state in 
the non-silencing control cells (Figure 5.15C).   
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Figure 5.15: PPARγ is involved in the inhibition of pro-inflammatory redox responses in LPS stimulated GSTO1-1 deficient macrophages. 
(A) PPARγ is induced in J774.1A Gsto1 knockdown macrophages. (B) PPARγ coactivator PGC1β is induced in Gsto1 knockdown cells. (C) Pre-
treating cells with increasing concentrations of GSTO1-1 inhibitor ML175 induces PPARγ expression in J774.1A macrophages in a dose dependent 
manner. 
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5.3.10 GSTO1-1 is required for p65 nuclear translocation 
NF-κB is a transcription factor that induces the expression of genes involved in 
inflammation [164, 355]. A large proportion of cytosolic NF-κB exists as a heterodimer 
of p65/p50 proteins associated with inhibitory IκB proteins [356]. Activation of pro-
inflammatory cascades in macrophages with LPS involves IκκB proteins that 
phosphorylate IκB and target it for ubiquitinylation and subsequent proteosomal 
degradation [357-360]. The free p65/p50 heterodimer then translocates into the nucleus 
and activates the transcription of pro-inflammatory genes [164, 167]. Our data suggest 
that GSTO1-1 is required for this process. The images in Figure 5.16A-B show the 
normal increased nuclear localization of p65 in J774.1A non-silencing control cells after 
LPS treatment. In contrast p65 does not accumulate significantly in the nucleus of 
GSTO1-1 deficient cells treated with LPS (Figure 5.16C-D).  The mean fluorescence 
intensity was quantified as described in the methods section and confirmed the 
significant increase in nuclear translocation of p65 in the non-silencing control and not 
in the GSTO1-1 deficient cells (Fig 5.16E). The failure of p65 to enter the nucleus in 
GSTO1-1 deficient cells indicates that these cells are unresponsive to LPS and would 
not induce NF-κB dependent inflammatory genes including NOX1 and other cytokines. 
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Figure 5.16: Nuclear translocation of p65 on TLR4 activation with LPS is 
dependent on the expression of GSTO1-1 
(A) The p65 and p50 subunits of NF-κB heterodimerize and remain associated with 
IκB in the cytosol. (B) On LPS stimulation via TLR4, IκB dissociates from the 
p65/p50 heterodimer allowing the complex to translocate into the nucleus and 
activate transcription of genes. (C-D) Translocation of p65 into the nucleus on LPS 
stimulation is attenuated in the absence of GSTO1-1. (E) Fluorescence intensity was 
quantified using Leica LAS AF software. Nuclear staining by Dapi is shown in 
blue;   FITC-p65 is shown in green.  
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5.3.11 Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) phosphorylation/activation 
is blocked in GSTO1-1 deficient macrophages 
IRAK4 is recruited immediately downstream of the TLR4-myddosome complex after 
LPS stimulation in macrophages. IRAK4 is auto-phosphorylated on TLR4 activation 
resulting in the subsequent phosphorylation and heterodimerization of IRAK1/2 (refer 
Figure 1.9). LPS treatment of the non-silencing control cells resulted in the 
phosphorylation of IRAK4 in 30 minutes however IRAK4 remained de-phosphorylated 
in LPS treated Gsto1 knockdown macrophages (Figure 5.17). Thus the failure to elicit 
this response in Gsto1 knockdown cells suggests that the effect of GSTO1-1 is further 
upstream of IRAK4, narrowing down potential targets of GSTO1-1 dependent 
modulation to the Myddosome complex and TLR4 itself. This result is inconclusive and 
slightly complicated to interpret due to the unexpected presence of phosphorylated 
IRAK4 in the unstimulated non silencing macrophages (though not to the extent of LPS 
activated macrophages). This may be a technical issue with the generic anti-phospho 
thr/ser antibody used which may be targeting LPS-independent phosphorylation of other 
residues on IRAK4. Thus, further experiments with more specific antibodies are 
required to confirm that GSTO1-1 is upstream of IRAK4. 
 
 
 
 
Figure 5.17: GSTO1-1 influences IRAK4 phosphorylation 
IRAK4 was phosphorylated on LPS stimulation in non-silencing control cells in 30 
minutes but the extent of phosphorylation was significantly lower in Gsto1 
knockdown cells.  
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5.3.12 GSTO1-1 deficient cells fail to elicit M1 typical phagocytic phenotype 
To evaluate the consequences of disrupted TLR4 signalling in GSTO1-1 deficient cells, 
the phagocytic ability of the cells was measured both qualitatively and quantitatively 
using two independent approaches in order to determine whether the cells behave like 
M1 macrophages upon LPS stimulation. J774.1A non-silencing control cells 
internalized fluorescently labelled dead bacteria efficiently indicating a collective 
response of all TLRs to the presence of pathogenic agents in the microenvironment. 
Further, J774.1A non silencing control cells primed with LPS for two hours prior to 
incubation with the fluorescently labelled dead bacteria exhibited significantly enhanced 
phagocytosis (Figure 5.18A). Interestingly, GSTO1-1 deficient cells showed poor 
efficacy in the internalization of the pathogenic particles and remained unstimulated 
post priming with LPS as well (Figure 5.18A). Cell viability was evaluated to eliminate 
any difference in the cell viability post infection (Figure 5.18B). To further narrow 
down the non-responsiveness of Gsto1 knockdown cells, latex beads coated with LPS 
were applied to the cells to specifically activate TLR4. GSTO1-1 deficient cells failed 
to internalize the LPS coated latex micro particles (in red) to the extent seen with the 
non-silencing control cells (Figure 5.18 C-D), indicating their inability to respond to 
pathogenic invasion. On quantification, an average of 2-3beads/cell was counted in the 
non-silencing control cells on LPS stimulation while the GSTO1-1 deficient cells 
phagocytosed <1 bead/cell (Figure 5.18 E).  
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Figure 5.18: Phagocytosis exhibited by classical M1 activated macrophages in response 
to LPS is attenuated in GSTO1-1 deficient cells. 
(A) Phagocytosis of dead bacteria in GSTO1-1 deficient macrophages was significantly 
attenuated (B) Cell viability remained unchanged between the non-silencing control and 
Gsto1 knockdown cells. (C and D) LPS stimulated TLR4 dependent phagocytosis was 
specifically blocked in GSTO1-1 deficient cells. The nucleus is stained with DAPI 
(blue), the plasma membrane is indicated by actin staining (green) and LPS coated latex 
beads are shown in red.(E) The number of phagocytosed beads were counted across 200 
cells/group and normalized to the cell count.  
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5.4 Discussion 
Macrophages exhibit pro-inflammatory responses by secreting bactericidal cytokines 
and reactive oxygen species (ROS). The secretion of TLR4 specific cytokines such as 
IL-1β requires the activation of two parallel pathways: TLR4-dependent activation of 
transcription of pro-IL-1β and recruitment of the NLRP3 inflammasome. Transcription 
of pro- IL-1β is switched on by NF-κB which requires the activation of a cascade of 
intermediate signalling molecules on TLR4 activation by lipopolysaccharide (LPS). A 
simultaneous potassium efflux into the cell signals the recruitment of the NLRP3 
inflammasome complex comprising of NLRP3, ASC and Procaspase-1 [160, 361-364]. 
Procaspase1 is cleaved to its active form, Caspase-1 which subsequently cleaves pro-IL-
1β into mature IL-1β [364]. The data presented here indicate that the TLR4 mediated 
expression of cytokines such as IL-1β and production of cytosolic ROS in response to 
LPS stimulation requires the presence of GSTO1-1.  Since GSTO1-1 has been 
implicated in several inflammatory diseases, it was hypothesized that GSTO1-1 is 
central to the redox wiring of macrophages. Interestingly, analysis of previously 
published data on the Immgen database also recognized GSTO1-1 and not GSTO2-2 
expression to be comparable with other TLR4 signalling proteins such as MyD88 and 
MAL levels in phagocytic cell types such as monocytes and macrophages (data on 
MyD88 and MAL are shown in Appendix A7 Figure 1A-B).  Redox responses 
including the excessive generation of ROS and simultaneous down regulation of anti-
oxidants has been described by several studies [148, 292, 344, 365]. The exact role of 
redox changes including protein post translation modifications in response to a pro-
inflammatory stimulus such as bacterial infection is not fully understood.  
For the purpose of this study, murine macrophage J774.1A cells that were used were 
stably transfected with either a Gsto1 targeting shRNA or a scrambled non-silencing 
control shRNA. These cells were generated in the Luke O’Neill laboratory (Trinity 
College Dublin) and have served as an excellent platform to investigate the function of 
GSTO1-1 in TLR4 activation. TLR4 activation by LPS results in the generation of both 
cytosolic and mitochondrial ROS though the consequences of increased ROS generation 
on NF-κB dependent activation of cytokines continue to attract speculations. The redox 
state of macrophages transfected with non-silencing control shRNA and Gsto1 targeting 
shRNA was determined by measuring cytosolic ROS levels and protein 
glutathionylation. Knocking down Gsto1 in J774.1A macrophages was sufficient to 
attenuate the generation of cytosolic ROS and inhibit the expression of NF-κB driven 
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cytokine secretion. Furthermore, Gsto1 knockdown cells failed to express typical pro-
inflammatory markers such as iNOS and COX2 on LPS stimulation. The inhibition of 
ROS production suggested that GSTO1-1 deficiency disrupted TLR4 signalling and not 
the NLRP3 inflammasome complex recruitment as TLR4 activation by LPS is required 
for the transcriptional activation of cytokines and the predominant cytosolic ROS 
generating enzyme complex NOX1. Previous studies have demonstrated that the 
oxidant/antioxidant axis is tightly regulated to maintain high ROS levels during the 
initial phase of LPS stimulation to counteract bacterial infections [292, 343, 352, 354, 
366, 367]. The present data show that the suppression of the expression and activity of 
several enzymes including catalase, Gpx3, HO-1, NQO1 and GCL in order to maintain 
the initial oxidative stress in response to LPS is dependent on the presence of GSTO1-1.   
Increased ROS has been shown to induce the glutathionylation of proteins in order to 
protect them from irreversible oxidative damage and since GSTO1-1 was found to 
catalyse the deglutathionylation of proteins, the global glutathionylation status of 
proteins was determined in Gsto1 knockdown cells on LPS stimulation. As expected, 
the total protein glutathionylation in the GSTO1-1 deficient cells was significantly 
higher than the control cells, suggesting that GSTO1-1 may also catalyse the 
deglutathionylation of specific proteins in J774.1A macrophages. LPS mediated ROS 
generation in the non-silencing control cells resulted in an increase in protein 
glutathionylation as predicted while the glutathionylation levels remained unchanged in 
the Gsto1 knockdown cells. The protein glutathionylation levels along with the 
unaltered oxidant/antioxidant axis and unchanged GSH/GSSG ratio in the GSTO1-1 
deficient cells collectively indicates the inability of GSTO1-1 deficient cells to elicit 
pro-inflammatory and anti-microbial responses mediated by TLR4. The suppression of 
antioxidants has been previously shown to be mediated via PPARγ and Nrf2 [352, 353, 
367, 368]. Though a significant up-regulation of PPARγ and its coactivator PGC1β 
were measured in GSTO1-1 knockdown cells, the establishment of a direct link between 
PPARγ and Nrf2 was beyond the scope of this study. Based on published literature 
[352, 354, 369] and the data discussed here, it is hypothesized that the effects on 
antioxidant expression and activity may be mediated via the up-regulation of PPARγ 
due to the block in the activation and nuclear translocation of NF-κB, which in turn 
maintains Nrf2 in an active state in LPS stimulated macrophages and thus preventing 
the suppression of antioxidant expression during the initial phase of ROS production 
(Figure 5.19).  
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Figure 5.19: TLR4 signalling scheme 1: A scheme describing the key 
signalling events occurring eventually leading to the nuclear translocation 
of NF-κB and the PPARγ mediated suppression of antioxidant enzymes. 
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There are multiple steps involved in the TLR4 activated cascade of signalling molecules 
leading to the activation of NF-κB and the expression of pro-inflammatory cytokines 
such as IL-1β [1, 165, 370]. A simplified representation of TLR4 signalling in 
macrophages and some of the key proteins involved are shown in Figure 5.20. A more 
detailed description of the pathway has been previously illustrated in Figure 1.9. The 
work presented in this thesis clearly demonstrates that there are proteins in the TLR4 
pathway that are impacted by GSTO1-1. Starting from the downstream key regulator of 
transcriptional regulation of pro-inflammatory cytokines and NOX1, the disruption in 
intermediate protein activity was determined. Since the nuclear translocation of NF-κB 
subunit p65 was blocked in Gsto1 knockdown cells, the effect of GSTO1-1 was placed 
further upstream. The activation of proteins partaking in the initial steps of the cascade 
were also evaluated to determine whether GSTO1-1 acts immediately downstream of 
TLR4. Since the activation and phosphorylation of IRAK4 (Figure 5.20) was absent in 
the Gsto1 knockdown cells, it is hypothesized that GSTO1-1 acts further upstream of 
IRAK4 which narrows down the site of action to the Myddosome complex. As 
mentioned in Chapter 1, the Myddosome complex comprises of MyD88, MAL and 
TLR4. Further investigations into the recruitment and association of these adaptor 
proteins will help elucidate the role of GSTO1-1 in TLR4 signalling.   
Phagocytosis is considered as a classical M1 phenotype marker and is initiated when a 
macrophage senses the presence of pathogens. When in direct contact with a pathogen, 
phagocytes such as macrophages and neutrophils form dendrite-like extensions and 
engulf surrounding pathogens. This phenomenon is further maintained and enhanced by 
the activation of the TLRs expressed on the phagocyte surface. Interestingly, Gsto1 
deficient cells showed poor efficacy in the internalization of the pathogenic particles 
and remained unstimulated post priming with LPS as well.  The difference in 
phagocytic ability between the unstimulated J774.1A non silencing control cells and 
GSTO1-1 deficient cells could be due to the unresponsiveness of the Gsto1 knockdown 
cells to TLR4 ligand LPS (pathogen cell wall). This was further validated when the 
Gsto1 knockdown cells failed to promote phagocytosis in response to LPS alone (LPS 
coated beads) determining the response of these cells to LPS alone, without other 
components contributing to the phagocytic phenotype.  
Since a pharmacological inhibitor of GSTO1-1 was found to block the production of 
ROS via the inhibition of NOX1, it seems likely that the regulatory effect of GSTO1-1 
Chapter 5 
131 
 
may be mediated by its catalytic activity.  A previous study introduced CRIDs as a class 
of cytokine inhibitory drugs that inhibited IL-1β secretion by interacting with the active 
site cysteine of GSTO1-1 (cysteine 32). CRID3 was found to be a poor inhibitor of 
GSTO1-1, with its IC50 in the micro molar range. In spite of the poor efficacy of the 
drug, a moderate decrease in the levels of NOX1 was detected in CRID3 treated cells. 
Thus, ML175 was determined to be a better chemical inhibitor for the purpose of this 
study. However since higher concentrations of ML175 resulted in significant cell death, 
the study was restricted in terms of concentrations that could be used in cells without 
causing cytotoxicity. The extensive characterization of ML175 undertaken by Tsuboi, 
K., et al., reported little toxicity and few off target effects.  It is possible that the higher 
toxicity observed in the present study was due to the DMSO used to solubilize the 
compound [350]. Though the concentrations used were well within the non-toxic range, 
it is worth noting that the compound may need to be developed further to reduce the 
cytotoxic effects before applying these findings to in vivo models.  It is interesting to 
note that ML175 had a dose dependent effect on the inhibition of TLR4 signalling 
suggesting that the mechanism of action of GSTO1-1 on TLR4 signalling is ‘druggable’ 
and can be tightly controlled to limit excessive inflammation that is associated with 
various health conditions such as neurodegenerative diseases and metabolic disorders 
rather than completely abolish TLR4 signalling which could have severe side effects.  
Since genetic variation in GSTO1-1 has been shown to be a determinant of the age at 
onset of Alzheimer’s and Parkinson’s diseases, it is tempting to speculate that 
polymorphic variants of Gsto1 may regulate inflammatory responses and the production 
of ROS altering the progression of many disorders. It has been shown that that the 
NLRP3 inflammasome complex is activated resulting in the over-secretion of IL-1β. 
This in turn resulted in the exacerbation of inflammation associated with the 
progression of neurodegeneration [371, 372]. Taken together, our data demonstrate 
significantly attenuation of ROS in Gsto1 knockdown cells, thus identifying a novel 
component of the ROS production pathway in LPS activated macrophages. Several 
studies strongly support the role of ROS in pro-inflammatory responses elicited in 
activated macrophages and nullifying this effect through pharmacological drugs has 
been shown to switch macrophages to an anti-inflammatory phenotype. The inhibition 
of GSTO1-1 by ML175 mediates responses typical of reported anti-inflammatories, 
hence providing the first evidence supporting the characterization of ML175 as a 
potential anti-inflammatory agent. 
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Figure 5.20: TLR4 signalling scheme 2: The absence of immediate 
phosphorylation of IRAK4 in Gsto1 knockdown cells places the action of GSTO1-
1 further upstream of IRAK4 and possibly in the myddosome complex. The 
proteins associating to form the myddosome complex are highlighted in the red 
box. 
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CHAPTER 6 
Glutathione transferase Omega 1 modulates 
metabolism in activated macrophages 
6.1 Introduction 
Macrophages are the key players contributing to innate immune responses that 
recognize foreign pathogens and inflammatory stimulants such as bacterial LPS. LPS 
has been shown to induce the generation of reactive oxygen species (ROS) and pro-
inflammatory cytokines such as IL-1β through the activation of TLR4 and the 
recruitment of downstream signalling proteins [162, 278-281]. In addition to their 
signalling role and their impact on the expression of pro-inflammatory cytokines, the 
ROS generated by the TLR4 pathway have also been shown to cause tissue damage and 
are central to the progression and pathology of many inflammatory diseases [280]. The 
role of GSTO1-1 in the activation of the TLR4 pro-inflammatory cascade and the 
generation of ROS via NF-κB  activation was extensively described in chapter 5 [345]. 
To further understand the mechanism by which GSTO1-1 mediates inflammatory 
responses in macrophages, the activation of parallel signalling pathways which are 
independent of NF-κB activation were investigated. In light of recent studies which 
demonstrate that TLR4 activation by LPS skews macrophages towards a more 
glycolytic phenotype (Figure 6.1) [1, 373-375], the metabolic profile of GSTO1-1 
deficient macrophages was determined. In response to LPS, GSTO1-1 deficient 
macrophages failed to produce excess lactate and induce HIF1α that plays a key role in 
maintaining the pro-inflammatory state of activated macrophages. The accumulation of 
TCA cycle intermediates, succinate and fumarate that occurs in LPS treated 
macrophages was also blocked in GSTO1-1 deficient cells. These data indicate that 
GSTO1-1 is required for LPS mediated signalling in macrophages and acts early in the 
LPS/TLR4 pro-inflammatory pathway.   
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Figure 6.1: Glycolysis and the TCA cycle (adapted from [1]) 
Intermediates highlighted in red are induced and in blue are repressed in LPS stimulated 
bone marrow derived macrophages (BMDMs) 
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6.2 Materials and methods 
 
6.2.1 Measuring mitochondrial ROS  
Cells were seeded in six-well dishes at a cell density of 5x10
5
 and treated with LPS as 
indicated. Cells were washed with PBS and then incubated with MitoSOX/Mitotracker 
(Life Technologies) for 30 minutes at 37°C [292]. The cells were washed twice and 
resuspended in PBS and analysed by fluorescence-activated cell sorting analysis 
(FACS). All measurements were normalized against baseline readings from unstained 
controls and then to untreated controls from each cell type. Data from three independent 
experiments were analysed using Flowjo FACS analysis software.   
 
6.2.2 Determining mitochondrial membrane potential  
Treated or untreated cells (1x10
5
), were resuspended in 1ml PBS. As a positive control, 
cells were treated with 50μM Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) for 
5 minutes [292]. Cells were incubated with JC-1 dye (Mitoprobe, Life Technologies) at 
37°C, 5% CO2 for 30 minutes according to the manufacturer’s instructions. Cells were 
then washed with PBS and resuspended in 100 μl of PBS and analysed by FACS with 
an emission wavelength of 488 nm. Data from three independent experiments were 
analysed using Flowjo FACS analysis software.   
 
6.2.3 Measurement of extracellular lactate levels 
Cells were seeded in 6-well dishes at a density of 5x10
5
 cells and treated with LPS as 
indicated. Briefly, media was collected at different time points and mixed with 3% 
perchloric acid. 0.05% methyl orange was then added to the samples (final 
concentration of 0.00083%) and mixed well. The pH of the samples was raised with 1M 
K2CO3 until the solution turned bright yellow. The volume was adjusted to 400 μl and 
1/10
th
 of the total volume (40 μl) was then incubated with NAD (1 mM) in a glycine 
hydrazine buffer (1M glycine, 0.4 M hydrazine sulphate, 5 mM EDTA, 0.5 M NaOH) 
and initial absorbance was measured at 340 nm at 37°C. The samples were then mixed 
with 19.8 U lactate dehydrogenase and absorbance was recorded every 10 minutes at 
340 nm, 37°C until the reaction was complete. The initial absorbance values were 
subtracted from the final readings and lactate concentrations were calculated based on 
the standard curve obtained from standards made from sodium lactate.  
 
6.2.4 Measurement of NADPH/NADP+ levels 
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Cellular NADPH/NADP levels were estimated by an enzymatic assay (Abnova). 
Briefly, 10
5
 cells were lysed in either NADP or NADPH extraction buffer and heated at 
60°C for 5 minutes. Samples were neutralized with the opposite buffer and centrifuged 
at 16000 x g for 10 minutes to remove all debris. The supernatant was incubated with 
the reaction buffer (containing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), glucose and glucose dehydrogenase) and absorbance was immediately 
read at 565 nm. The reaction was allowed to progress at room temperature and the final 
absorbance was measured after 30 minutes. The initial absorbance values were 
subtracted from the final readings and NADPH/NADP ratios were calculated based on 
NADP standards. 
 
6.2.5 Extracellular flux measurements (OCR and ECAR) 
For real-time analysis of the bioenergetics profile of activated macrophages, cells were 
analysed with an XFe-96 Extracellular Flux Analyser (Seahorse Bioscience) as 
described previously [373, 374]. Cells were seeded at a density of 130,000/well in XFe 
96 plates and treated with LPS as indicated. The cells were washed and allowed to 
recover in XF media supplemented with 5.5 mM glucose and 1 mM pyruvate for one 
hour at 37°C without CO2. The Oxygen Consumption Rate (OCR) and Extracellular 
Acidification Rate (ECAR) were measured and results were normalized to readings 
from untreated cells at respective time points. 
 
6.2.6 GC/MS analysis of metabolites in macrophages    
Sample preparation: Cells were seeded at a density of 5x10
5
 cells/well in 6-well dishes 
and treated with LPS as indicated. Post treatment, cells were lysed in 1:1 methanol 
water solution and derivitized in methoxyamine-HCl in anhydrous pyridine and N-
methyl-N-(trimethylsilyl)-trifluoroacetamide. The derivatized samples were analysed by 
GC/MS with a full scan range of 50-600m/z transition (Agilent 7890A, Agilent 5975C 
MS inert XL EI/CI MSD with triple axis detector, Inc. Santa Clara, CA, USA). 
Metabolites were screened using AnalyzerPro and identified against the NSIT library. 
The peak area of Kreb’s intermediates succinate and fumarate were normalized to 
essential amino acids in each sample. All readings were measured in triplicate. 
 
6.2.7 LC/MS analysis of metabolites in macrophages  
Sample preparation: Cells were seeded at a density of 5x10
5
 cells/well in 6-well dishes 
and treated with LPS as indicated. Post treatment, cells were washed with PBS and 
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lysed in 1:1 methanol water solution and pre-treated as described above in the GC/MS 
sample preparation. The supernatant was dried using a vacuum concentrator (Savant 
Speedvac) and resuspended along with the standards in double distilled degassed water. 
Samples were vortexed and filtered through a 0.45μm GHP membrane in a Nanosep 
MF Centrifuge tube (Pall Co., Port Washington, WI, USA) before LC-MS/MS analysis. 
Sugar phosphates and other metabolic intermediates were analysed using an optimised 
Agilent 6530 Accurate-Mass Q-TOF LC/MS (Agilent Technologies, Inc. Santa Clara, 
CA, USA) at the ANU Mass Spectrometry Facility. Samples were subjected to 
optimised ESI in the Jetstream interface in negative polarity under the following 
conditions: gas temperature 250°C, drying gas 9 L min–1, nebuliser 25 psig (172.4 
kpa), sheath gas temperature 250°c and flow rate of 11 L min–1, capillary voltage 2500 
V, fragmentor 145 V, and nozzle voltage 500 V. Mobile phase A consisted of water 
with 0.1% formic acid and mobile phase B consisted of 90% methanol,10% water and 
0.1% formic acid. Samples were injected onto an Agilent Phonomenex Luna 3U HILIC 
200A (50 x 2 mm, 3 micron) column and analytes were eluted in mobile phase B.  The 
QTOF was operated in targeted MS/MS mode using collision induced dissociation 
(CID; N2 collision gas supplied at 18 psi (124.1 kpa), m/z 1.3 isolation window) where 
the MS extended dynamic range was set from m/z 100–1000 at 3 spectra s–1, and 
MS/MS m/z 50–1000 at 3 spectra s–1. Data were extracted and analysed using Agilent 
Technologies Masshunter software. Mass spectrometry was carried out at the Mass 
Spectrometry Facility, Research School of Biology with the help of Dr. Thy Thuong.  
 
6.3 Results 
6.3.1 Mitochondrial dysfunction in LPS stimulated macrophages is abrogated in Gsto1 
knockdown cells 
LPS has previously been shown to increase mitochondrial ROS generation and 
contribute to the bactericidal response in macrophages [148, 292, 343, 344, 376]. A 
significant increase in mitochondrial ROS was detected in LPS treated non-silencing 
control cells which was absent in the Gsto1 knockdown cells (Figure 6.2A), suggesting 
that GSTO1-1 mediates mitochondrial ROS production in addition to its previously 
demonstrated effect on cytosolic ROS (Chapter 5).  
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JC-1 is a cationic dye that exhibits potential-dependent accumulation in the 
mitochondria and consequently is considered a good marker to measure mitochondrial 
depolarization. Monomeric JC-1 yields green fluorescence (525 nm) which shifts to red 
(590 nm) when the dye accumulates in the mitochondria forming J-aggregates. Hence, 
mitochondrial depolarization is indicated by a decrease in the red/green fluorescence 
ratio. We detected a decrease in the mitochondrial membrane potential (ψ) in LPS 
treated J774.1A non-silencing control cells. In contrast, the GSTO1-1 deficient cells 
showed no change in the mitochondrial membrane potential (Figure 6.2B).  
 
 
 
 
 
 
 
It has been previously established that an altered mitochondrial membrane potential is 
associated with an imbalance in the AMP/ADP ratio that is monitored by AMP-
activated protein kinase (AMPKα) a major sensor of intracellular energy status [292] As 
recent evidence suggests a significant link between energy homeostasis and redox state 
in macrophages [292, 343], we further investigated the role of GSTO1-1 in modulating 
the LPS stimulated decrease in the mitochondrial membrane potential by evaluating the 
activation of AMPKα to phospho-AMPKα (p-AMPKα). The results indicate that the 
activation of AMPKα to p-AMPKα is inhibited by a pro-inflammatory stimulus such as 
LPS, and this inhibition is blocked in Gsto1 knockdown cells (Figure 6.3A). By 
Figure 6.2: GSTO1-1 regulates mitochondrial ROS and mitochondrial membrane 
potential in LPS activated macrophages. (A) LPS treated non-silencing control cells 
showed a significant (p=0.05) increase in mitochondrial ROS which was absent in the 
Gsto1 knockdown cells. (B) A significant (p<0.05) decrease in the mitochondrial 
membrane potential (ψ) in LPS treated J774.1A non-silencing control cells was absent 
in the GSTO1-1 deficient cells. 
Chapter 6 
139 
 
knocking down GSTO1-1, the cells failed to respond to LPS and p-AMPKα levels 
remained unchanged. To further determine if the restoration of active AMPKα levels is 
dependent on the catalytic activity of GSTO1-1, we tested the ability of ML175 to 
activate AMPKα. As shown in Figure 6.3B, AMPKα activation was restored by 
GSTO1-1 inhibitor ML175 in a concentration dependent manner. This result further 
identifies GSTO1-1 as a novel anti-inflammatory target.  
To determine whether the downstream effects of GSTO1-1 on ROS production and 
cytokine secretion are mediated via AMPKα, we tested the hypothesis that the effect of 
GSTO1-1 on NOX1 expression is dependent on the activation of AMPKα. J774.1A 
non-silencing control cells and Gsto1 deficient cells were treated with Compound C (6-
[4-(2-Piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-pyrrazolo[1,5-a]-pyrimidine), a 
synthetic inhibitor of AMPKα. Pre-treatment of Gsto1 knockdown cells did not reverse 
the effect of GSTO1-1 on NOX1 transcript levels (Figure 6.3C) suggesting that 
phosphorylation of AMPKα in LPS treated cells may be an indirect consequence of the 
upstream regulatory switch provided by GSTO1-1. Hence, it is concluded that the 
inhibitory effect of GSTO1-1 on NOX1 transcription (reported in Chapter 5) is not 
dependent on AMPKα. 
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Figure 6.3: GSTO1-1 is required for the inactivation of AMPKα in LPS stimulated macrophages 
(A) The inhibitory effect of LPS on AMPKα phosphorylation in J774.1A wildtype macrophages is reversed in GSTO1-1 deficient cells (B) 
AMPKα activation was restored by ML175 in LPS activated macrophages.  (C) Pre-treatment of J774.1A macrophages with AMPKα inhibitor 
Compound C (ComC) for 2 hours did not reverse the non- responsiveness of Gsto1 knockdown cells suggesting that the block in the 
transcriptional activation of NOX1 is independent of AMPKα 
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6.3.2 Reconfiguration of cellular metabolism during pro-inflammatory (M1) 
polarization 
An imbalance in the energy homeostasis as reflected by the activation of AMPKα was 
further evaluated by determining the downstream effects of metabolic dysregulation. 
The two main metabolic pathways, glycolysis and the citric acid cycle (TCA cycle) 
have been shown to be severely impacted by LPS.  LPS activated macrophages acquire 
a pro-inflammatory M1 phenotype which is associated with a highly glycolytic profile 
[1, 298, 373, 377]. These activated macrophages tend to secrete excess lactic acid and 
accumulate high levels of TCA intermediates such as succinate. The accumulation of 
succinate during the LPS mediated activation of macrophages stabilizes the 
transcription factor HIF1α and promotes the activation of pro-inflammatory cytokines 
such as IL-1β [1], thus it appears that the metabolic phenotype is essential for the 
maintenance of pro-inflammatory responses in LPS activated macrophages. To 
determine the metabolic state of GSTO1-1 deficient macrophages, the Extracellular 
Acidification Rate (ECAR) and the Oxygen Consumption Rate (OCR) in response to 
LPS were measured.  The LPS induced increase in ECAR that occurred in J774.1A non-
silencing control cells was blocked in GSTO1-1 deficient cells (Figure 6.4A). OCR 
levels inversely reflected ECAR changes in both control and GSTO1-1 deficient cells.  
Due to increased glycolysis, the OCR showed a steady decline in control cells whereas 
the GSTO1-1 deficient macrophages showed no change in the OCR (Figure 6.4B). 
Complementing the ECAR measurements in GSTO1-1 deficient cells, lactate secreted 
into the media by the cells on LPS stimulation was quantified. As expected, a 
significant increase in the extracellular lactate levels in non-silencing control cells was 
detected in 24 hours (Figure 6.4C). However the Gsto1 knockdown cells did not alter 
their lactate secretion, indicating that the cells were unresponsive to LPS and failed to 
acquire a glycolytic phenotype (Figure 6.4C). To determine if the unresponsiveness to 
LPS is dependent on the catalytic activity of GSTO1-1, cells were treated with ML175 
prior to LPS. Pre-treatment with ML175 decreased the level of extracellular lactate 
secreted by wildtype J774.1A macrophages in a dose dependent manner (Figure 6.4D). 
Since increased flux through the Pentose Phosphate Pathway (PPP) generates NADPH 
that is required by NADPH oxidases to generate high levels of ROS after TLR4 
activation, the effect of LPS on the PPP was investigated in Gsto1 knockdown cells. We 
found that NADPH levels were significantly increased in LPS stimulated macrophage 
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cells but no increase was observed in Gsto1 knockdown cells (Figure 6.4E) or in 
wildtype cells treated with ML175 (Figure  6.4F).  
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6.3.3 LPS induced accumulation of succinate and the stabilization of HIF1α 
It has been previously shown that there is a significant increase in the intermediate 
metabolites funnelling into glycolysis and TCA cycle such as fructose-6-phosphate, 
succinate, fumarate, after LPS activation (Figure 6.1) [373]. Metabolomics performed 
after LPS activation of J774.1A cells revealed a build-up of TCA intermediates 
succinate and fumarate (Figure 6.5 A-B).  The increase in the abundance of succinate, 
fumarate and citrate in LPS treated macrophages was abolished in GSTO1-1 deficient 
cells, complementing the absence of a glycolytic phenotype in these cells (Figure 6.5A-
C). The abundance of TCA metabolites was normalized to the total number of cells and 
to the essential amino acids detected in the cell lysates. A similar trend was observed in 
the levels of upstream glycolytic intermediate glucose-6-phosphate in GSTO1-1 
deficient cells (Figure 6.5D). This trend in sugar phosphates was previously reported to 
dampen the pro-inflammatory responses of TLR4 activated macrophages [373].  
Activation of HIF1α has been shown to play a key role in maintaining the pro-
inflammatory state of activated macrophages [1]. Bone marrow macrophages from 
Hif1α-/- mice were unresponsive to LPS and did not secrete IL-1β on TLR4 activation. 
The succinate build-up on LPS stimulation inhibits Prolyl Hydroxylase (PHD) resulting 
in the stabilization of HIF1α [1]. In this study the activation status of HIF1α was 
evaluated in GSTO1-1 deficient macrophages to determine if the observed absence of 
succinate accumulation in these cells resulted in the suppression of HIF1α activation.  
Figure 6.4: GSTO1-1 deficiency prevents macrophages from acquiring a glycolytic 
phenotype in response to LPS. (A) The LPS induced increase in ECAR in non-silencing 
J774.1A macrophages over 24 hours was blocked in the GSTO1-1 deficient 
macrophages. (B) The LPS induced decrease in OCR measured in non-silencing 
J774.1A macrophages did not occur in GSTO1-1 deficient macrophages. (C) The 
extracellular lactate levels in the media collected from the LPS treated non silencing 
control J774.1A macrophages were significantly increased over 24 hours. This trend 
was largely absent and the media lactate levels remained unchanged in Gsto1 
knockdown cells treated with LPS. (D) Wildtype J774.1A macrophages treated with 
LPS showed a significant dose dependent decrease in the extracellular lactate level 
when GSTO1-1 was inhibited with ML175. (E) NADPH levels were significantly 
(p<0.01) increased in LPS treated J744.1A non-silencing macrophages but no increase 
was measured in the GSTO1-1 deficient cells. (F) Pre-treatment with ML175 
maintained unchanged levels of NADPH in LPS treated wildtype J774.1A 
macrophages. 
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The results indicated that the induction of HIF1α stimulated by LPS is significantly 
attenuated in GSTO1-1 deficient cells (Figure 6.6A). Furthermore, the inhibition of 
GSTO1-1 with ML175 decreased the expression of HIF1α in a dose dependent manner 
(Figure 6.6B).  
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Figure 6.5: LPS dependent re-programming of the TCA cycle in M1 macrophages is altered by Gsto1 knockdown. (A-B) The accumulation 
of succinate and fumarate intermediates in LPS treated J774.1A non-silencing macrophages was significantly attenuated in GSTO1-1 
deficient cells. (C) Citrate levels were not induced in response to LPS in Gsto1 knockdown macrophages. (D) The ratio of glycolytic 
intermediates fructose-6-phosphate (F6P) to glucose-6-phosphate (G6P) was significantly higher in LPS treated non silencing J774.1A 
macrophages as a result of the glycolytic phenotype acquired by the cells. This trend was absent in Gsto1 knockdown cells suggesting a 
failure to acquire a glycolytic phenotype in response to LPS.  
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6.4 Discussion  
Innate immunity is considered as the first line of defence against invading pathogens in 
mammalian cells. Macrophages are the key players contributing to innate immune 
responses that recognize foreign pathogens and inflammatory stimulants such as 
bacterial LPS. LPS has been shown to induce the generation of reactive oxygen species 
(ROS) and pro-inflammatory cytokines such as IL-1β through the activation of TLR4 
and the recruitment of downstream signalling proteins in macrophages. Previous studies 
have established that macrophages activated via the LPS/TLR4 pathway produce ROS 
and develop a glycolytic phenotype characterized by the increased production of lactate 
and the accumulation of succinate that stabilizes HIF1α and regulates the expression of 
IL-1β [1, 373-375]. Macrophages deficient in GSTO1-1 are non-responsive to LPS and 
do not activate NF-κB after TLR4 activation (Chapter 4).  In this chapter, the impact of 
GSTO1-1 on TLR4 signalling occurring in parallel with the activation of NF-κB-
dependent transcriptional regulation of pro-inflammatory genes was further elucidated.  
GSTO1-1 was found to be required for the production of mitochondrial ROS which 
contributes significantly to the total cytosolic ROS measured in the previous chapter.  
As a consequence of the high mitochondrial ROS, the mitochondrial membrane 
potential was significantly affected resulting in an imbalance in AMP/ADP which in 
turn leads to the phosphorylation/activation of AMPKα. ROS are major mediators of 
cytotoxicity and are directly responsible for much of the pathology that is associated 
with inflammation. As inflammation contributes to the pathology and exacerbation of a 
Figure 6.6: LPS induced stabilization of HIF1α  
(A) Induction and stabilization of HIF1α by LPS in macrophages was notably 
attenuated in GSTO1-1 deficient cells. (B) Pre-treatment with ML175 blocked the LPS 
induced stabilization of HIF1α in wildtype macrophages, mimicking the phenotype 
observed in GSTO1-1 deficient cells.  
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range of metabolic disorders and neurodegenerative diseases, it is possible that the 
implicated role of GSTO1-1 and its allelic variants in diseases such as Alzheimer’s 
disease, Parkinson’s disease, vascular dementia and stroke, amyotrophic lateral 
sclerosis, and chronic obstructive pulmonary disease (COPD) [210, 212-215, 272], is 
due to the modulation of the redox state of proteins involved in the disease-associated 
inflammatory responses. 
Several lines of evidence suggest that LPS induces metabolic reprogramming in 
macrophages in response to pathogen infection [1, 298, 363, 373, 374, 378]. 
Additionally recent evidence demonstrates that the secretion of cytokines on LPS 
stimulation depended on the inhibition of Prolyl Hydroxylase (PHD) and subsequent 
stabilization of HIF1α in response to the accumulation of succinate through the TCA 
cycle in the mitochondria [1]. The previous chapter detailed the consequences of 
GSTO1-1 deficiency on the typical pro-inflammatory responses elicited in LPS 
stimulated macrophages. The findings were further strengthened by characterizing the 
metabolic profile of GSTO1-1 deficient cells to determine whether GSTO1-1 could alter 
the glycolytic reprogramming reported by others.  
Published literature strongly suggest that LPS causes a glycolytic switch in 
macrophages, directing them towards a more catabolic phenotype characterized by 
increased generation of glycolytic intermediates such as Fructose-6-phosphate and 
increased channelling of glycolytic intermediate glucose-6-phosphate through the PPP 
shunt [1, 373]. GSTO1-1 deficient macrophages failed to switch towards a glycolytic 
phenotype and therefore no increase in glycolytic and PPP shunt intermediates was 
detected. Furthermore, the findings correlated well with published data on the responses 
mediated via the TCA cycle. LPS stimulation led to a build-up of TCA intermediates 
including succinate which in turn activated HIF1α by inhibiting PDH. However the 
Gsto1 knockdown cells showed no disruption in the TCA cycle and consequently failed 
to stabilize HIF1α. These findings bring us back to the initial results suggesting an 
overall unresponsiveness of GSTO1-1 deficient macrophages towards LPS. Since LPS 
did not lead to the stabilization of HIF1α (Figure 6.6), pro-IL-1β levels also remained 
un-induced (Figure 5.5). Additionally, it is also speculated that accumulation of citrate 
would result in an increase in acetyl-CoA in the cytosol of macrophages as a direct by-
product of citrate metabolism in macrophages [379]. The acetyl-CoA generated could 
then be channelled into phospholipid biosynthesis resulting in the production of 
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arachidonic acid, a substrate for prostaglandin synthesis. The NF-κB dependent 
induction of COX2 has already been described in Chapter 5. Taken together, the two 
pathways merge to initiate and maintain inflammatory responses stimulated by LPS in 
macrophages. It was also hypothesized that another product of citrate metabolism, 
oxaloacetate, could potentially contribute to ROS generation though a mechanism 
wasn’t elaborated further [379]. This part of the study indicates that GSTO1-1 is 
required for most LPS dependent TLR4 signalling in macrophages and plays a critical 
role in maintaining internal energy and redox homeostasis. Indeed, immune signalling is 
a metabolically expensive process and is severely impacted under metabolically starved 
conditions [298, 378].  The metabolic changes unfolding in response to pathogen 
invasion would allow for an up-regulation in the production of biosynthetic 
intermediates to meet the energy demands of pro-inflammatory macrophages. 
Since the pharmacological inhibitor of GSTO1-1, ML175 was found to inhibit cells 
from acquiring a glycolytic phenotype, characterized by the alterations in glycolytic and 
TCA intermediates. This supports the contention that the regulatory effect(s) of 
GSTO1-1 may be mediated by its catalytic activity.  
The pro-inflammatory responses activated by LPS are orchestrated via several parallel 
pathways that include the activation of NF-κB, and the metabolic reprogramming to a 
glycolytic phenotype (similar to cancer cells). Both these pathways promote anti-
bacterial responses through the production of ROS and the secretion of pro-
inflammatory cytokines.  These findings support the hypothesis that GSTO1-1 is an 
indispensable upstream modulator of TLR4 mediated responses and is necessary for 
orchestrating the metabolic and redox re-profiling of LPS activated macrophages. Since 
all the parallel pathways are disrupted by GSTO1-1 deficiency, it further supports the 
hypothesis that the target of GSTO1-1 is a protein early in the pathway and probably 
within the Myddosome complex (Figure 6.7) 
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Figure 6.7: A scheme linking the metabolic pathways involved in maintaining a 
pro-inflammatory state in macrophages with the downstream expression of 
cytokines. Inhibition of GSTO1-1 with ML175 blocks the activation of multiple 
pathways originating at TLR4 and diverging downstream of the 
TLR4/Myddosome complex (highlighted in red). 
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Chapter 7 
Characterization of Gsto1
-/-
 mice and their 
response to bacterial endotoxin 
7.1 Introduction 
Stimulation of macrophages with LPS results in the production of various cytokines 
such as TNFα, IL-1, IL-6, IL-10 and enzymes contributing to ROS production [168, 
292, 345, 380]. LPS in appropriate quantities can activate pro-inflammatory responses 
resulting in unfavourable conditions for pathogens. However, hyper-activation of 
macrophages by either excessive LPS or prolonged exposure to LPS can lead to 
endotoxic shock [380-384]. In the present study, mice were injected with E.coli O55:B5 
LPS to evaluate the role of GSTO1-1 in the response to LPS in vivo. LPS is a mixture of 
polysaccharide and lipid A, and much of LPS responses are mediated by the lipid A 
portion [168, 385]. Since the deficiency of GSTO1-1 resulted in the attenuation of 
TLR4 signalling in macrophage cell line J774.1A, it was hypothesized that Gsto1
-/-
 mice 
would tolerate an LPS challenge. 
7.2 Materials and Methods 
7.2.1 Animals 
Gsto1 knockout mice were generated by Taconic Biosciences (U.S.A) and became 
available late in the course of the project (November 2014). Heterozygotes were mated 
to generate knockout and wildtype control littermates. Due to the poor number of 
homozygote knockouts born from heterozygote x heterozygote breeding (9 Gsto1
-/-
 
from 328 progeny), knockout siblings were mated and wildtype littermates from the 
heterozygote x heterozygote crosses were also mated to generate two strains of Gsto1
-/-
 
and Gsto1
+/+
 mice. The phenotype of the Gsto1
-/-
 mice used in this study was not fully 
characterized due to unforeseen difficulties in the breeding and the resulting scarcity of 
mice. The Gsto1
-/-
 mice bred well when the homozygote line was established and it 
remains unclear why they could not be produced from the heterozygote mating. Mice 
were maintained at the ANU Biosciences facility under controlled animal room 
conditions. The animals were fed regular animal diet and water ad libitum.  
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7.2.2 Enzyme assays 
Biochemical assays were carried out as described in Chapter 2-5.   
7.2.3 Organ collection and homogenization 
Organs were harvested in assay specific buffers. For immunoblots and biochemical 
assays, tissues were extracted, washed in PBS and homogenized in T-PER (Thermo 
Scientific) using an Ultraturux homogenizer. Homogenates were centrifuged at 20000 x 
g at 4°C to remove tissue debris and stored at -20°C until further use. For assays 
requiring low denaturing and non-reducing conditions, tissues were homogenized in 20 
mM tris pH 7.2, 1% NP-40, EDTA, 100 mM N-ethylmaleimide as above and used 
immediately upon preparation. Tissues for histological analysis were washed 
thoroughly in PBS and fixed immediately in 10% neutral buffered formalin.  
7.2.4 Histology 
Tissues for histochemical analysis were fixed in 10% neutral buffered formalin and 
embedded in paraffin at the Microscopy and Cytometry Research Facility (MCRF).  
Tissue sections were cut at a thickness of 4 microns and stained with hematoxylin-
eosin. Tissue embedding, sectioning and H&E staining were carried out by Ms. Anne 
Prins (MCRF) and histological analysis was carried out at the Canberra Hospital by 
Professor. Jane Dahlstrom.   
7.2.5 Haematology 
Mice (8 weeks of age) were left untreated or injected with 50 mg/kg LPS for 12 hours 
and 200-220 μl of blood was collected into heparin-coated sterile tubes by retro-orbital 
bleeding. Blood samples were immediately analysed using ADVIA Haematology 
systems (Siemens) at the Australian Phenomics Facility.  
7.2.6 Injections and treatments 
Indicated doses of LPS (Sigma) were intra-peritoneally injected (5-50 mg/kg). For body 
temperature measurements, temperature-recording probes (DAS-7009 smart reader, 
BMDS) were inserted sub-cutaneously 24 hours prior to LPS injections. The body 
temperature was monitored over 24 hours to confirm that no infection occurred due to 
the insertion of the probe.  For LPS experiments, body temperature of less than 24°C 
was considered as ‘death as an endpoint’ and mice were euthanized immediately by 
CO2 asphyxiation if the body temperature dropped to 24°C or less for 2 consecutive 
readings in accordance with the ANU animal ethics protocol.  
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For experiments with butylated hydroxyanisole (BHA), female mice (between 7-8 
weeks of age) were fed ad lib. either regular chow (control) or chow supplemented with 
0.5% (w/w) BHA (Sigma) for 14 days. Mice were euthanized by CO2 asphyxiation as 
recommended by the ANU animal ethics committee.  
7.2.7 ELISA 
Cytokine specific ELISAs were carried out as described in Chapter 5.  
7.2.8 Isolation of Bone marrow derived macrophages 
Bone marrow macrophages were isolated and differentiated as previously described. 
The femur and tibia from mice were extracted at the hip joint and placed in cold DMEM 
media (DMEM Glutamax from Gibco Life technologies). Attached muscle tissue was 
removed and the femur was separated from the tibia. The ends of each bone were cut to 
expose the bone marrow. The bone marrow was flushed out of each bone using a 10ml 
syringe fitted with a 23G needle into a 50ml tube. Cells were centrifuged at 800 x g for 
5 minutes and the supernatant was discarded. The pellet was incubated in RBC lysis 
buffer (Sigma) for 5 minutes. Lysis was stopped by resuspending the cells in DMEM 
media. The centrifugation step was repeated and the supernatant was discarded. The cell 
pellet was re-suspended in DMEM media supplemented with 20% L-929 conditioned 
media seeded in three 10 cm petri dishes (non tissue-culture grade sterile plastic dishes) 
and allowed to differentiate for 7 days at 37°C, 5% CO2. At the end of 7 days, cells 
were washed, counted and re-seeded as required.  
7.3 Results 
7.3.1 Characterizing GSTO1-1 deficiency in Gsto1
-/-
 mice 
The general characteristics of Gsto1
-/-
 mice including body weight and organ weights 
were evaluated in order to determine whether GSTO1-1 deficiency caused any 
developmental/growth abnormalities. As shown in Figure 7.1A, the total body weight of 
Gsto1
-/-
 mice (8 weeks of age, males) clustered well within the limits set by the wildtype 
littermates. Furthermore, the major organs were visually normal and the organ weights 
did not differ from the wild type controls (Figure 7.1B), suggesting no organ 
deformities in the Gsto1
-/-
 mice under normal physiological conditions.  
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Immunoblotting of liver extracts revealed that GSTO1 was absent in Gsto1
-/-
 mice while 
the Gsto1
+/-
 mice expressed half the amount detected in wildtype mice (Figure 7.2A). 
To further confirm that the expression of GSTO1-1 was completely absent, the enzyme 
activity of GSTO1-1 with 4-NPG as substrate was determined and was undetectable in 
the liver of Gsto1
-/-
 mice (Figure 7.2B) (n=3) while the heterozygotes exhibited half the 
activity measured in wildtype mice. The distribution of GSTO1-1 across a range of 
tissues was also determined to evaluate tissue specificity. Immunoblotting for GSTO1-1 
in tissue extracts from various organs showed that GSTO1-1 is expressed in comparable 
amounts in in the liver, kidney, heart, lungs and spleen (Figure 7.2C).  
Figure 7.1: Body and organ weights of Gsto1
-/-
 mice 
(A) The body weights of Gsto1
-/-
 and wildtype littermate controls were similar at 8 
weeks of age. (B) Individual organ weights were comparable between Gsto1
-/-
 mice 
and wildtype controls. 
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A B C 
Figure 7.2: Characterization of Gsto1
-/-
 mice (n=3) 
(A) Knockout of GSTO1-1 expression in liver homogenates of Gsto1
-/-
 mice was confirmed by immunoblotting. (B) GSTO1-
1 specific 4-NPG reductase activity was undetectable in Gsto1
-/-
 mice while the activity in liver homogenates of Gsto1
+/-
 mice 
was significantly halved compared to the wildtype. (C) GSTO1-1 is expressed in abundance in all the tissues evaluated in 
wildtype mice.  
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7.3.2 Expression profile of glutathione transferases in Gsto1
-/-
 mice 
Previously published studies on Gstz1 knockout mice revealed an induction in the 
proteins levels of other GSTs as an antioxidant response to the increased oxidative 
stress in these mice [386].  To determine whether Gsto1
-/-
 mice encountered a similar 
increase in oxidative stress, liver lysates were extracted and proteins were separated by 
SDS PAGE. Interestingly, screening the expression levels of GSTs in male Gsto1
-/-
 
mice revealed a consistent decrease in the expression of Nrf2 driven GSTs including 
GSTA1/2, GSTT1, GSTT2 (Figure 7.3 A). However, the expression of GSTs such as 
GSTM2, GSTP, GSTK and GSTO2-2 remained the same as the wildtype mice. The 
expression levels of NQO1, considered a good indicator of oxidative stress in cells and 
a target of Nrf2 dependent regulation, were also seen to be significantly lower in the 
knockout mice. The trend in GST expression levels was maintained in both male and 
female Gsto1
-/-
 mice however females showed a more prominent decrease in the 
expression of GSTA4, GSTA1/2 and NQO1 (Figure 7.3B).  
Because 1-chloro 2,4-dinitrobenzene (CDNB) is a good substrate for some of the GSTs 
that showed lower expression levels in the livers of Gsto1
-/-
 mice, the GST activity of 
the liver cytosolic extracts was measured with CDNB. Wildtype mice (Gsto1
+/+
) had 
CDNB activity of 11.9 ± 2.05 μmol/mg protein/minute compared with 7.3 ± 1.2 
μmol/mg protein/minute in Gsto1-/- mice (Figure 7.2C). This difference in GST activity 
between the wildtype and Gsto1
-/-
 mice correlated well with the difference in protein 
expression reported in Figure 7.3A-B.  The residual GST activity measured in the 
Gsto1
-/-
 mice may be due to the unchanged GSTP expression. To support this 
hypothesis, the GST activity in Gstp1/2
-/-
 mice was measured (Figure 7.3C). The 
activity in Gstp1/2
-/-
 mice was significantly diminished (0.3 ± 0.82) which would 
suggest that GSTP may be a major contributor of the GST activity measured in the liver 
of Gsto1
-/-
 mice. 
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7.3.3 Gsto1
-/-
 mice are resistant to LPS induced endotoxic shock 
LPS responsiveness was demonstrated by ip injection of age matched Gsto1
-/-
, Gsto1
+/-
 
and wildtype Gsto1
+/+
 mice with high doses of LPS and monitoring their survival. At a 
dose of 10 mg/kg, almost all wildtype mice died within 96 hours post LPS injection 
(12.5% survived) (Figure 7.4A). The Gsto1
-/-
 and mice showed high resistance to LPS 
induced endotoxic shock and survived while the Gsto1
+/-
 mice showed intermediate 
survival rates in between those of wildtype and the Gsto1
-/-
 mice (66.7% survived). At a 
sub-lethal dose of 5 mg/kg, almost all wildtype mice died (37.5% survived) while all the 
Gsto1
-/-
 and Gsto1
+/-
 mice survived (Figure 7.4B). To monitor the deterioration in the 
animal’s health, each mouse was subcutaneously implanted with a temperature-
transmitting probe 24 hours before LPS injection. The temperature of the mice, which 
was considered as a direct readout of the response of the animal to the injected LPS, 
was recorded every 3 hours. As shown in Figure 7.4C and D, the body temperature 
readings across the three groups correlated well with their respective survival rates. The 
Gsto1
-/-
 mice showed no significant drop in body temperature in response to LPS. On 
the other hand, the wildtype mice underwent hypothermia within 12 hours after LPS 
injection at both doses. The lethality of the doses was also reflected in the extent of 
temperature drop recorded in the wildtype mice. An average drop of 7°C was recorded 
in wildtype mice injected with 5 mg/kg LPS while the drop was >10°C in wildtype mice 
injected with 10 mg/kg LPS. Interestingly, the Gsto1
+/-
 mice presented an intermediate 
response. Their survival was considerably higher than the wildtype mice at both doses 
of LPS and their body temperature decreased within the first 24 hours (Figure 7). 
However, their rapid recovery from LPS induced systemic inflammation was reflected 
by the gradual increase in body temperature and other physical characteristics including 
activity and response to touch. Some of the wildtype mice did recover slightly from LPS 
induced hypothermia though not to the extent seen with the heterozygotes. 
Figure 7.3: Expression profiling of GSTs in Gsto1
-/-
 mice  
(A) GST expression in male mice; (B) GST expression in female mice; (C) GST 
activity with CDNB was moderately lower in Gsto1
-/-
 mice than the wildtype mice 
(WT). GST activity with CDNB was significantly attenuated in Gstp1/2
-/-
 mice 
homogenates of Gsto1
+/-
 mice was significantly halved compared to the wildtype (C).  
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Figure 7.4: Susceptibility of Gsto1
-/-
 mice to LPS induced endotoxic shock 
(A) Wildtype mice and Gsto1
+/-
 mice were highly susceptible to a lethal dose of 10 mg/kg E.coli O55:B5 LPS and died 
within 96 hours due to septic shock while the Gsto1
-/-
 mice survived the treatment. (B) Gsto1
-/-
 and Gsto1
+/-
 mice survived a 
sub-lethal dose of 5 mg/kg LPS but the wildtype mice died due to severe systemic inflammation. LPS induced hypothermia 
in mice treated with 5 mg/kg LPS (C) and 10 mg/kg LPS (D) was monitored until the mice were euthanized.  
Chapter 7 
159 
 
7.3.4 Pathological changes associated with GSTO1-1 deficiency 
Light microscopy on tissues showed that 5 mg/kg LPS had no significant effect on the 
heart, lung, kidney and spleen. The liver in three out of five wildtype mice showed mild 
inflammation. None of the Gsto1
-/-
 mice showed any signs of inflammation in the liver. 
Two of the five wildtype mice showed marked changes in the spleen with significant 
recruitment and accumulation of macrophages in the germinal centres of the spleen, 
showing tingable body macrophages which is considered as a marker of LPS toxicity 
[387]. The remaining three mice did not show this severe damage. Two of the five 
wildtype mice also showed reduced red pulp. However, none of the knockout and 
heterozygotes showed any difference.   
 
Time course of LPS treatment: 
Liver: Mice were injected intra-peritoneally with 50 mg/kg LPS and euthanized at 
0.5,1,3,6 and 12 hours post injection. The 30 minutes time point showed no signs of 
inflammation in the liver in both wildtype and Gsto1
+/-
 mice. At 1 hour post LPS, all the 
wildtype and Gsto1
+/-
 mice showed significant necrosis in the liver (Figure 7.5A, C-D).  
, which was completely absent in the livers of the Gsto1
-/-
 mice (Figure 7.5B). All 
wildtype mice showed severe liver damage in terms of necrosis and acute inflammation 
and one Gsto1
-/-
 mouse showed minimal damage though it was considered insignificant 
when compared to the extent of liver damage observed in the wildtype mice. More 
significant differences in the liver between the wildtype and Gsto1
+/-
 mice were seen at 
6 hours post LPS. Two of three wildtype mice showed necrosis and acute inflammation 
in the liver (Figure 7.5E) but none of the heterozygotes showed any liver damage 
(Figure 7.5F). To summarize, all but one wildtype showed severe liver necrosis when 
injected with LPS for greater than 30 minutes and the Gsto1
+/-
 mice did not show an 
inflammatory phenotype when exposed to LPS indicating that Gsto1
+/-
 mice are less 
susceptible to endotoxic shock while the Gsto1
-/-
 mice are resistant to LPS induced 
septic shock. 
 
Spleen: In the time course experiments conducted, no significant changes were seen in 
the tissues harvested from mice treated with 50mg/kg LPS for 30 minutes in both 
wildtype and Gsto1 heterozygous mice. At 1, 3 and 6 hour time points, one of three 
wildtype mice showed Tingible body macrophages (Figure 7.6A-B) in the spleen while 
none of the Gsto1
-/-
 mice showed any abnormalities at 1 and 3 hours post LPS (Figure 
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7.6C). However, one of two mice at 6 hours showed a similar phenotype as the wildtype 
mouse.   
In terms of red pulp changes in the spleen, there were no significant changes observed 
in both groups at 30 minutes and one hour post LPS injection. At 3 hours, one of three 
wildtype mice showed abnormal red pulp changes while none of the heterozygote mice 
developed any abnormalities. At 6 hours post LPS, all three wildtype mice showed 
abnormal changes in the red pulp in the spleen while only one of two heterozygotes 
showed similar changes (Figure 7.6D-E). The Gsto1
-/-
 mice showed no signs of 
inflammation at both 3 hours and 6 hours post LPS injection. 
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Figure 7.5: Light microscopy showing liver pathology in Gsto1
−/−
 mice.  
(A) Wildtype mouse injected with 50 mg/kg LPS shows acute inflammation and 
necrosis (highlighted in yellow) within 1 hour post injection. (B) Gsto1
-/-
 mouse 
injected with 50 mg/kg LPS (1 hour) showed normal liver histology. (C) 
Wildtype mouse injected with 50 mg/kg LPS shows acute inflammation and 
necrosis (yellow arrow) within 1 hour post injection. (D) Magnified view of the 
necrotic tissue shown in (C) reveals presence of infiltrating neutrophils in 
wildtype mouse (50μm). (E) Wildtype mouse injected with 50 mg/kg LPS shows 
acute inflammation and increase in number of single cell necrotic foci in 12 
hours post injection (highlighted in yellow). (F) Gsto1
-/-
 mouse injected with 50 
mg/kg LPS (1 hour) showed normal histology 12 hours post LPS injection. 
A 
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Figure 7.6: Light microscopy showing spleen pathology in Gsto1
−/−
 mice.  
(A) Wildtype mouse injected with 50 mg/kg LPS shows acute inflammation (highlighted in yellow) within 3 hour post 
injection. (B) Magnified view of the inflamed pockets reveals tingable body macrophages in wildtype mouse spleen. (C) 
Gsto1
-/-
 mouse injected with 50 mg/kg LPS (3 hours) showed normal spleen histology. (D) Wildtype mouse injected with 50 
mg/kg LPS shows acute inflammation 6 hours post LPS injection while Gsto1
-/-
 mouse showed normal spleen histology (E). 
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7.3.5 Haematological changes associated with GSTO1-1 deficiency 
To characterize the impact of GSTO1-1 deficiency, the haematology profile of Gsto1
-/-
 
mice was evaluated. Mice (8 weeks of age) (n=4) were left untreated or injected with 50 
mg/kg LPS for 12 hours. There were no significant differences in the red blood cell 
indices of wildtype and Gsto1
-/-
 mice left untreated and treated with LPS (Table 7.1).   
LPS caused a marked reduction in the platelet and total white blood cell counts in both 
LPS treated groups. The absolute cell count of neutrophils was increased in both the 
LPS treated groups though there was no notable difference between the wildtype and 
Gsto1
-/-
 mice.  Interestingly, though other WBCs including basophils, eosinophils and 
lymphocytes were depleted in the LPS treated mice (both wildtype and Gsto1
-/-
), the 
monocyte profile was considerably different between the wildtype and Gsto1
-/-
 mice. 
The monocyte count in untreated Gsto1
-/-
 mice was significantly lower than the 
wildtype counterparts under normal physiological conditions. LPS caused a significant 
depletion in the monocyte cell count in the wildtype mice. In contrast, the monocyte 
count remained unchanged in LPS treated Gsto1
-/-
 mice (Table 7.1). Similarly, 
eosinophil count in Gsto1
-/-
 mice was also lower than the wildtype counts in the 
untreated groups. In summary, the differential leucocyte counts were affected to a 
similar extent in both the LPS treated wildtype and Gsto1
-/-
 mice. However, the 
monocyte counts remained unresponsive to LPS in the Gsto1
-/-
 mice. Monocytes 
differentiate into resident macrophages in tissues, which exacerbates inflammation in 
the affected tissue and are considered the prime cause for septic shock culminating in 
lethality. Since the data presented in this study thus far demonstrate increased tolerance 
of Gsto1
-/-
 mice to LPS, it is not unexpected that the monocyte counts in Gsto1
-/-
 mice 
did not show any difference on LPS injection. The lower monocyte and eosinophil 
counts in the Gsto1
-/-
 mice under normal physiological conditions is curious and 
warrants further investigation.  
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7.3.6 Cytokine profile in LPS treated Gsto1
-/-
 mice 
The LPS response of Gsto1
-/-
 mice was further examined by determining the serum 
cytokine levels in mice injected with 50 mg/kg LPS. Wild-type mice produced high 
levels of cytokines TNF-α, IL-6 and IL-1β in response to LPS which peaked in 30-60 
minutes (Figure 7.7 A-C). In contrast, the Gsto1
-/-
 mice remained relatively 
unresponsive to LPS and produced significantly lower levels of all three cytokines 
measured in this study (Figure 7.7 A-C). The peak in serum cytokine levels in the 
wildtype mice was similar to the trend reported by published data [380, 381]. The data 
at each time point are based on three mice and duplicate measurements. Additional mice 
need to be added to this experiment when they become available to address the 
statistical errors. Since infiltrating macrophages were observed in wildtype mice treated 
with 50 mg/kg LPS within 6 hours, we determined the expression level of IL-1β in LPS 
treated liver samples. Increased IL-1β transcript levels were measured in wildtype mice 
treated with 50 mg/kg LPS for 12 hours (Figure 7.7D). In contrast, IL-1β transcript 
levels remained un-induced in the livers from Gsto1
-/-
 mice suggesting the absence of a 
pro-inflammatory response in the Gsto1
-/-
 mice. The increased survival reported in the 
Gsto1
-/-
 mice treated with LPS may be attributed to the lack of liver necrosis together 
with the failure to elicit cytokine expression in response to LPS.  
 
 
WT WT + 50 mg/kg LPS Gsto1-/- Gsto1-/- + 50 mg/kg LPS
WBCP (x10E03 cells/µl) 10.3 ± 1.06 3.4 ± 0.36 9.8 ± 0.44 4.7 ± 0.24
RBC (x10E06 cells/µl) 11.7 ± 0.57 11.6 ± 0.17 11.6 ± 0.31 12.3 ± 0.07
HGB (g/L) 209 ± 9.33 210 ± 2.58 209 ± 6.45 218 ± 2.94
HCT 0.5 ± 0.02 0.5 ± 0.01 0.5 ± 0.01 0.5 ± 0.01
MCV (fl) 45.9 ± 0.91 44.9 ± 0.57 45.9 ± 0.17 44.5 ± 0.43
PLT (x10E03 cells/µl) 934 ± 63.21 613.3 ± 87.69 1013.5 ± 33.97 706 ± 31.99
neutrophils (x10E03 cells/µl) 1.1 ± 0.19 2.4 ± 0.35 0.9 ± 0.05 2.8 ± 0.44
lymphocytes (x10E03 cells/µl) 8.3 ± 0.85 0.6 ± 0.02 8.1 ± 0.42 0.9 ± 0.16
monocytes (x10E03 cells/µl) 0.4 ± 0.05 0.1 ± 0.02 0.2 ± 0.04 0.2 ± 0.04
eosinophils (x10E03 cells/µl) 0.2 ± 0.04 0.1 ± 0.01 0.1 ± 0.01 0.1 ± 0.01
basophils (x10E03 cells/µl) 0.04 ± 0.02 0.005 ± 0.005 0.045 ± 0.03 0.02
Table 7.1: Haematology profile of Gsto1
-/-
 mice 
WBC: white blood cell count peroxidase method; RBC: red blood cell count; HGB: 
haemoglobin; HCT: haematocrit; MCV: mean corpuscular volume; PLT: platelet 
count. Data are presented as mean ±standard error of n=4.  
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Figure 7.7: Impaired response to LPS in Gsto1
-/-
 macrophages. 
Mice were injected with 50 mg/kg of E.coli O55:B5 LPS for indicated time 
periods. Concentrations of TNF-α (A), IL-6 (B) and IL-1β (C) in the serum 
were measured by ELISA. The serum cytokine levels were significantly lower 
in Gsto1
-/-
 mice suggesting hypo-responsiveness of the mice to LPS. (D) IL-1β 
transcript levels were significantly induced in response to LPS treatment in the 
liver of wildtype mice. The induction of IL-1β was absent in the Gsto1-/- mice. 
Data are presented as mean ±standard error of n=3. 
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7.3.7 LPS induced NADPH oxidase 1 transcript levels were attenuated in Gsto1
-/-
 mice 
The induction of NOX1 and the resulting increased ROS production in J774.1A 
macrophages was described in Chapter 5. The study further demonstrated the absence of 
NOX1 induction in GSTO1-1 deficient macrophages. In order to understand the LPS 
mediated changes in the liver of LPS injected mice, we determined whether hepatic 
NOX1 was induced in wildtype and Gsto1
-/-
 mice in response to LPS. As shown in 
Figure 7.8, NOX1 transcription was induced in the liver of wildtype mice injected with 
50 mg/kg LPS for 12 hours. However, the NOX1 transcript levels remained unchanged 
in LPS injected Gsto1
-/-
 mice. This result further confirmed the previously reported role 
of GSTO1-1 in LPS mediated ROS generation via induction of NOX1 (refer Chapter 5).  
 
 
7.3.8 Anti-oxidant enzyme profile of Gsto1
-/-
 mouse liver remains unaltered in response 
to LPS 
The expression of the rate-limiting enzyme in GSH synthesis, GCLc was previously 
shown to be inhibited by LPS in macrophages (Chapter 5). GSTO1-1 deficient 
macrophages were found to be unresponsive to LPS and maintained unchanged levels 
of antioxidants including GCLc, NQO1 and HO-1 in the presence of LPS. The 
antioxidant response in Gsto1
-/-
 mice post LPS was characterized to determine whether 
the LPS mediated suppression of Nrf2 driven genes was attenuated in Gsto1
-/-
 mice (as 
observed in GSTO1-1 deficient macrophages). 
The transcript levels of all the antioxidant enzymes measured, GCLc, NQO1 and HO-1 
were significantly suppressed by LPS (50 mg/kg LPS) in wildtype mouse livers (Figure 
Figure 7.8: Induction of hepatic NADPH oxidase 1 in the liver by LPS is 
dependent on GSTO1-1. Data are presented as mean ±standard error of n=3. 
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7.9A-C). However, the suppression of the transcription of all three Nrf2 driven genes 
was abolished in the LPS treated Gsto1
-/-
 mouse liver which is similar to the trend 
demonstrated in GSTO1-1 deficient J774.1A macrophages. Interestingly, the transcript 
levels of GCLc and NQO1 were notably lower in untreated Gsto1
-/-
 mouse livers 
(Figure 7.9A-C). This was not unexpected given the previous finding that the protein 
expression of most Nrf2 driven GSTs such as GSTA1/2, GSTT1, GSTT2, and GSTA3 
were markedly decreased in Gsto1
-/-
 mouse livers (Figure 7.3). The data taken together 
suggest the regulation of Nrf2 induced antioxidant enzymes may be dependent on the 
expression of GSTO1-1. 
 
7.3.9 ML175 inhibits TLR4 mediated cytokine expression in bone marrow derived 
macrophages (BMDMs) 
Since Gsto1
-/-
 mice did not suffer from LPS induced endotoxic shock and even the 
heterozygote Gsto1
+/-
 mice were partially protected, we investigated the possibility that 
the GSTO1-1 inhibitor ML175 would suppress the production of pro-inflammatory 
cytokines in primary wildtype BMDMs. 
Media concentrations of inflammatory cytokines including IL-6 and pro-IL-1β were 
measured after LPS challenge in BMDMs derived from wildtype mice. The cells were 
treated with ML175 as described in Chapter 5 followed by LPS stimulation. As shown 
in Figure 7.10A, ML175 inhibited IL-6 secretion in wildtype primary BMDMs in a dose 
dependent manner. Since the effect of ML175 on primary BMDMs is similar to that 
Figure 7.9: Suppression of LPS mediated hepatic antioxidants is abolished in Gsto1
-/-
 
mice 
Transcription of hepatic GCLc (A), NQO1 (B) and HO-1 (C) were significantly 
suppressed in wildtype mice. The transcript levels of the antioxidants were 
consistently lower in Gsto1
-/-
 mouse liver and remained unaltered post LPS treatment. 
Data are presented as mean ± standard error of n=3. 
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measured previously in ML175 treated J774.1A macrophages (Chapter 5 Figure 5.4), it 
is reasonable to conclude that the J774.1A GSTO1 knockdown cell line is a suitable 
model to study the mechanism of action of GSTO1-1. The specificity of ML175 for 
TLR4 inhibition was further investigated by measuring cytokine secretion on activation 
of TLR1/2, TLR7 and TLR9 in primary BMDMs. IL-6 expression determined by 
ELISA showed no difference in the levels of IL-6 in ML175 treated BMDMs when 
stimulated with PAM3CSK4 (TLR1/2), R848 (TLR7) or CpG (TLR9). However a 
moderate decrease in IL-6 expression was observed in TLR7 activated macrophages at 
higher doses of ML175 (Figure 7.10B-D). Furthermore, the expression of parental pro-
IL-1β was determined in ML175 treated BMDMs as well. The expression of pro-IL-1β 
was significantly inhibited in ML175 treated BMDMs, confirming that TLR4 signalling 
are targeted by ML175 (Figure 7.10E). Signalling downstream of NF-κB resulting in 
the activation of MAPKK and MAPK eventually leading to the phosphorylation of p38 
was also blocked in ML175 treated macrophages (Figure 7.10F).  
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Figure 7.10: ML175 inhibits TLR4 activation in primary bone marrow derived 
macrophages 
(A) LPS induces the expression of IL-6 via TLR4. TLR1/2 (B), TLR7 (C) and TLR9 
(D) dependent IL-6 expression remained unchanged when the BMDMs were 
stimulated with their respective ligands. (E) Activation of pro-IL-1β by LPS is 
significantly attenuated in ML175 treated BMDMs. (F) Activation/phosphorylation of 
p38 by MAPK was blocked in ML175 treated macrophages. Data are presented as 
mean ±standard error of n=3. Immunoblots are representative of three replicates. 
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7.3.10 GSTO1-1 deficiency suppresses Nrf2 driven antioxidant enzyme expression in the 
liver under normal physiological conditions 
The relatively lower constitutive expression of antioxidant enzymes including 
GSTA1/2, GSTT1 and GSTT2 in Gsto1
-/-
 mice was an unexpected finding. Since the 
constitutive and butylated hydroxyanisole (BHA) inducible expression of these 
antioxidants is known to be dependent on transcriptional activation by Nrf2 [388, 389], 
the responsiveness of Gsto1
-/-
 mice to Nrf2 inducer BHA was determined. Mice were 
fed BHA supplemented chow for 14 consecutive days and the food intake was 
monitored daily. Though a previous report suggested inconsistency in food consumption 
in BHA treatment groups due to the taste of dietary BHA [390], this study recorded 
comparable consumption rates of BHA supplemented chow by wildtype and Gsto1
-/-
 
mice (Figure 7.11A).  Female mice were used in this experiment based on previous 
studies on the differential regulation of Nrf2 between sexes [388, 389]. Expression of 
Nrf2 driven GSTs including GSTA1/2, GSTA4, GSTT1, and GSTT2 in the livers of 
female wildtype and Gsto1
-/-
 mice showed significant induction with BHA (Figure 
7.11B-C). Additionally, the expression of other Nrf2 dependent genes such as NQO1 
and glutathione synthesis protein GCLm also showed considerable induction with BHA 
suggesting that the inducible expression of Nrf2 driven antioxidants by dietary BHA in 
the liver is not dependent on the expression of GSTO1-1 (Figure 7.11B). Due to 
unexpected difficulties in breeding of the Gsto1
-/-
 mice, the availability of mice was 
restricted and hence the number of mice used in this experiment was limited to 2/group.  
 7.4 Discussion 
The role of GSTO1-1 in inflammatory signalling activated via TLR4 in J774.1A 
macrophages was extensively described in the previous chapters. We generated Gsto1
-/-
 
mice in order to further investigate the physiological relevance of the downstream 
effects of GSTO1-1 deficiency in vivo. The phenotype of Gsto1
-/-
 mice including body 
weight and organ weight were found to be comparable to the wildtype mice. The 
expression of other GSTs in the Gsto1
-/-
 mice was also evaluated to confirm the 
specificity of the targeted knockout approach employed to generate the Gsto1
-/-
 mice 
and to determine whether the knockout of Gsto1 resulted in the induction of other 
GSTs, a trend observed previously in Gstz1
-/-
 mice [386]. 
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Figure 7.11: Induction of Nrf2 driven genes by butylated hydroxyanisole (BHA) (n=2) 
(A) Consumption of BHA supplemented chow was comparable between the wildtype and Gsto1
-/-
 mice. (B) Wildtype and Gsto1
-
/-
 mice fed on a BHA supplemented diet for two weeks showed remarkable induction of Nrf2 driven antioxidants including 
GSTA1/2, GSTT1, GCLm and GSTM2 in the liver. (C) Nrf2 dependent expression of GSTA4 and NQO1 were also induced in 
the liver lysates from wildtype and Gsto1
-/-
 mice to a similar extent. 
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Unlike the Gstz1
-/-
 mice, the Gsto1
-/-
 mice were found to express a few GSTs, namely 
GSTA1/2, GSTT1 and GSTT2 in lower abundance in the liver lysates compared to their 
wildtype counterparts. A previous study by Hayes et al. reported a similar trend in GST 
expression in Nrf2
-/-
 mice, which was more pronounced in females than in the males 
[388]. Here, we show a similar gender-based difference in the expression of GSTA1/2, 
GSTT1 and GSTT2. Since Nrf2 has been shown to be regulated by the glutathionylation 
of its interacting protein Keap-1 [391], it is speculated that the redox state of Keap-1 
may be modulated by GSTO1-1 which in turn resulted in the differential expression of 
GSTs in the Gsto1
-/-
 mouse livers. This was further supported by the finding that a non-
GST Nrf2 driven gene, NQO1 also showed lower expression levels in Gsto1
-/-
 mice.  To 
further investigate this theory, Gsto1
-/-
 mice and their wildtype littermates were placed 
on a BHA supplemented diet for 2 weeks. Since BHA is a potent inducer of Nrf2 
signalling, it was hypothesized that while the GST profile would be induced in the 
wildtype mice, the expression levels would remain unaltered in the Gsto1
-/-
 mice as seen 
in the Nrf2
-/-
 mice [388, 389].  Though the lower expression levels of GSTs and NQO1 
remained consistent across Gsto1
-/-
 mice, the BHA fed mice showed comparable 
induction of the tested Nrf2 driven enzymes proving the hypothesis false. However, due 
to restricted animal numbers used in this study and the lack of analysis of the Keap-
1/Nrf2 association and subsequent Nrf2 nuclear localization, this study remains 
inconclusive and warrants further investigation. 
Since GSTO1-1 deficient macrophages were unresponsive to TLR4 activation by LPS, 
the susceptibility of Gsto1
-/-
 mice to LPS induced systemic inflammation was evaluated. 
This study was divided into two independent parts:  
 Survival rate of Gsto1-/- mice injected with a sub-lethal doses of LPS (5 mg/kg 
and 10 mg/kg) was compared to their wildtype counterparts 
 A time line was constructed to examine LPS induced tissue damage and the 
extent of inflammation in mice treated with a lethal dose of 50 mg/kg LPS for 
up to 12 hours.  
 Comparison of the survival rates of Gsto1
-/-
 mice versus Gsto1
+/+
: 
In the 5 mg/kg LPS treatment group, the wildtype mice showed a higher lethality rate 
with all the mice being euthanized in 24-96 hours while mice from Gsto1
+/-
 and Gsto1
-/-
 
treated groups survived the sub-lethal dose of LPS. In the 10 mg/kg LPS treatment 
group, the wildtype and Gsto1
+/-
 mice showed similar survival rates but the Gsto1
-/-
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homozygotes tolerated the higher dose as well. The survival rate and body temperature 
curve of the heterozygotes was found to lie in between those of the wildtype and the 
Gsto1
-/-
 mice. The observation that heterozygotes showed partial protection from LPS 
mediated inflammation strongly suggests that the inhibition of GSTO1-1 by synthetic 
compounds could provide a novel avenue for drug development targeting TLR4 
associated inflammatory disorders such as rheumatoid arthritis.    
Time course of LPS treatment: 
To further understand the progression of TLR4 mediated inflammation in Gsto1
+/+
 and 
Gsto1
-/-
 mice, mice were injected with 50/kg LPS and euthanized at different time 
points ranging from 0.5 hours-12 hours. Since cytokine expression and ROS production 
peak immediately after exposure to LPS [380, 381], it was necessary to accommodate 
shorter time points in the study. The parameters analysed over 12 hours included: 
a. Histological changes in affected tissues such as liver and spleen: 
Liver and spleen were the primary tissues that showed signs of LPS induced 
damage. Analysis of tissue sections revealed significant necrosis and 
inflammation in the liver of wildtype mice. The extent of damage in the 
heterozygote mice varied from minimal to none.  The Gsto1
-/-
 mice showed no 
necrosis or inflammation suggesting that they were tolerant to LPS induced 
sepsis. The spleen in wildtype mice showed pockets of inflammation and the 
occurrence of ‘Tingable macrophages’ was prominent (a sign of acute 
inflammation). The Gsto1
-/-
 mice showed no significant changes in the spleen 
morphology supporting the results obtained from the survival rate experiments 
and confirming that GSTO1-1 is required for TLR4 a mediated inflammatory 
response 
b. Serum cytokines induced in response to LPS: 
The serum TNF-α, IL-6 and IL-1β levels were significantly induced in the 
wildtype mice within 30-60 minutes. The immediate peak in TNF-α and IL-6 
levels in response to LPS was largely absent in the Gsto1
-/-
 mice. The serum 
cytokine levels observed in Gsto1
-/-
 mice confirmed the results obtained from 
the GSTO1-1 deficient J774.1A cells and provides conclusive data that GSTO1-
1 deficiency impairs TLR4 mediated cytokine signalling in vivo. 
c. Alterations in the haematology indices: 
The haematology profile of the Gsto1
-/-
 mice was similar to the wildtype mice 
with no notable difference in the individual blood counts except for the 
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monocyte counts which were markedly depleted in normal Gsto1
-/-
 mice. It is 
interesting to note that while the wildtype and Gsto1
-/-
 mice showed comparable 
decrease in the differential cell counts of leucocytes in response to LPS (12 
hours 50 mg/kg), the monocyte counts remained unaffected in LPS treated 
Gsto1
-/-
 mice for reasons not fully understood.  It is important to note that 
monocytes differentiate into resident macrophages found in the different tissues 
and thus the difference in the precursor cell count may contribute to the unique 
inflammatory profile observed in the Gsto1
-/-
 mice. 
d. Modulation of the oxidant/antioxidant axis due to LPS induced ROS generation: 
ROS production in response to LPS is an immediate event triggered via the 
induction of NOX1 (cytosolic source) and from the mitochondria as previously 
described in Chapter 5-6. Excessive ROS generation in response to 
inflammatory stimuli such as LPS acts not only as an anti-bacterial response but 
has also been shown to exacerbate inflammation associated tissue damage [8, 
147, 148, 341, 344, 376]. Since the oxidant/antioxidant axis is tightly regulated 
to enhance ROS production via the suppression of antioxidants and the 
deficiency of GSTO1-1 abolished this response in LPS treated macrophages, 
the oxidant and antioxidant levels were determined in the liver tissue of Gsto1
-/-
 
mice.  NOX1 transcription was induced over 100-fold in the liver of wildtype 
mice while the induction was significantly blocked in the Gsto1
-/-
 mouse livers. 
Complementing the increased oxidant levels, the transcript levels of GCLc, 
NQO1 and HO-1 were suppressed in the liver of wildtype mice (to enhance 
ROS production) while the Gsto1
-/-
 mice showed no change in the antioxidant 
levels suggesting the absence of ROS in the liver. The increased NOX1 levels 
and consequently ROS generation may be a major contributor to the severe 
necrosis observed in the liver sections obtained from the LPS treated wildtype 
mice. Due to technical difficulties associated with the detection of ROS (both 
cytosolic and mitochondrial) in tissues, the total ROS produced in the liver 
samples was not quantified.  
It is interesting to note that though Srx and GSTO1-1 are efficient deglutathionylating 
enzymes, the deficiency of the two proteins appears to have opposite downstream 
consequences in vivo. Planson et al. (2011) have reported that though Srx
-/-
 mice have 
no phenotypical abnormalities under normal physiological conditions, the mice are 
hyper-responsive to LPS [392]. The pro-inflammatory responses in Srx
-/-
 mice were 
delayed by several hours (20 hours) but remained intense even after the inflammatory 
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responses subsided in the wildtype mice. However, further investigations revealed that 
the deficiency of Srx in mice resulted in the constitutive inhibition of the anti-oxidant 
activity of Prx2. As described in sections 1.3.2(a) and 1.4.5, the sulfinylated form of 
Prdx2 is functionally inactive and is reduced to the active form specifically by Srx. The 
absence of Srx in the mice resulted in the inactivation of Prdx2 and subsequently led to 
the exacerbation of LPS mediated ROS accummulation over a period of time causing 
the reported delay in inflammatory responses and lower survival rates in the Srx
-/-
 mice. 
Additional experiments identified gene expression changes occurring in the Srx
-/-
 mice 
that were typical of the wildtype mice except that the changes were also induced in the 
late stages rather than in the early phase of the pro-inflammatory responses. In contrast, 
Gsto1
-/-
 are unresponsive to LPS indicating the absence of an early/immediate response 
to the presence of LPS. Since our in vitro data on macrophages revealed a significant 
attenuation in ROS generation in GSTO1-1 deficient macrophages, it is not 
unreasonable to speculate that the in vivo oxidant/anti-oxidant status of Gsto1
-/-
 mice 
will be similar to the Srx
-/-
 mice. However, the mechanism and pathway targeted by the 
absence of Srx is most likely unrelated to the mechanism(s) modulated by GSTO1-1. 
Our findings strongly support the hypothesis that GSTO1-1 is required upstream of the 
TLR4 pathway, possibly at or immediately downstream of TLR4.  
Due to unavoidable delays in the generation and breeding of the Gsto1
-/-
 mice, the 
tolerance of Gsto1
-/-
 mice to LPS was not fully characterized and work is currently in 
progress to investigate the mechanism by which Gsto1
-/-
 mice remain unresponsive to 
LPS. The inflammatory profile of Gsto1
-/-
 mice is yet to be fully understood and the 
specificity of GSTO1-1 to TLR4 in vivo needs to be demonstrated. In parallel, the 
specificity of GSTO1-1 to TLR4 in vivo will be studied by administering the small 
molecule inhibitor of GSTO1-1, ML175, in vivo. The data gathered in this study 
demonstrated that ML175 is a potent inhibitor of TLR4 signalling in wildtype bone 
marrow derived macrophages. However, higher doses of ML175 were found to inhibit 
TLR9 and TLR7 although to a lesser extent. Thus this study recognizes the need for the 
development of more specific and potent inhibitors of GSTO1-1 for in vivo applications. 
The observation that the response of Gsto1
+/-
 heterozygote mice to LPS was in between 
the wildtype and Gsto1
-/-
 mice and the finding that ML175 can inhibit the expression of 
pro-IL-1β in a dose dependent manner, strongly suggests the potential for a novel 
avenue for the therapeutic applications for GSTO1-1 inhibitors.  
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CHAPTER 8 
Redox modulation of TLR4 signalling: Cysteines 
in MAL are critical for TLR4 activation by LPS 
8.1 Introduction 
Recent studies have shown that GSTO1-1 catalyses the glutathionylation cycle. Our 
current results show that GSTO1-1deficiency increases the overall level of protein 
glutathionylation (Chapter 4). The data in Chapter 4 also indicate that there may be 
some specificity in the proteins that are deglutathionylation substrates for GSTO1-1.  A 
number of studies have suggested that protein glutathionylation can provide a reversible 
switch that can regulate protein function and potentially regulate pathways in a manor 
analogous to protein phosphorylation [67, 69, 75, 129, 305]. Since the GSTO1-1 
inhibitor ML175 has recapitulated all the effects of Gsto1 knockdown in Chapters 5 and 
6 it was reasonable to speculate that GSTO1-1 may regulate the TLR4 pathway by the 
reversible glutathionylation of key protein(s).  Previous studies have shown that 
TRAF6, Iκκβ, NF-κβ and Caspase 1 within the TLR4 signalling and IL-1β release 
pathways can be glutathionylated and therefore may be targets for GSTO1-1 mediated 
regulation [61, 64, 118, 160]. However, the results in chapters 5 and 6 indicate that the 
regulation of TLR4 signalling by GSTO1-1 appears to occur upstream of these proteins. 
TLR4 activation by LPS requires the recruitment of adaptor proteins (Figure 1.9) called 
MyD88 and MyD88 adaptor like protein (MAL), collectively called the Myddosome 
complex [361, 393]. The inhibition of IRAK4 phosphorylation in GSTO1-1 deficient 
cells (Chapter 5) and the common effect of GSTO1-1 deficiency on parallel activation 
pathways strongly suggest that the target or site of action of GSTO1-1 is a component 
of the Myddosome complex. 
Since MyD88 is shared among all TLRs it seems unlikely that it is the target of GSTO1-
1 as signalling via most TLRs is not dependent on GSTO1-1 (Chapter 4). Since MAL is 
specific to TLR4 and TLR1/2, the glutathionylation of MAL was evaluated to determine 
if LPS altered the glutathionylation of MAL and if GSTO1-1 was required to catalyse 
the reaction.  
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Based on the previously published crystal structure of MAL, there are eight cysteine 
residues of which two pairs have been predicted to be engaged in disulphide bonds with 
one another and of the remaining four, two residues are exposed on the protein surface 
and hence may be susceptible to oxidative stress induced modifications [282]. The two 
exposed cysteine residues C91 and C157 are more than 5Å apart and hence are unlikely 
to interact with one another via a disulphide bond unless there are conformational 
changes in solution that are not evident in the crystal structure. Thus, it is possible that 
GSTO1-1 may modulate the glutathionylation state of cysteines C91 and C157 and 
disrupt the recruitment and interaction of MAL with TLR4 or MyD88. The inability of 
MAL to form the Myddosome complex could contribute to all aspects of the GSTO1-1 
dependent TLR4 signalling phenotype observed in macrophages and Gsto1 knockout 
mice in Chapters 4, 5 and 6. In this Chapter the role of cysteines C91 and C157 in MAL 
function and their susceptibility to glutathionylation or deglutathionylation by GSTO1-1 
has been investigated.  
 
8.2 Materials and methods 
8.2.1 Materials 
Purified proteins MAL, C157A MAL and C91A MAL were kind gifts from Prof. 
Bostjan Kobe, University of Queensland, Australia. plasmids pMAL, pC157A MAL, 
pEV, pC91A, pC91A/C157A were provided by Prof. Luke O’Neill, Trinity College, 
Dublin. GSTO1-1 and its allelic variants were expressed and purified as described in 
Chapter 2.  
 
8.2.2 Cell culture 
HEK293/TLR4/MD2 cells were maintained in DMEM media with 10% FBS, 2 mM 
glutamine and a cocktail of antibiotics (HG Gold/Blasticidin/Normomycin). J774.1A 
cells were maintained as described previously. HEK293T cells were grown in DMEM 
media with 10% FBS and 2 mM glutamine. 
 
8.2.3 Peptide synthesis 
The peptide sequence ‘QDPWCKYQ‘ was synthesized by ChinaPeptides Co. Ltd. 
(Shanghai, China). The peptide was glutathionylated and purified by HPLC at the BRF, 
JCSMR,ANU. 
 
8.2.4 In vitro deglutathionylation assay 
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10 μg of purified wildtype MAL (WT MAL), C157A MAL and C91A MAL were 
precipitated in ice cold acetone at -20°C overnight to remove DTT in the protein buffer. 
The proteins were resuspended in 20 mM tris pH 8.0 and glutathionylated with 10 mM 
GSSG for 1 hour at 37°C. The excess GSSG was removed by repeating the precipitation 
step.  The proteins were resuspended in 20 mM tris pH 8.0 and incubated with 1μg of 
GSTO1-1 for indicated time points at 37°C. The reaction was stopped by adding 4X 
Laemmli sample loading buffer and the two proteins were separated on a 4-12% 
gradient gel (Biorad) using the Biorad iBolt system due to the similar  molecular 
weights of MAL and GSTO1-1. The proteins were transferred onto a nitrocellulose 
membrane and probed for glutathionylation using anti-glutathione and GSTO1-1 using 
our in-house rabbit anti-GSTO1-1 serum. The membranes were developed as previously 
described in Chapter 2.  
8.2.5 Transfections 
HEK293/TLR4/MD2 cells were transfected using Genejuice (Millipore). Cells were 
seeded at a density of 3X10
5
 cells/well in 6-well dishes and incubated overnight in 
supplemented DMEM media. On the day of transfection, indicated plasmids and 
transfection reagent were added in a 3:1 ratio in serum free media and incubated for 15 
minutes at room temperature. The transfection mix was added to each well drop-wise 
and the cells were incubated for 24-48 hours. LPS was added to cells 24 hours post 
transfection and incubated further for 24 hours (wherever indicated).  
 
8.2.6 NF-κB luciferase assay 
HEK 293T cells were transfected with 60ng of plasmid encoding NF-κB luciferase and 
20ng of plasmid encoding Thymidine kinase (TK) promoter driven renilla luciferase 
control reporter gene as described above using Genejuice in 96-well flat bottom plates. 
Plasmids encoding wildtype MAL, C157A MAL, C91A MAL and empty vector (pEV) 
were co-transfected with the NF-κB/renilla plasmids in triplicates in concentrations 
ranging from 0 - 80ng.  24 hours post transfection, the media was removed from each 
well and cells were lysed in 1X Passive lysis buffer and luminescence was measured as 
per manufacturer’s instructions (Promega Glomax Dual reporter luciferase assay kit). 
All luciferase readings were normalized to their respective TK renilla luciferase 
readings.  
 
8.2.7 Cysteine oxidation detection assay 
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The sulfenic acid form of cysteines was detected using a biotin conjugated DCP probe 
(Millipore). HEK 293/TLR4/MD2 cells were seeded in 10 cm culture dishes overnight 
and treated with LPS for 24 hours. Cells were washed with PBS and lysed in 1 mM 
DCP-Bio1. The lysates were centrifuged at 16000 x g for 10 minutes to remove cell 
debris and incubated on ice for 2 hours. Unreacted DCP-Bio1 was removed by 
precipitating the proteins in ice cold acetone at -20°c overnight. Proteins were 
resuspended in 1% SDS lysis buffer. DCP-Bio1 bound proteins were pulled down using 
streptavidin beads and immunoblotted as before. Over expressed MAL proteins were 
probed with a rabbit anti-HA antibody (Sigma).   
 
8.3 Results 
8.3.1 In vitro deglutathionylation of MAL by GSTO1-1 
The Myddsosome complex is comprised of TLR4, adaptor proteins MyD88 and MyD88 
adaptor like protein (MAL). Since MyD88 is common to most TLRs and MAL is 
specific to TLR4 and TLR1/2, we decided to investigate the ‘active’ state of MAL in 
LPS stimulated Gsto1 knockdown cells. Since LPS induces oxidative stress in 
macrophages as an anti-microbial response, it is not unreasonable to hypothesize that 
the ROS generated may modulate the redox state of proteins in the TLR4 pathway. To 
determine if GSTO1-1 can catalyse the deglutathionylation of MAL, a synthetic peptide 
representative of the flanking sequence surrounding cysteine 157 (C157) of MAL 
‘QDPWCKYQ‘ was synthesized. The peptide was artificially glutathionylated as 
described previously and the ability of GSTO1-1 to deglutathionylate the peptide was 
determined by measuring the fluorescence emitted by the adjacent tryptophan as 
glutathione was removed from the cysteine residue. Wildtype GSTO1-1 (A140) 
deglutathionylated the modified cysteine residue in MAL more efficiently than the 
D140 GSTO1-1 polymorphic variant (Figure 8.1A).  A similar study of Cys 91 was not 
undertaken because a suitable reporter tryptophan residue was not present in the natural 
sequence. In additional studies, we tested the ability of GSTO1-1 to deglutathionylate 
artificially glutathionylated MAL (whole protein) by incubating the two proteins 
together for increasing time periods. The deglutathionylation of cysteines in MAL was 
studied with whole purified wildtype MAL and two cysteine mutants C157A and C91A. 
All three proteins were glutathionylated to a similar extent by incubation with GSSG 
(Figure 8.1B Time 0). As shown in Figure 8.1B, GSTO1-1 deglutathionylated wildtype 
MAL within 60 minutes (Figure 8.1B middle panel). MAL mutants bearing single 
mutations of the two cysteine residues C91 and C157 were found to be highly unstable 
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in solution and degraded over time at 37°C (Figure 8.1B lower panels).  Consequently it 
was not possible to determine if there were differences in the rate of deglutathionylation 
of these specific residues.   
Figure 8.1: In vitro deglutathionylation of MAL by GSTO1-1 
(A) A peptide sequence spanning MAL residues ‘QDPWCKYQ’ (153-160) was 
synthesized and glutathionylated at Cys 157 artificially. The intrinsic fluorescence 
of the Trp residue adjacent to C157 increased significantly in the presence of 
wildtype GSTO1-1 and to a lesser extent with the D140 allelic variant of GSTO1-1, 
as a result of the deglutathionylation of C157. (B)  Purified MAL, C91A MAL and 
C157A MAL were glutathionylated and incubated with GSTO1-1 for indicated time 
periods. The glutathionylation levels of the blotted MAL proteins were detected 
with an anti-glutathione antibody. Wildtype MAL was enzymatically 
deglutathionylated by GSTO1-1 in 60 minutes.  
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8.3.2 Cysteines are critical for MAL to function as an adaptor for TLR4 activation 
MAL function was quantitatively assessed by its ability to drive the expression of 
luciferase from a NF-κB reporter construct. HEK293T cells were co-transfected with 
NF-κB driven luciferase reporter construct, a TK renilla luciferase coding construct 
(internal control) and with increasing concentrations of pMAL or MAL cysteine 
mutants C91A, C157A and a C91A/C157A double mutant in order to determine if 
mutations in the cysteine residues affect MAL function. The stable expression of 
wildtype MAL and the cysteine mutants was confirmed by immunoblotting for the HA-
tagged protein in whole cell lysates extracted from transfected HEK293T cells (Figure 
8.2A). As shown in Figure 8.2B, wild type MAL was sufficient to activate NF-κB 
transcription indicated by the expression of luciferase. The C91A mutant failed to elicit 
a similar response suggesting that C91 is critical for the activity of MAL while the 
C157A mutant was able to drive NF-κB expression to a small extent that was 
significantly lower than wildtype MAL. As expected, expression of the double mutant 
also failed to activate NF-κB expression.  
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Figure 8.2: Functional relevance of cysteine modifications in MAL 
(A) Over expression of MAL and the cysteine mutant encoding plasmids in HEK 
293T cells. (B) Expression of wildtype MAL was sufficient to switch on the 
expression of NF-κB promoter-driven luciferase reporter gene but the single 
mutant C91A, failed to activate the reporter gene transcription in HEK293T cells 
while the C157A mutant had a significantly lower activity at higher DNA 
concentrations. Mutating both cysteine residues abolished the activity of MAL 
completely.  
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8.3.3 LPS induced glutathionylation of MAL is dependent on GSTO1-1 
Recent structural analysis of the Toll/interleukin-1 receptor homology domain (TIR) of 
MAL has revealed several cysteines that are likely to be susceptible to oxidation and/or 
post translational modifications [282] . In this study MAL and its mutants C91A, 
C157A and C91A/C157A were tagged with HA and expressed in HEK 293/TLR4/MD2 
and immunoprecipitated under non-reducing conditions to determine the 
glutathionylation state of MAL cysteines. Wildtype MAL was heavily glutathionylated 
in the cells irrespective of TLR4 activation with LPS while the individual cysteine 
mutants and the double mutant C91A/C157A were glutathionylated to a lesser extent 
(Figure 8.3A).  
Glutathionylation of endogenous MAL was detected in J774.1A non-silencing control 
cells after LPS stimulation (Figure 8.3B-C). In contrast MAL was only weakly 
glutathionylated in GSTO1-1 deficient cells after LPS stimulation suggesting that 
GSTO1-1 is required for the glutathionylation of MAL.     
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Figure 8.3: Redox state of MAL in cell models 
(A) HEK293/TLR4/MD2 cells were transfected with HA tagged MAL and cysteine mutants C91A, C157A and C91A/C157A   . 
Glutathionylation of MAL was detected in HA-MAL expressing cells in both untreated and LPS treated conditions. The glutathionylation of 
transfected MAL was considerably lower in the cells transfected with the three mutants suggesting that C91 and C157 are glutathionylated in 
this cell model. (B) Endogenous MAL was immunoprecipitated and probed for glutathionylation with an anti-glutathione antibody in 
J774.1A cells 
+/-
 GSTO1-1. MAL was glutathionylated in response to LPS in the non silencing control cells but not in the Gsto1 knockdown 
cells. The membrane was probed with anti-MAL to confirm equal pull down of MAL in both cell types. (C) Glutathionylated proteins were 
isolated using an anti-glutathione antibody from J774.1A cells 
+/-
 GSTO1-1 and probed for MAL. Glutathionylated MAL was detected in 
LPS stimulated non silencing control cells but not in Gsto1 knockdown cells, confirming that MAL is glutathionylated in response to LPS in 
macrophages.   
A B C 
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8.3.4 Cysteines in MAL are susceptible to oxidation on LPS stimulation 
The redox balance between oxidation and glutathionylation was further investigated by 
evaluating the oxidative state of cysteines in MAL over expressed in 
HEK293/TLR4/MD2 cells (stable transfectants expressing TLR4 and MD2) post LPS. 
Proteins oxidized on LPS treatment were detected using a biotin tagged- 3-(2,4-
dioxocyclohexyl)propyl 5-((3aR,6S,6aS)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-6-
yl)pentanoate (DCP-Bio-1) probe that has high affinity for the sulfenic acid form (-
SOH) of cysteine residues [394]. DCP bound proteins were isolated using streptavidin 
beads. A detailed outline of the assay is described in Figure 8.4A.  The sulfenic acid 
oxidized state (oxidation state +1) was detected in the single mutants C91A and C157A 
and the double mutant C91A/C157A (Figure 8.4B). Interestingly, oxidation of wildtype 
MAL cysteines was not detected in this cell model. The absence of significant oxidation 
of the double mutant suggests that other cysteines in MAL may not be oxidized. In the 
C157A mutant expressing cells, MAL is significantly oxidized and since C91 is the 
only cysteine available on the surface of the mutated protein, this suggests that C91 is 
functionally critical for TLR4 signalling. These findings complement results obtained 
on the glutathionylation state of MAL described in Figure 8.3. The oxidation of 
cysteines in the mutants may also explain the inability of the mutant MAL proteins to 
drive NF-κB dependent transcription of the luciferase reporter gene described in Section 
8.3. This study demonstrates that the cysteines in wildtype MAL are glutathionylated in 
the different cell models in order to protect them from oxidation from ROS generated 
on LPS stimulation and consequently protein degradation.   
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A 
B 
Figure 8.4: Cysteines in MAL are susceptible to LPS induced oxidation 
(A) Detection of sulfenic acid form of cysteine residues in cells using a biotin tagged- 3-(2,4-dioxocyclohexyl)propyl 5-((3aR,6S,6aS)-
hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-6-yl)pentanoate (DCP-Bio-1) probe. (B) HA-tagged wildtype MAL did not undergo oxidation in 
response to LPS in HEK293/TLR4/MD2 cells. The C157A was considerably oxidized to the sulfenic acid form on LPS treatment.  
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8.3.5 Cysteines are critical for the interaction between MAL and MyD88 
The recruitment and interaction of MAL and MyD88 with TLR4 are essential for the 
activation of the downstream signalling molecules (Figure 1.9). HA tagged MAL and its 
cysteine mutants were co-expressed in HEK293 cells with Myc tagged MyD88 to 
determine whether C91 and C157 play a role in the physical interaction between the two 
proteins. It is important to note that the cell model used (HEK293) was not ideal as 
these cells do not express TLR4 and hence do not respond well to LPS. In spite of 
technical issues, HA-tagged MAL was found to interact with Myc-tagged MyD88 
consistently across 3 biological replicates (Figure 8.5). However, there was a marked 
decrease in the association of MyD88 with the mutant MAL proteins suggesting that the 
cysteines may be required for the formation of the Myddosome complex by partaking in 
the association of MAL with MyD88.  
 
Figure 8.5: Cysteines are critical for the interaction between MAL and MyD88 
HA-MAL and its cysteine mutants were co-transfected into HEK293 cells with 
Myc-MyD88. MAL was immunoprecipitated using an anti-HA antibody and 
immunoprecipitated proteins were probed with anti-Myc.  The interaction of MyD88 
with wildtype MAL was detected in cells transfected with wildtype MAL but the 
interaction was less obvious in the cysteine mutant transfected cells.  The blot is 
representative of three independent experiments. 
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8.4 Discussion 
The catalytic role of GSTO1-1 in the glutathionylation and deglutathionylation of 
proteins has been investigated in Chapter 4. It is interesting to note that the 
deglutathionylation activity of GSTO1-1 was detected in vitro and was also clearly 
evident in cells, Furthermore, a  peak in glutathionylation levels was measured in T47-D 
cells over expressing GSTO1-1 under oxidative stress conditions indicates that GSTO1-
1 may also catalyse the forward glutathionylation reaction under suitable redox 
conditions (refer Figure 4.9A). In order to understand the implications of this novel 
function of GSTO1-1, it is interesting to consider the diseases and physiological 
conditions in which GSTO1-1 has been implicated in prior studies. In the last decade, a 
series of studies strongly suggested that GSTO1-1 plays a previously uncharacterized 
role influencing a range of unrelated diseases whose progress and severity is modified 
by inflammation. Thus, one of the aims of this project was to understand the 
mechanism(s) by which GSTO1-1 modulates inflammatory responses.  
In previous chapters, the downstream effects of GSTO1-1 deficiency were extensively 
characterized in macrophages and it was revealed that GSTO1-1 is essential for the 
activation of TLR4 and switching on the downstream pro-inflammatory responses 
against infection.  Hence, it was hypothesized that GSTO1-1 may be modulating 
inflammatory responses via TLR4 by catalysing the 
glutathionylation/deglutathionylation of proteins partaking in the TLR4 signalling 
cascade after LPS stimulation. Since LPS induces ROS generation in macrophages and 
we have shown that this increase in both cytosolic and mitochondrial ROS is mediated 
by GSTO1-1, it is possible that GSTO1-1 may glutathionylate proteins under the ROS 
induced oxidative stress in the cell. Taken together, all the results presented in the 
previous chapters support the theory that GSTO1-1 modulates the TLR4 pathway 
upstream of IRAK4 and NF-κB, potentially placing it in the Myddosome complex. As 
described earlier, the Myddosome complex is formed by the recruitment of MyD88, and 
MAL to TLR4.  
Since the effect of GSTO1-1 is specific to TLR4 (refer Figure 5.3), MyD88 seemed to 
be an unlikely target as it is shared among multiple TLRs. On the other hand, MAL is 
known to be specific to TLR4 and the heterodimer TLR1/2. Though TLR1/2 signalling 
was not affected by GSTO1-1 deficiency (see Figure 5.3), MAL was still considered as 
a prime target of GSTO1-1 for the purpose of this study as it is possible to have 
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differences in signalling and interactions between the proteins downstream of the two 
TLRs.  TLR4 was also considered as a potential target of GSTO1-1 as it has been 
shown that a synthetic compound TAK-242 (Resatorvid) can inhibit TLR4 signalling by 
physically binding to the TIR domain and blocking Cys747 which is critical for TLR4 
dimerization and activation [362, 395]. 
Purified MAL protein and the two surface-exposed cysteine residues C91A and C157A 
could be artificially glutathionylated in vitro with high concentrations of GSSG 
suggesting that there are other cysteine residues in MAL that are susceptible to 
glutathionylation. However this cannot be confirmed as the C91A/C157A double 
mutant purified protein was not available to test its susceptibility to glutathionylation.  
GSTO1-1 was demonstrated to deglutathionylate MAL in vitro although the effect did 
not appear to be physiologically relevant in subsequent studies carried out in whole 
macrophages. 
In the macrophage cell model J774.1A, endogenous MAL was found to be maintained 
in a deglutathionylated state in non-silencing control and Gsto1 knockdown cells but 
was glutathionylated in response to LPS stimulation only in the non-silencing control 
cells expressing GSTO1-1. MAL remained deglutathionylated in the absence of 
GSTO1-1 in LPS treated Gsto1 knockdown cells. This suggests that GSTO1-1 either 
directly catalyses the glutathionylation of MAL on LPS stimulation or MAL is an 
indirect target of spontaneous/catalysed glutathionylation that occurs in response to the 
ROS generated on LPS activation in macrophages. Since this study did not determine 
the glutathionylation status of TLR4, it is possible that GSTO1-1 modulates TLR4 
either through a physical interaction or by (de)glutathionylating TLR4 and activating 
the TLR4 cascade which in turn would result in ROS production. On analysing the 
activity of MAL i.e. its ability to drive NF-κB dependent gene expression, it was 
concluded that cysteine 91 (C91) was critical for the functioning of MAL as both the 
single mutant C91A and the double mutant C91A/C157A failed to induce NF-κB 
activated luciferase expression in HEK293T promoter expression system. The C157A 
single mutant was capable of driving NF-κB activity to a lower extent, suggesting that 
MAL remained functionally active without C157. Since cysteines in MAL are 
functionally important, MAL undergoes glutathionylation to protect the cysteines from 
irreversible oxidation.  If MAL is directly glutathionylated by GSTO1-1, we may 
consider MAL as the redox switch under the regulation of GSTO1-1. However, if MAL 
Chapter 8 
190 
 
glutathionylation in GSTO1-1 expressing macrophages is a consequence of LPS 
induced ROS, MAL is not the direct target of GSTO1-1 and further studies should be 
directed towards investigating the dimerization and activation of TLR4 in GSTO1-1 
deficient cells.  
Since J774.1A macrophages are relatively difficult to transfect by standard transfection 
methods (liposomal reagent based), HEK293/TLR4/MD2 cells were used an ‘over-
expression’ model to further investigate the glutathionylation of MAL and the cysteine 
mutants. Cells over expressing wildtype MAL maintained the over expressed protein in 
a glutathionylated state even in the absence of LPS unlike endogenous MAL in J774.1A 
cells where MAL was glutathionylated only in response to LPS. Interestingly, a similar 
observation was reported in relation to the phosphorylation of MAL in over-expression 
systems where in MAL was phosphorylated irrespective of LPS stimulation [396]. The 
C91A single mutant was also glutathionylated, though to a significantly lower extent 
when compared to the wildtype. Furthermore, the C157A mutant was more 
glutathionylated than the C91A which was reflected in their relative activity (Figure 
8.2). The activity of the C157A mutant was comparable to the wildtype protein whereas 
mutating C91 abolished MAL’s activity. Taken together, it can be concluded that 
though other cysteines are susceptible to glutathionylation; C91 appears to be critical 
for the activity of MAL and its glutathionylation protects it from irreversible ROS 
induced oxidative damage. To further support the hypothesis, the oxidation state of 
MAL was evaluated. Since wildtype MAL was glutathionylated in LPS treated 
HEK293T cells, no oxidized MAL was detected in the cells over expressing the 
wildtype protein. However, MAL was shown to be oxidized in cells transfected with the 
single mutants and the double mutant. This gives rise to the possibility that the cysteines 
may be important for the correct folding and maintaining the quaternary structure of 
MAL and mutating the residues may be making other cysteines including C91 more 
susceptible to oxidation by increasing steric hindrance and preventing glutathione from 
binding and/or GSTO1-1 from catalysing the glutathionylation of cysteines, especially 
C91. There is evidence showing that the C91A and C157A purified proteins may be 
unstable (Figure 8.1B) though transfected cells show considerable expression of both 
mutants in HEK 293T cells indicating that the lack of activity of the C91A mutant is not 
completely attributed to the loss of protein (Figure 8.2A). Establishing a J774.1A stable 
transfectant expressing the active site mutant C32A would be an ideal system to confirm 
whether the catalytic activity of GSTO1-1 is responsible for regulating TLR4 signalling. 
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However this was beyond the scope of this study and will be considered for further 
investigation. Due to technical difficulties transfecting J774.1A cells, the ability of 
TLR4 to homodimerize in the absence of GSTO1-1 was not investigated and is still 
considered a potential target of GSTO1-1.  
The disruption of the LPS triggered MAL-MyD88 interaction in the C91A and C157A 
expressing is additional evidence supporting the functional relevance of the two 
cysteines in the formation of the myddosome complex. The GSTO1-1 dependent 
cellular glutathionylation of MAL observed in LPS treated cells may be explained either 
by the excessive ROS generation in GSTO1-1 expressing macrophages on TLR4 
activation, consequently leading to MAL glutathionylation or by the direct catalysis of 
MAL glutathionylation by GSTO1-1. If the former explanation holds true and MAL is 
glutathionylated as a result of the ROS generated by the TLR4 signalling cascade, then 
it may be concluded that the glutathionylation of MAL is not the GSTO1-1 mediated 
switch regulating the pathway. However, it is evident from the work carried out here 
that the target of GSTO1-1 lies in the myddosome complex warranting the need to 
investigate the glutathionylation state of other proteins recruited to the complex. If 
MAL is a direct glutathionylation target of GSTO1-1 as strongly suggested by our 
previous findings that GSTO1-1 catalyses the glutathionylation of proteins under 
oxidative stress, the cysteines undergoing GSTO1-1 catalysed glutathionylation should 
be identified. The data presented here on the excessive oxidation of cysteines in C157A 
mutant expressing HEK293T cells and the lack of activity of the C91A mutant 
collectively identifies C91 as a functionally essential cysteine in MAL and a suitable 
target of glutathionylation by GSTO1-1.   
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CHAPTER 9 
Discussion  
9.1 Significance of results 
Glutathione transferase Omega (GSTO1-1), a member of the glutathione transferase 
(GST) superfamily of Phase II detoxification enzymes, has been characterized as an 
atypical GST with minimal functional resemblance with other GSTs [179, 197, 262]. 
GSTO1-1 has previously been shown to exhibit dehydroascorbate reductase activity and 
glutaredoxin-like thiol transferase activity with chemical substrates such as 2-
hydroxyethyl disulphide (HEDS) [262, 275]. Due to its structural similarity to 
glutaredoxin, a thiol transferase catalysing enzyme, and its inability to recognize 
xenobiotic substrates typical of other GSTs, it was clear that its primary function 
remained to be elucidated. Tissue distribution studies identified GSTO1-1 in diverse 
tissues with varied expression levels albeit the expression of GSTO1-1 was remarkably 
high in phagocytic immune cells such as macrophages, neutrophils and dendritic cells 
when compared to non-phagocytic immune cells including B-cells (www.immgen.org). 
Though a significantly high expression level has been observed in the heart and liver, 
the link between the tissue specific expression and its functional significance is not fully 
understood. Interestingly, unlike other members of the GST family (except for GSTP), 
immunostaining of GSTO1-1 revealed the translocation of the protein into the nucleus 
and localization in the nuclear membrane for reasons yet to be understood [197, 263].  
GSTO1-1 was identified as a GST a decade ago due to its close sequence and structural 
similarity with the family and its ability, though minimal, to catalyse classic 
detoxification reactions with common GST substrates. GSTO1-1 possesses the typical 
GST fold comprising of the N-terminal ‘thioredoxin’ resembling domain, embedding 
the GSH binding site, and the C-terminal helical domain [262]. Most GSTs possess a 
tyrosine or serine residue at their active site, responsible for catalysing conjugation 
reactions between GSH and electrophilic substrates [179, 262]. The active site residue 
in GSTO1-1 was identified as a cysteine (Cys-32) flanked by proline and phenylalanine, 
uncharacteristic of mammalian GSTs [262]. On detailed dissection of the crystal 
structure, the active site was found to be in a wide crevice that can potentially 
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accommodate large substrates suggesting potential interactions with protein- glutathione 
mixed disulphides (P-SSG).   
There have been a few studies published over the years describing oxidative stress 
dependent activity of GSTO1-1 in nematodes and in Drosophila [261, 267, 397]. A loss 
of function mutation in the parkin gene in Drosophila has been established as a model 
for neurodegeneration caused by mitochondrial dysfunction [261]. The mutant shows 
defective mitochondrial functioning owing to impaired mitochondrial ATP synthase 
activity. The study demonstrated that over expression of GSTO1-1 in parkin mutants 
partially restored the activity and assembly of the mitochondrial F1F0-ATP synthase by 
the glutathionylation of the β subunit of ATP synthase and hence protecting it from 
oxidative stress induced damage [261, 397]. This study was published in parallel with 
our findings that GSTO1-1 deglutathionylates proteins under normal physiological 
conditions in mammalian cells. Since we also showed that increased oxidative stress led 
to higher global glutathionylation levels in GSTO1-1 expressing T47-D breast cancer 
cells, we can argue that the GSTO1-1 catalysed glutathionylation of ATP synthase 
reported in parkin mutants by Kim et al. may be due to the preferential catalysis of 
glutathionylation over deglutathionylation by GSTO1-1 under the high oxidative stress 
observed in the parkin mutants.  
A study carried out by Gabel et al. identified GSTO1-1 as a target of Cytokine Release 
Inhibitory Drugs (CRIDs) [264]. The study suggested the involvement of GSTO1-1 in 
the posttranslational processing of IL-1β in human monocytes. Since the C32A GSTO1-
1 mutant failed to elicit responses similar to the wildtype protein, the study speculated 
that the catalytic activity is key to IL-1β processing. The occurrence of a GSH/ P-SSG 
binding site on GSTO1-1 and the striking similarity between the crystal structures of the 
protein and glutaredoxin raises the question whether GSTO1-1 participates in the 
posttranslational glutathionylation or deglutathionylation of protein(s) involved in the 
activation and secretion of IL-1β in macrophages.  
Co-incidentally, a recent study identified the induction of GSTO1-1 transcription by 
HMGB1 (high-mobility group protein 1) in response to LPS/GalN-triggered mouse 
liver injury [398]. HMGB1 is a nuclear component involved in the transcriptional 
regulation of genes and has also been shown to act as a late mediator of lethality when 
secreted extracellularly as observed in LPS/GalN-triggered mouse liver injury. The 
study revealed increased binding of HMGB1 to the promoter sequence of Gsto1 in 
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LPS/GalN injected mice.  Since HMGB1 directly interacts and activates TLR4/MD2 on 
the surface of macrophages when secreted extracellularly [399], it may regulate the 
expression of GSTO1-1 and modulate protein transcription and activity in response to 
LPS in macrophages. This serves as another line of evidence supporting the speculated 
but previously uncharacterized role of GSTO1-1 in inflammation. 
Aside from the well characterized role of reversible glutathionylation in the protection 
of proteins against oxidative stress, glutathionylation in the absence of oxidative stress 
has also been shown to affect protein function. Glutathionylation has been shown to 
have an impact on the regulation of the cell cycle, apoptosis and inflammation [20, 22, 
27, 142], as well as the contractile activity of actin and the phosphatase activity of 
Protein Tyrosine Phosphatase1B [29, 69]. Therefore, the mechanisms and catalytic 
mediators of the glutathionylation cycle are of great interest under both oxidative and 
non-oxidative conditions.  
In this study, GSTO1-1 was found to catalyse the deglutathionylation of protein thiols 
in vitro and in a human breast cancer cell line, T47-D. We have identified targets 
specifically deglutathionylated by GSTO1-1 in T47-D cells, including β-actin and two 
members of the family of heat shock proteins; Hsp70 and Hsp7c by mass spectrometry 
though the identity of the exact cysteines was not further investigated at this stage. We 
validated the deglutathionylation of actin by GSTO1-1 with immunoprecipitation and 
immunoblotting in cells overexpressing GSTO1-1. The finding that GSTO1-1 
deglutathionylated a limited number of proteins in the total glutathionylated protein 
pool suggests that GSTO1-1 exhibits target specificity though the parameters conferring 
this specificity are not clear. It is important to note that the GSH-binding site in 
GSTO1-1 lies in a relatively open crevice that is large enough to fit interacting proteins. 
This would raise the possibility that the specificity of GSTO1-1 towards protein targets 
arises from the physical (transient) association of the protein target with GSTO1-1, 
thereby allowing the glutathionylated residue to bind with the GSH-site and transfer the 
glutathione moiety to form a disulphide with Cys 32 of GSTO1-1 (Figure 4.12). 
GSTO1-1 is then recycled to its active state by free GSH in the immediate environment. 
Also, parameters contributing to the reactivity of the target cysteine thiol such as its 
pKa, basicity of its flanking residues or residues in close proximity may add to the 
substrate specificity. The substrate specificity of GSTO1-1 in deglutathionylation is 
very important since the data presented in this study indicate a regulatory role for 
GSTO1-1 in inflammation. Our work suggests that the inhibition of GSTO1-1 could be 
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a suitable target for therapeutic intervention in curbing inflammatory diseases 
characterized by hyperactivity of TLR4. Target specificity would rule out off-target 
effects of GSTO1-1 manipulation by synthetic drugs such as ML175 and increase drug 
efficacy with minimal side effects.  
Significantly, T47-D cells overexpressing GSTO1-1 were found to undergo rapid 
glutathionylation on treatment with S-nitrosoglutathione (GSNO), a known 
glutathionylating agent. This suggests the possibility that GSTO1-1 may also catalyse 
glutathionylation of proteins under physiological oxidative conditions. However the 
present data do not exclude the possibility that the reaction is indirect and results from 
the generation of GSSG by reactions catalysed by GSTO1-1.  Since the 
glutathionylation and de glutathionylation of proteins has previously been 
predominantly attributed to Grx family thioltransferases, the current results add a novel 
protein to the limited list of enzymes catalysing glutathionylation cycle reactions.  
 Following the characterization of GSTO1-1 as an efficient catalyst in the 
glutathionylation cycle, the physiological relevance of this function was further 
investigated in a biological setting. Since genetic variation in the Omega class GST 
genes has been associated with the age at onset of Alzheimer’s and Parkinson’s diseases 
and amyotrophic lateral sclerosis (ALS), and the last decade has accumulated indirect 
evidence for the involvement of GSTO1-1 in inflammation and inflammation associated 
diseases [210-217, 272], the project aimed at establishing a link between the implicated 
functions of GSTO1-1 and its role in the glutathionylation cycle. Interestingly, all the 
diseases that GSTO1-1 has been reported to influence are quite diverse in terms of 
symptoms, causes, tissues affected and pathways involved. However, inflammation is a 
common factor linking all the reported diseases that has been shown to exacerbate the 
underlying condition and its progression.. Neurodegeneration occurring in Alzheimer’s’ 
disease and Parkinson’s disease is almost always is associated with hyper-activity of 
inflammatory signalling pathways. Increased cytokine secretion and ROS production by 
infiltrating neutrophils and macrophages aggravates tissue damage seen in 
neurodegenerative disease, thus exacerbating the disease and speeding up the 
progression and spread [280, 281, 287, 372].  Up-regulation of GSTO1-1 during 
inflammatory responses has been previously reported by independent studies though the 
mechanism of action is still open to speculation [213, 273]. Furthermore, the revelation 
by meta-studies that the polymorphisms, D140 in particular, associate quite strongly 
with the age at onset and progression of neurodegenerative diseases such as Alzheimer’s 
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and Parkinson’s disease further strengthens the evidence in support of a redox role for 
GSTO1-1 in inflammation associated diseases [210, 212, 272].  Increased ROS 
accompanying neurodegeneration not only causes excessive tissue damage but also 
disrupts protein activity by post translational modifications [148, 154, 341]. Over 
exposure of proteins to ROS results in the irreversible oxidation of protein thiols and 
subsequent loss of activity and proteosomal degradation. Hence, the results presented 
here suggesting that the polymorphic variants of GSTO1-1 have differential 
glutathionylating and deglutathionylating activities is a significant finding that may link 
all the previously implicated roles of GSTO1-1 in inflammatory diseases. It is not 
unreasonable to speculate that GSTO1-1 may either be glutathionylating proteins and 
protecting them from inflammation associated irreversible oxidation or 
deglutathionylating glutathionylate proteins and restoring their activity.  
The D140 variant in particular was found to have lower deglutathionylating activity but 
higher glutathionylating activity. The reported linkage between D140 GSTO1-1 
expression and progression of neurodegeneration may be attributed to increased protein 
glutathionylation and inhibition of the function of proteins that are required for normal 
physiological functioning in neural cells. Since GSTO1-1 was shown to have target 
specificity, the polymorphisms would impact only a few proteins and not all 
(de)glutathionylated proteins. It is curious that a single point mutation in GSTO1-1 
(A140D) altered the activity of the protein significantly. In order to understand the 
nature of this polymorphism, a closer look into the structure of GSTO1-1 was 
warranted. Since the polymorphism encodes an alanine to an aspartic acid substitution, 
the change in the residue’s charge (neutral to negative charge) was considered as a 
possible reason for the differential activity by a previously uncharacterized alteration in 
protein folding. In order to predict structural changes occurring due to the A140D 
substitution, and to evaluate the proximity of the alanine / aspartic residues on both 
subunits to the active site cysteines,  a model of the GSTO1-1 dimer was constructed in  
PyMOL from the PDB coordinates 1EEM. As shown in Figure 9.1A, the Ala /Asp 
residue resides towards the N-terminal end of helix 5 and is exposed to solvent. The 
residue at position 140 in the A subunit is 27.9A from the A subunit active site Cys 32 
and 36.2A from the B subunit Cys 32. Due to the large distance between the residue at 
position 140 and the active site cysteine residues on either subunit, it is highly unlikely 
that the residue substitution could directly alter the structure or hinder the interaction of 
substrate proteins with GSTO1-1.  The substrate peptide (SQLWCLSN) was modelled 
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on the active site of GSTO1-1 which presented a clear view of the distance between 
potential substrates and A140, further confirming that based on the crystal structure the 
lower deglutathionylating activity of D140 GSTO1-1 with the peptide is not due to an 
alteration in the protein structure resulting in direct steric hindrance, when alanine is 
substituted with aspartate (Figure 9.1B). Additionally, mutating the alanine to aspartate 
in Pymol showed no detectable difference in the positioning of the loop containing the 
residue except for a slight clash of the side chain of aspartate with the amino acid 
adjacent which wasn’t considered significant enough to cause any structural alterations. 
However, when the factors contributing to the flexibility of crystal structures were 
considered, the loop between helix 4 and the residues at the start of helix 5 (containing 
A140) were found to have a high B-Factor and appeared to be relatively mobile (Figure 
9.1C, in red).   Since the assays were carried out with the purified proteins in solution, it 
is possible that the position of helix 5 may be altered by the charge change resulting 
from the A140D substitution, causing the loop and helix to move around more in 
solution and potentially dislodge or destabilize the interacting target protein from the 
active site crevice. The consequence of the A140D substitution on the structure of 
GSTO1-1 has not been characterized previously and warrants in depth structural 
analysis by techniques such as X-ray crystallography, NMR and circular dichroism. 
However since both the allelic variants were stable when purified (no precipitation 
observed), significant disruption to protein folding in solution seems unlikely. Hence 
the cause of the difference in glutathionylating and deglutathionylating activity of the 
two allelic variants remains unclear.  
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Figure 9.1: Structural implications of the A140D substitution in GSTO1-1 
(A) GSTO1-1 dimer is presented in cartoon mode with the helices in blue, β-strands in pink. The alanine and cysteine residues on both monomers 
are highlighted in space-fill/sphere mode. (B) Interaction of the peptide SQLWCLSN with the active site Cys 32 is highlighted in sphere mode. (C) 
Evaluation of the B-factors (representing the flexibility/rigidity of the crystal structure identified the helix and loop containing A140 as highly 
dynamic (blue<green<yellow<orange<red). 
Figure 9.1A,B were made by Emeritus Prof. Philip Board (Australian National University) and Assoc. Prof. Aaron Oakley (University of 
Wollongong); Figure 9.1C was designed with assistance from Dr. Soumya Jose, Australian National University) 
A B C 
36.2 Å 
SQLWCLSN 
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As illustrated in Figure 9.2, the hypothesis that GSTO1-1 may be modulating proteins 
associated with inflammation was addressed by 4 aims. We first established that 
GSTO1-1 is an essential component in the TLR4 cascade required for the activation of 
pro-inflammatory responses including cytokine secretion and maintaining the 
oxidant/antioxidant axis for excessive anti-microbial ROS production in response to 
LPS in macrophages (Figure 9.2 aim 1). Furthermore, the inability of GSTO1-1 
deficient cells to phagocytosize LPS coated beads is a clear indication of 
unresponsiveness of Gsto1 knockdown cells to TLR4 activation.  
Secondly, it was necessary to determine whether the catalytic activity of GSTO1-1 is 
required for the activation of pro-inflammatory responses of macrophages to LPS 
(Figure 9.2 aim 2). This would help rule out the possibility that GSTO1-1 mediates its 
effects on TLR4 signalling by physical interaction with protein(s) in the TLR4 
signalling pathway without the requirement of a functional active site cysteine residue. 
To establish this point, the synthetic inhibitor ML175 previously shown to inhibit the 
catalytic activity of GSTO1-1 [350], was used on wildtype macrophages and their pro-
inflammatory responses to LPS were compared with the response of the genetically 
modified Gsto1 knockdown macrophages. As described in Chapters 5-7, all the effects 
resulting from knocking down GSTO1-1 in J774.1A macrophages were recapitulated in 
ML175 treated macrophages. Taken together these results suggested that the catalytic 
activity of GSTO1-1 is required for TLR4 signalling. Furthermore, the response to 
ML175 was always dose dependent, suggesting that GSTO1-1 is a strong target for 
pharmacological regulation of TLR4 signalling. The TLRs have been well recognized as 
targets for anti-inflammatory drugs and a recent review has listed over 20 compounds 
targeting TLRs in clinical trials for a variety of indications [163]. TLR4 specific 
compounds are currently being tested for the treatment of acute and chronic 
inflammation, chronic pain, allergic rhinitis and sepsis. Thus the discovery that the 
TLR4 pathway leading to the generation of ROS and the expression of pro 
inflammatory cytokines is dependent on GSTO1-1 activity has identified the potential 
of ML175 as a novel anti-inflammatory drug. Further investigations will be required to 
optimize the dosage in additional cell types apart from macrophages to minimize the 
observed toxicity. Alongside, it would be necessary to consider incorporating potential 
modifications in the compound, which would decrease the in vitro cytotoxicity of 
ML175 without compromising on its inhibitory property. Once a concentration range 
across multiple cell types in vitro is established, issues concerning drug toxicity (LD50) 
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and drug efficacy would be better understood. The next step in the bench to bedside 
protocol would be to extend the anti-inflammatory applications of ML175 to in vivo 
models. The translation of the use of synthetic compounds from in vitro to in vivo 
applications may be carried out as advised in the National Institute of Health, U.S.A 
(NIH) (http://www.epa.gov/hpv/pubs/general/nih2001b.pdf). 
The third aim (Figure 9.2 aim 3) focussed on determining if multiple pathways 
independent of NFκB but responsive to TLR4 activation are impacted by GSTO1-1 
deficiency. The metabolic profile of the cells was evaluated in order to further 
understand and characterize the phenotype and TLR4 mediated metabolic regulation in 
GSTO1-1 deficient macrophages. The Warburg effect was defined in 1954 by Otto 
Warburg as the metabolic deregulation observed in cancer cells where glycolysis is 
favoured by the cells even in the presence of oxygen. The occurrence of aerobic 
glycolysis in cancer cells was widely accepted however the possibility of a similar 
phenotype in other cell types such as immune cells and cancer associated invading 
macrophages was not initially accepted [400]. In the last decade, the exploitation of the 
metabolic profile of tumour associated macrophages has been shown to reduce the 
extent of tumour metastasis [401]. During tumour progression a gradual switching of 
macrophage polarization, from pro-inflammatory ‘M1’ to an anti-inflammatory 
phenotype ‘M2’ [402]. This transition establishes suitable conditions for tumour growth 
and metastasis. Excessive secretion of cytokines such as IL-1β has also been shown to 
exacerbate the progression of metabolic disorders. IL-1β secretion by activated 
macrophages has previously been linked to chronic inflammation associated with the 
development of insulin resistance in adipocytes and insulin secretion by pancreatic islets 
[172, 369, 374, 403-407]. Adipocytes themselves express TLR4 receptors on their 
surface and are highly responsive to LPS and free fatty acids (FFAs) [405, 407]. IL-1β 
secreted by adipocytes is sufficient to trigger the release of chemokines that attract 
activated pro-inflammatory macrophages, resulting in inflammation. Subsequently, IL-
1β secreted by the infiltrating macrophages further exacerbates insulin resistance in 
adipocytes [172, 405-407].  
The typical macrophage M1 phenotype characterized by increased glycolysis, 
accumulation of TCA intermediates, expression of NFκB dependent cytokines and ROS 
generation was absent in Gsto1 deficient cells [1, 343, 344, 374, 375, 400, 408]. The 
attenuation of the glycolytic switch in GSTO1-1 deficient macrophages is believed to be 
a downstream effect of an upstream block in the TLR4 signalling pathway. Increased 
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phosphorylation of AMPKα in GSTO1-1 deficient cells was similar to the expression 
profile seen in macrophages treated with metformin [292, 298, 409]. Metformin is a 
well-known anti-diabetic drug which in recent times has gained recognition as a 
potential anti-cancer agent as well [410-413]. Metformin is a potent activator of 
AMPKα and has been shown to induce AMPKα phosphorylation in macrophages which 
in turn upregulates PGC1β levels [414]. The increased PGC1β expression resulted in the 
deacetylation and inhibition of NFκB nuclear translocation and eventually in the 
inhibition of IL-1β transcription [377, 414]. Though there is some dispute on the anti-
inflammatory properties of metformin and the mechanism involved, it is certain that 
AMPKα activation is inhibitory to the pro-inflammatory responses in macrophages.  
Since GSTO1-1 deficient cells maintained activated AMPKα levels and high PGC1β 
transcript levels even in the absence of LPS, GSTO1-1 inhibition by synthetic inhibitors 
could not only be tested as anti-inflammatories but may also be considered for other 
metformin-like properties including the anti-cancer effects mediated via AMPKα.  
The NLRP3 inflammasome has been shown to play a predominant role in modifying the 
pro-inflammatory state of both M1 and M2 macrophages [172] in response to ROS. 
Thus inhibiting TLR4 signalling with an inhibitor of GSTO1-1 would block the entire 
cascade of inflammatory events. The inhibition of TLR4 mediated pro-inflammatory 
responses by inhibiting GSTO1-1 in macrophages could possibly result in the reversal 
of insulin resistance and other IL-1β associated metabolic disorders. 
Taken together, the three aims described above led to the conclusion that: 
 GSTO1-1 is exclusive to TLR4 and plays an indispensable role in the activation 
of inflammatory signalling mediated via TLR4. 
 
 The absence of IRAK4 phosphorylation which is an upstream signal for NFκB 
activation in Gsto1 knockdown cells suggests that GSTO1-1 acts upstream of 
IRAK4, potentially in the Myddosome complex. As mentioned in Section 5.4 
the presence of low levels of ‘phosphorylated’ IRAK4 in the unstimulated cells 
makes this piece of evidence slightly inconclusive. However, the failure of 
GSTO1-1 deficient cells to phagocytosize LPS coated beads is additional 
evidence pointing to the upstream activity of GSTO1-1 on LPS stimulation.  
 
 Working around the above mentioned limitation, this study provided further 
evidence supporting the upstream positioning of GSTO1-1 in the TLR4 pathway 
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by determining the metabolic status of the GSTO1-1 deficient cells. Since the 
glycolytic switch triggered by LPS is not entirely dependent on IRAK4 
phosphorylation and NFκB activation, the absence of a typical pro-inflammatory 
M1 glycolytic phenotype in Gsto1 knockdown cell places GSTO1-1 above 
IRAK4.  
Hence, the inhibition of downstream recruitment and activation of proteins initiating 
from IRAK4  in the TLR4 cascade that is required for cytokine secretion and ROS 
production and the complete absence of a classical M1 phenotype (phagocytic and 
glycolytic) suggests that GSTO1-1 may be a component of the Myddosome complex or 
act on proteins in the complex. 
The fourth aim focussed on identifying potential targets of GSTO1-1 within the 
myddosome complex. LPS induced ROS has been shown to induce the post 
translational modification of proteins. Su et al. performed a large scale mass 
spectrometric analysis of glutathionylated proteins in RAW264.7 cells treated with LPS 
[415]. The study identified approximately 265 proteins that are differentially 
glutathionylated on LPS stimulation. MyD88 an essential component of the Myddsome 
complex was identified among the glutathionylated proteins in LPS treated cells. This is 
the first line of evidence suggesting that cysteines in MyD88 are susceptible to 
glutathionylation. However this is not unexpected as a previous study identified MyD88 
to be nitrosylated upon activation with LPS [416]. Since MyD88 is  a common 
accessory protein to multiple TLRs and the effect of GSTO1-1 was found to be specific 
to TLR4, the redox modifications of MyD88 were considered an unlikely cause for the 
downstream effects observed in GSTO1-1 deficient macrophages.  Other proteins in this 
pathway that have been affected by glutathionylation include TRAF6, caspase-1, IKKβ 
and NFκB subunits p65 and p50 [61, 64, 118, 119, 160]. These proteins are all 
downstream of the target of GSTO1-1.While the glutathionylation of TRAF6 on LPS 
activation of TLR4 was catalysed by glutaredoxin; the glutathionylation of caspase-1 
was dependent on the expression of the antioxidant SOD1. The experiments carried out 
in this study have placed GSTO1-1 upstream of IRAK4 and NFκB and demonstrated 
the attenuation of multiple pathways activated by LPS in macrophages. The induction of 
ROS and the subsequent glutathionylation of MAL were detected in macrophages 
expressing GSTO1-1 but not in GSTO1-1 deficient cells.  Based on the discovery that 
GSTO1-1 has measurable deglutathionylating activity the initial hypothesis proposed 
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that GSTO1-1 may deglutathionylate protein(s) partaking in TLR4 signalling thereby 
contributing to the results described. However, initial analysis of the redox state of 
MAL suggests that GSTO1-1 may modulate the glutathionylation of MAL by either 
inducing ROS in response to LPS or may directly catalyse the glutathionylation of 
MAL.  The difference in these two possibilities is significant. If MAL is 
glutathionylated by ROS that have been generated after LPS stimulation it seems 
unlikely that MAL is the target for the GSTO1-1 activity that regulates the pathway.  In 
contrast, if GSTO1-1 is responsible for the direct glutathionylation of MAL then it is 
likely that MAL is the prime target for regulation by GSTO1-1. If MAL is not the target 
of GSTO1-1, it is important that the investigation focuses on TLR4. The cysteine 
residue Cys 747 in the TIR domain is critical for the homodimerization of TLR4 on LPS 
stimulation [395]. Since the deficiency of GSTO1-1 prevents the phosphorylation of 
IRAK4, it is possible that the Myddosome complex is recruited but does not correctly 
interact with the TIR domain of TLR4 due to the glutathionylation of Cys 747 in the 
absence of GSTO1-1.   
The Gsto1
-/-
 mice became available only towards the end of the project and hence 
characterization of the phenotype of these mice is incomplete. Since GSTO1-1 deficient 
macrophages remain unresponsive to TLR4 stimulation by LPS, it was hypothesized 
that Gsto1
-/-
 mice would be tolerant to LPS and would fail to elicit typical pro-
inflammatory responses including the secretion of cytokines and production of ROS. As 
expected, Gsto1
-/-
 mice did not respond to sub lethal doses of LPS (5 mg/kg and 10 
mg/kg) and failed to induce cytokines. In contrast, the wildtype counterparts 
experienced hypothermia within 9-12 hours post LPS injection and did not survive for 
more than 24-96 hours. An analysis of the histology of tissues extracted from LPS 
treated wildtype and Gsto1
-/-
 mice revealed a remarkable difference in the morphology 
of the liver and spleen. The wildtype mice experienced severe necrosis and showed 
signs of acute inflammation including the infiltration of neutrophils and hepatic 
steatosis. The spleen in wildtype mice also showed acute inflammation in the red pulp 
regions along with the formation of tingable macrophage bodies. The knockout mice did 
not show any significant morphological changes while the extent of liver and spleen 
damage in heterozygotes were termed as ‘mild inflammation’ by Professor Jane 
Dahlstrom who analysed the samples.  
Taken together, the absence of LPS induced tissue damage, failure to elicit cytokines, 
attenuation of the up-regulation of NOX1 transcription and the maintenance of a high 
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anti-oxidant redox environment in response to intra-peritoneally injected LPS strongly 
supports the novel role of GSTO1-1 in TLR4 pro-inflammatory signalling. However, 
the specificity of GSTO1-1 to TLR4 in vivo is yet to be fully investigated. 
This study establishes an indispensable role for GSTO1-1 in TLR4 signalling and LPS 
associated inflammatory responses. Characterization of the glutathionylating and 
deglutathionylating activities of the polymorphic variants of GSTO1-1 revealed a 
significant difference which could explain the reported role of GSTO1-1 in 
inflammatory diseases. The effect of the polymorphic variant D140 on TLR4 signalling 
would be an interesting aspect to investigate. If TLR4 signalling is dependent on the 
polymorphic variant of GSTO1-1, it would further support the hypothesis that the 
regulatory effects of GSTO1-1 in inflammation are mediated by its 
(de)glutathionylation activity. We further conclude that this effect may be due to the 
glutathionylation of the upstream TLR4 specific adaptor MAL. However due to time 
constraints, this theory is yet to be fully investigated.  
9.2 Future directions 
9.2.1 Identifying the glutathionylation targets of GSTO1-1 in macrophages 
A global mass spectrometry analysis of GSTO1-1 expressing versus deficient 
macrophages, similar to the work done on T47-D breast cancer cells (refer Chapter 4) 
would identify potential glutathionylation targets of GSTO1-1. This would include 
targets in the TLR4 cascade and other pathways that are regulated by GSTO1-1. A 
global increase in glutathionylation was measured in GSTO1-1 expressing macrophages 
in response to LPS induced ROS. Identification of these proteins could then be followed 
up by experimental validation as previously done.   
9.2.2 In vivo validation of endotoxic responses to LPS 
The susceptibility of Gsto1
-/-
 mice to LPS was investigated towards the end of this 
project when the mice became available. Further studies are in place to characterize the 
phenotype of the mice. LPS response in the mice should be evaluated by measuring 
cytokine levels in the serum and in bone marrow derived and peritoneal macrophages. 
TLR4 signalling could be characterized further by determining the activation of 
intermediate signalling molecules that have been carried out in the J774.1A GSTO1-1 
deficient macrophages. Since different types of immune cells respond to LPS in whole 
mice, it is important to determine their individual responses as it is possible that the 
effects observed in macrophages may not be occurring in other cell types. This would 
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also help narrow down the target of GSTO1-1 macrophages by comparing the activation 
of signalling molecules among different immune cells in response to LPS. Additionally, 
the specificity of GSTO1-1 to TLR4 in vivo needs to be investigated to confirm the 
results gathered from the macrophages in vitro.  
9.2.3 Characterizing Gsto2
-/-
 mice 
With the intention to provide a ‘negative control’ group deficient in GSTO2-2, we had 
generated a V174A Gsto2 mutant mouse model (available via the Australian Phenomics 
Facility ENU mutant library). Unfortunately, the homozygotes (mut/mut) were found to 
express GSTO2-2 in all tissues with considerable activity. Hence the data are not 
presented in this thesis.  It would be interesting to characterize the response of Gsto2
-/-
 
mice to LPS. Based on the results described in this thesis, inhibition of TLR4 signalling 
is specific to GSTO1-1 and therefore Gsto2
-/-
 mice are expected to be susceptible to 
LPS induced endotoxic shock unlike Gsto1
-/-
 mice. 
9.2.4 Testing disease models 
The in vivo work thus far has been done using commercially available high purity LPS 
as a TLR4 stimulant. It would be necessary to test the susceptibility of Gsto1
-/-
 mice to 
live bacteria such as Salmonella typhimurium to confirm the resistance of these mice to 
infection.   
As over expression of cytokines has been reported to exacerbate diseases such as cancer 
and metabolic conditions, it would be interesting to use Gsto1
-/-
 mice as an immune 
model to test the progression of inflammation associated diseases. Our laboratory has 
established a cancer model by injecting cancer cells such as 4T-1 (murine breast cancer) 
in normal mice and MDA-MB-231 (human breast cancer cells) in Rag1
-/-
 
immunocompromised mice. A similar approach would help understand if cancer cells 
are able to grow and metastasize in Gsto1
-/-
 mice. Ideally, if Gsto1
-/-
 mice are incapable 
of eliciting pro-inflammatory responses, the injected cancer cells wouldn’t metastasize.  
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9.3 Conclusion 
This study identifies a novel role of GSTO1-1 in the 
glutathionylation/deglutathionylation of proteins with target specificity. The regulatory 
role of GSTO1-1 was further elucidated as an essential component of TLR4 mediated 
inflammatory responses in macrophages stimulated by LPS. Blocking chronic oxidative 
stress associated with exacerbated cytokine secretion and neurodegeneration could 
therefore be of benefit in limiting the pathology and progression of Alzheimer’s disease.  
This study also demonstrated that the inhibition of GSTO1-1 by ML175 mediates 
responses that are typical of reported anti-inflammatories, hence providing the first 
evidence that ML175 and related compounds are a new family of anti-inflammatory 
agents. 
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APPENDICES 
 
Appendix A1: Common Reagents and their sources 
 
Reagent Source 
 
Acetic acid 
 
Chem-supply (Gillman) (Australia) 
Biorad (U.S.A) 
Amresco (USA) 
Amresco (USA) 
Sigma (U.S.A) 
Sigma-Aldrich (USA) 
30% Acrylamide : Bisacrylamide 
Agar 
Agarose 
Ammonium persulphate 
Ampicillin 
Anti-rabbit IgG (peroxidase conjugated) Dako Pty. Ltd. (Australia) 
β-mercaptoethanol Sigma (U.S.A) 
Bovine Serum Albumin (BSA) New England Biolabs (USA) 
Chloroform 
Coomasie Brilliant blue Phast Gel Blue R 
Ethanol 
GelRed Dye 
Glycerol 
Methanol 
One Kb DNA ladder 
One Kb Plus DNA ladder 
Rapid Step ECL Reagent 
Sodium Acetate 
Sodium Chloride 
Sodium di-hydrogen orthophosphate 
Sodium Dodecyl Sulphate 
Sodium Hydroxide 
di-Sodium Hydrogen Orthophosphate 
Sucrose 
Super RX Medical X-ray Film 
TEMED 
Tris 
Trypan Blue 
Sigma (U.S.A) 
Pharmacia Biotech (Sweden) 
Ajax Finechem (Australia) 
Jomar Biosciences (Australia) 
Chem-supply (Gillman) (Australia) 
Chem-supply (Gillman) (Australia) 
Invitrogen (U.S.A) 
Invitrogen(U.S.A.) 
CalBiochem, Merck Pty Ltd (Australia) 
BDH AnalaR, Merck Pty Ltd (Australia) 
BDH AnalaR, Merck Pty Ltd (Australia) 
Ajax Finechem (Australia) 
Sigma (U.S.A) 
Ajax Finechem (Australia) 
BDH AnalaR, Merck Pty Ltd (Australia) 
Ajax Finechem (Australia) 
Fuji (Japan) 
Sigma (U.S.A) 
BioradSigma-Aldrich (USA) 
Sigma (U.S.A) 
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Appendix A2: Consumables and their Sources: 
 
Material Source 
Tissue Culture dishes Nunc (USA) 
96-well plates Corning Costar (U.S.A) 
Pipette tips Axygen (U.S.A.) 
Tissue culture Pipettor Thermo Fischer Scientific (Australia) 
Eppendorfs Sarstedt (Germany) 
Pipettes Gilson (U.S.A) 
 
 
 
 
 
Appendix A3: Enzymes and their Sources 
 
Enzyme Source 
Restriction endonucleases and their 10X Buffers 
KOD Hot Start DNA Polymerase and 10X Buffer 
T4 DNA Ligase and 10X Buffer 
Taq DNA Polymerase and 10X Buffer IV 
New England Biolabs (U.S.A) 
Novagen (Japan) 
Promega (Australia) 
ABGene (U.K.) 
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Appendix A4: Cell culture media and reagents 
 
Media Composition/Dilutions 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
 
 
Luria Broth (LB) 
 
 
 
LB-Amp plates 
 
 
 
Roswell Park Memorial Institute- 1640 
medium (RPM1-1640) 
 
 
PBS (Life technologies Catalogue number: 
00-3002) 
 
 
100X PSN (catalogue number: 15640-055) 
 
2.5% Trypsin (Catalog number: 15090-
046) 
 
200mM Glutamine (Catalog number: 
25030-081) 
H16 Powder 
Sodium hydrogen carbonate 
Sterile double distilled water 
 
Tryptone 
Yeast Extract 
Sodium Chloride 
 
LB 
1.5% (w/v) Agar 
100μg/ml Ampicillin 
 
RPMI powder 
Sodium hydrogen carbonate 
Sterile double distilled water 
 
Dissolve 1 tablet/100ml double 
distilled water.  
 
 
Dilute 1/100 in sterile PBS 
 
Dilute 1/10 in sterile PBS 
 
 
Dilute 1/100 in sterile PBS 
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Appendix A5: Buffers and solutions 
 
Buffer/Solution Composition 
SDS-PAGE destaining solution 10% Acetic acid 
30% Methanol 
4X Resolving gel buffer 1.5M Tris pH 8.8 
0.4% (w/v) SDS 
10X Running Buffer 25mM Tris 
192mM Glycine 
0.1%  (w/v) SDS 
4X Stacking gel buffer 500mM Tris pH 6.8 
0.4% (w/v) SDS 
Coomasie blue protein staining Solution 0.2% stock solution: Phast Gel Blue R tablet 
: 60% Methanol 
Working solution: Mix with 20% acetic acid 
in a 1:1 dilution 
SDS protein Loading dye 250 mM tris, pH 6.8 
10% SDS 
30% Glycerol 
0.02% Bromophenol blue 
5% β-Mercaptoethanol 
 
Sucrose Gel Loading dye 
 
15mM EDTA 
60%  (w/v) Sucrose 
A dash of Bromophenol Blue 
1X TBE Buffer 900mM Tris-Borate 
20mM EDTA pH 8.0 
TFBI 30mM Potassium Acetate 
50 mM MnCl2.4H2O 
100 mM KCl 
10 mM CaCl2.2H2O 
15% Glycerol 
TFBII 10 mM Sodium-MOPS 
75 mM CaCl2.2H2O 
10 mM KCl 
15% Glycerol 
10X Transblot Buffer 12mM Tris 
96mM Glycine 
20% (v/v) Methanol 
10X Tris buffered saline with tween 
Buffer (TBS-T) 
50mM Tris,PH 7.4 
150mM NaCl 
0.1% Tween-20   
Western blot blocking buffer 5% (w/v) skim milk powder in 1X TN buffer 
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Appendix A6: Primer sequences 
 
 
Primer Sequence 
Catalase 5′ AGCGACCAGATGAAGCAGTG 3′ 
5′ TCCGCTCTCTGTCAAAGTGTG 3′ 
COX2 5′ CCCTGAAGCCGTACACATCA 3′ 
5′ TGTCACTGTAGAGGGCTTTCAATT 3′ 
GAPDH 5′ AGGTCGGTGTGAACGGATTTG 3′ 
5′ TGTAGACCATGTAGTTGAGGTC 3′ 
GCLc 5′ GGGGTGACGAGGTGGAGTA 3′ 
5′ GTTGGGGTTTGTCCTCTCCC 3′ 
GCLm 5′ AGGAGCTTCGGGACTGTATCC 3′ 
5′ GGGACATGGTGCATTCCAAAA 3′ 
Gpx3 5′ GCCAGCTACTGAGGTCTGACAGA 3′ 
5′ CAAATGGCCCAAGTTCTTCTTG 3′ 
HO-1 5′ GAGATAGAGCGCAACAAGCAG 3′ 
5′ CTTGACCTCAGGTGTCATCTC 3′ 
IL-10 5′ GCT CTT ACT GAC TGG CAT GAG 3′  
5′ CGCAGCTCTAGGAGCATGTG 3′ 
iNOS 5′ CAGCACAGGAAATGTTTCAGC 3′ 
5′ TAGCCAGCGTACCGGATGA 3′ 
NOX1 5′ TCCATTTCCTTCCTGGAGTGGCAT 3′ 
5′ GGCATTGGTGAGTGCTGTTGTTCA 3′ 
NQO1 5′ GCCTGAGCCCAGATATTGTG 3′ 
5′ GGAAAGGACCGTTGTCGT 3′ 
PGC1β 5′ TCCTGTAAAAGCCCGGAGTAT 3′ 
5′ GCTCTGGTAGGGGCAGTGA 3′ 
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 Appendix A7 
Figure 1: Expression profiling of MyD88 (A) and MAL (B) in mouse immune 
cells (Immgen www.immgen.org). 
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C 
Figure 1C: Detailed description of subset nomenclature terminology used in Figure 
5.1A-B, Appendix 7 Figure 1A-B) 
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Appendix A8 
 
 
Antibody Conditions 
anti-glutathione Virogen ( 101-A-100), mouse monoclonal 
1/1000 dilution, 4°C overnight 
anti-GSTO1-1 In-house antibody generated at JCSMR, rabbit polyclonal 
1/1000 dilution, 2 hours room temperature 
anti-β-actin Abcam (ab8227), rabbit polyclonal 
1/5000 dilution, 2 hours room temperature 
anti-NOX1 Abcam (ab55831), rabbit polyclonal 
1/1000 dilution, 4°C overnight 
anti-p65 Santacruz (sc-372), rabbit polyclonal 
1/1000 dilution, 4°C overnight 
anti-glutaredoxin 1 Abcam (ab45953), rabbit polyclonal 
1/1000 dilution, 4°C overnight 
anti-IL-1β R&D biosystems ( AF-401-NA), goat polyclonal 
1/1000 dilution, 4°C overnight 
anti-PPARγ Cell Signalling (C26H12), rabbit monoclonal 
1/1000 dilution, 4°C overnight 
anti-IRAK4 Cell Signalling (4363), rabbit polyclonal 
1/1000 dilution, 4°C overnight 
anti-phospho 
Thr/Ser 
Cell Signalling (9631), rabbit polyclonal 
1/1000 dilution, 4°C overnight 
anti-AMPK Cell Signalling (2532), rabbit polyclonal 
1/1000 dilution, 4°C overnight 
anti-pAMPK Cell Signalling (2531), rabbit polyclonal 
1/1000 dilution, 4°C overnight 
anti-HIF1α Abcam (ab51608), rabbit monoclonal 
1/1000 dilution, 4°C overnight 
anti-GSTO2-2 In-house antibody generated at JCSMR, rabbit polyclonal 
1/1000 dilution, 2 hours room temperature 
anti-GSTK In-house antibody generated at JCSMR, rabbit polyclonal 
1/1000 dilution, 2 hours room temperature 
anti-GSTA1/2 In-house antibody generated at JCSMR, rabbit polyclonal 
1/1000 dilution, 2 hours room temperature 
anti-GSTZ1 In-house antibody generated at JCSMR, rabbit polyclonal 
1/1000 dilution, 2 hours room temperature 
anti-GSTP1/2 In-house antibody generated at JCSMR, rabbit polyclonal 
1/1000 dilution, 2 hours room temperature 
anti-GSTT2 In-house antibody generated at JCSMR, rabbit polyclonal 
1/1000 dilution, 2 hours room temperature 
anti-GSTM2 In-house antibody generated at JCSMR, rabbit polyclonal 
1/1000 dilution, 2 hours room temperature 
anti-GSTA4 In-house antibody generated at JCSMR, rabbit polyclonal 
1/1000 dilution, 2 hours room temperature 
anti-NQO1 Abcam (ab34173), rabbit polyclonal 
1/1000 dilution, 4°C overnight 
anti-GSTT1 In-house antibody generated at JCSMR, rabbit polyclonal 
1/1000 dilution, 2 hours room temperature 
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anti-phospho p38 
MAPK 
Cell Signaling (9211), rabbit polyclonal 
1/1000 dilution, 4°C overnight 
anti-GCLm Abcam (ab81445), rabbit polyclonal 
1/1000 dilution, 4°C overnight 
anti-HA Sigma (H3663), mouse monoclonal  
1/1000 dilution, 4°C overnight 
anti-MAL Abcam (ab17218), rabbit polyclonal 
1/1000 dilution, 4°C overnight 
anti-Myc Sigma (C3956),  rabbit polyclonal 
1/1000 dilution, 4°C overnight 
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